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Abstract
Group A beta haemolytic Streptococcus (GAS) is a bacteria that causes a range o f 
invasive and autoimmune complications in humans. It is also the commonest single 
cause o f tonsillitis in children. Occasionally, in predisposed individuals, GAS can 
induce an immune mediated brain syndrome with particular vulnerability o f the basal 
ganglia. This results in extrapyramidal movement disorders (classically chorea) and 
psychiatric disease. Recently the clinical spectrum o f disease associated with GAS has 
been expanded to include motor tics. The clinical aim o f this thesis was to define the 
clinical spectrum o f CNS disease associated with GAS in a tertiary referral sample. I 
found that a broader range o f extrapyramidal movements (chorea, tics, dystonia and 
Parkinsonism) and psychiatric disease (obsessive-compulsive disorder, anxiety, 
depression and attention deficit hyperactivity disorder) occurred in patients with post­
streptococcal autoimmune neuropsychiatric disease.
The proposed mechanism o f brain injury is cross-reactivity o f the immune response 
between GAS and brain antigens (molecular mimicry). A number o f investigators 
have previously demonstrated auto-antibodies that bind to brain auto-antigens in the 
serum o f post-streptococcal neuropsychiatric patients. Using protein purification 
strategies (2-dimensional electrophoresis, ion exchange and hydrophobic interaction 
chromatography followed by mass spectrometry), I identified the brain antigens as 
neuronal isoforms o f the glycolytic enzymes enolase, pyruvate kinase and aldolase. 
These findings were confirmed with commercial antigens, recombinant human 
antigens and commercial antibodies. These enzymes are present in the neuronal 
cytoplasm, but also on the membrane surface where they have a number o f functions. 
Collaborative investigation into the effects o f anti-neuronal glycolytic enzyme
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antibodies on neurones in vitro demonstrated increased neuronal apoptosis compared 
to controls. In addition, the enzymes are present on the membrane surface o f GAS, 
therefore representing a potential example o f molecular mimicry.
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Chapter 1. Introduction- clinical phenomenology of 
post-streptococcal neuropsychiatric disease
1.1.Aims of the introduction
The aims o f the introduction are as follows:
1. To review the clinical spectrum o f post-streptococcal neuropsychiatric 
syndromes.
2. To review the current understanding o f the pathogenesis o f post-streptococcal 
neuropsychiatric syndromes.
3. To establish clear aims for the clinical and immunological aspects o f this 
thesis.
1.2. Overview of post-infectious neurological syndromes
Human beings live on this planet in a complex environment. We are constantly under 
attack by a broad range o f infectious and toxic insults. Our immune system is 
responsible for protecting us against infection. However, occasionally the host 
immune system can over-respond to the infectious precipitant and result in immune 
attack against itself, a concept known as post-infectious autoimmunity. The term 
‘post-infectious’ infers that the infectious precipitant has induced an aberrant immune 
response in the host that then attacks its own body. Infections have been proposed in a 
broad spectrum o f immune-mediated neurological disease, and examples are 
summarised in the table below (Table l .a):
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Table La. Recognised post-infectious CNS syndromes
Proposed infectious Recognised neurological Predominant brain region
precipitant disorder involvement
Group A Streptococcus Sydenham’s chorea Basal ganglia
Varicella Zoster virus Post-varicella ataxia Cerebellum
Multiple viruses/bacteria Acute disseminated 
encephalomyelitis, optic 
neuritis, transverse 
myelitis
White matter
The mechanism by which the infectious agent interacts with the immune system and 
results in neurological disease is likely to be complex and varies from infectious agent 
to infectious agent. The neurological syndromes associated with Group A 
Streptococcus w ill be the subjects o f this thesis.
1.3. Group A streptococcus
1.3.1.Group A streptococcus and humans
Group A streptococcus (GAS) (Streptococcus pyogenes) is a common pathogen in 
humans and one o f the most versatile pathogens. It causes common infections 
(pharyngitis, impetigo, cellulitis, scarlet fever) but also severe life-threatening 
disorders (puerperal sepsis, necrotising fasciitis, myositis, toxic shock syndrome and 
CNS infections). The case fatality o f these severe complications ranges from 20-45% 
(Bisno et al., 2003). In addition, there are 2 classic non-supporative ‘autoimmune’ 
complications: acute rheumatic fever and acute post-streptococcal glomerulonephritis. 
W ithin the rheumatic fever spectrum is the CNS complication, Sydenham’s chorea.
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The other major criteria o f rheumatic fever include carditis, polyarteritis, erythema 
marginatum and subcutaneous nodules (Special writing group o f the committee on 
rheumatic fever, 1992).
The recent advances in molecular biology have improved our understanding o f GAS 
virulence. Virulence has been attributed to the ability o f an organism to impair 
phagocytosis and the ability to adhere to epithelial cells. Virulence factors o f GAS are 
listed in table 1 .b.
Table l.b. Proposed virulence factors o f  GAS bacteria (Bisno et al., 2003).
Virulence factor (known or postulated)
GAS CONSTITUENT
Anti-phagocytic •  M protein
• M-protein like (Mrp and Enn)
• Hyaluronic acid capsule
•  C5a peptidase
Adherence to epithelial cells • Lipoteichoic acid
(adhesions) •  Fibronectin binding proteins
• M protein
•  Hyaluronic acid capsule
Internalisation •  M protein
•  Protein FI
Invasion •  Hyaluronic acid capsule
•  M protein
Spread through tissues • Hyaluronidase
• Streptokinase
• SpeB (cysteine protease)
• DNases A-D
Systemic toxicity •  Streptolysin O
• Streptolysin S
• Superantigen exotoxins
Particular attention has focussed on the M protein, a polypeptide chain complexed in 
an alpha-helical coil on the cell membrane. The M protein gene (emm) has been 
sequenced, and there are more than 124 recognised M genotypes now identified (emm 
types). Certain M serotypes have been associated with particular clinical syndromes.
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Specifically, an M18 serotype was associated with an increase in rheumatic fever in 
the United States during the 1980’s. Likewise, M l and 3 have been frequently 
isolated in patients with severe invasive disease (Bisno et al., 2003).
The M protein has been the focus o f extensive investigation in GAS pathogenesis. 
Consequently, it has been incriminated in the pathogenesis o f rheumatic fever 
although the evidence for this is incomplete (discussed later).
Another important virulence factor related to resistance to phagocytosis is the ability 
o f GAS to form a capsule, which is predominantly composed o f hyaluronic acid (a 
high molecular weight polymer consisting o f N-acetylglucosamine and glucuronic 
acid). Different streptococcal strains differ in their degree o f encapsulation. The 
strains with better capsule production have a mucoid appearance on blood agar 
cultivation. The degree o f encapsulation is associated with resistance to phagocytosis, 
and the ability to induce autoimmunity. Therefore, heavily encapsulated GAS strains 
(mucoid strains) are associated with acute rheumatic fever (Pilot I, 1944; Stollerman 
GH, 1996): In one study, only 3% o f GAS strains causing uncomplicated pharyngitis 
had a mucoid morphology, whereas 42% o f isolates from rheumatic fever were 
mucoid. The continuing incidence o f rheumatic fever in Utah is partly attributed to the 
high rate o f mucoid streptococci in the community (Veasy LG et al., 2004).
W ith relevance to autoimmunity, GAS capsular hyaluronate is a poor immunogen and 
antibodies against this product are rarely found in humans (F illit HM et al., 1988). 
Encapsulation has also been proposed to promote more persistent throat colonisation 
(Wessels and Bronze, 1994).
A recent discovery is the recognition that GAS can internalise into epithelial cells 
(LaPenta D et al., 1994). The biological significance o f internalisation is unknown,
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although cellular penetration provides sanctuary from phagocyte, human antibody and 
certain antibiotics.
GAS strains also produce a range o f extracellular products, particularly enzymes. 
Streptolysin O is a haemolysin, and is toxic to a variety o f cells including leukocytes 
and heart tissue (Madden JC et al., 2001). DNases A-D are enzymes that liquefy pus 
and facilitate streptococcal spread. Hyaluronidase degrades hyaluronic acid in the host 
connective tissue. Antibodies to these extracellular products are an important part o f 
the serodiagnosis o f streptococcal infection.
GAS also produces pyrogenic exotoxins, which can act as bacterial superantigens. 
Superantigens are potent immune stimulators by causing excessive and non-specific 
T-cell activation. This results in excessive proinflammatory cytokine production, and 
an inflammatory cascade. This process is thought to be relevant to Streptococcal toxic 
shock syndrome (Bisno et al, 2003). The superantigen theory is not known to be 
relevant in rheumatic fever and related post-streptococcal neuropsychiatric disease.
1.3.2.Group A streptococcus in rheumatic fever
The most popular hypothesis regarding the pathogenesis o f rheumatic fever (RhF) is
that o f  molecular mimicry: the theory o f antigenic sim ilarity between constituents o f 
GAS and human tissue (specifically heart, synovium and neuron), and subsequent 
cross-reactivity o f the immune system between GAS and the host (discussed later). 
There are examples o f such antigenic sim ilarity in a variety o f diseases, although there 
is incomplete evidence that these processes are pathogenically significant (Rose NR,
1998).
Different strains o f GAS vary in their rheumatogenic potential, as best demonstrated 
by certain M serotypes being repeatedly associated with RhF (Bisno AL, 1980; Smoot 
JC et al., 2002). The rheumatogenic strains have distinct characteristics. Specifically,
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they are commonly encapsulated and produce mucoid colonies. Also, the M protein 
molecules in rheumatogenic strains share particular antigenic domains, which are 
capable o f mounting a strong IgG response in RhF patients (Bessen DE et al., 1990; 
Bessen DE et al., 1995).
1.4. The Basal Ganglia
1.4.1.Definitions and anatomy
The basal ganglia describe a group o f nuclei located near the middle o f the brain. The 
basal ganglia and other deep nuclei structures (including the thalami) are also referred 
to as the deep grey matter. The basal ganglia are further separated into the follow ing 
regions:
• Striatum (caudate and putamen)
•  Pallidum (lateral and medial globus pallidus)
Other nuclei closely associated with the basal ganglia or sometimes included in the 
term ‘basal ganglia’ are the subthalamus and substantia nigra.
1.4.2.Functional organisation and basal ganglia circuitry
It has been demonstrated over the last 20 years that regions o f the brain are best
considered as parts o f circuits, rather than discrete and unconnected areas (Graybiel 
AM , 1995). The basal ganglia form part o f a circuit: the basal ganglia receive 
information from the cerebral cortex that subsequently outputs this information to the 
thalamus, which subsequently feeds back to the cerebral cortex (figure 1.1).
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Figure 1.1. Simple schematic representation o f basal ganglia circuitry.
Basal ganglia
Thalamus
Cerebral cortex
However, it is apparent that this circuit is more complex and involves both direct and 
indirect pathways through the basal ganglia. Balance o f these pathways is required for 
normal movements. I f  there is imbalance in these pathways, there could be resulting 
pathological over-excitation o f the cerebral cortex (potentially resulting in 
hyperkinetic movement disorders) or over-inhibition o f the cerebral cortex 
(potentially resulting in hypokinetic movement disorders). The primary 
neurotransmitters involved in this process are glutamate (excitatory) and gamma- 
aminobutyric acid (GABA- inhibitory) (Graybiel AM , 1995). A more accurate model 
o f this circuitry is now presented. The direct (excitatory) and indirect (inhibitory) 
pathways are presented in figure 1.2 and 1.3 respectively. Figure 1.4 presents the 
combined pathways.
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Figure 1.2. Direct pathway of basal ganglia circuitry. Activation o f the direct 
pathway results in inhibition o f the internal pallidum, consequent reduced inhibition 
o f the thalamus, with consequent increased activation o f  the cerebral cortex (resulting 
in overall excitation).
Cerebral cortex
Thalamus
Internal pallidum 
(medial globus pallidus)
Striatum
D1 Receptor
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Figure 1.3. Indirect pathway of basal nannlia circuitry. Activation o f  the indirect 
pathway results in inhibition o f  the external pallidum (lateral GP), consequent 
reduced inhibition o f the subthalamus, consequent increased excitation o f  internal 
pallidum, with consequent increased inhibition o f  the thalamus, with consequent 
reduced excitation o f the cerebral cortex (inhibition).
Subthalamus
Cerebral cortex
Thalamus
Internal pallidum 
(medial globus pallidus)
External pallidum 
(lateral globus pallidus)
D2 Receptor
Striatum
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Figure 1.4. Direct and indirect pathways o f basal ganglia circuitry, resulting (under 
non-pathological states) in a balance between excitation and inhibition (Graybiel 
AM, 2001).
Subthalamus
Cerebral cortex
Thalamus
Internal pallidum 
(medial globus pallidus)
External pallidum 
(lateral globus pallidus)
Striatum 
D2 Receptor D1 Receptor
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1.5.Epidemiology and precipitants of Sydenham's chorea
1.5.1.Historical perspective and Thomas Sydenham
Thomas Sydenham ( l 624-1689) was a British physician referred to as the British
Hippocrates. During the middle ages, a curious disease ‘ St. Vitus chorea’ or ‘chorea 
Sancti V it i ’ was described which was thought to be a hysterical response to religious 
superstition. Thomas Sydenham recognised a separate disorder that affected children. 
Confusingly, his original description in his last book Schedula monitoria de novae 
febris ingressa (Chapter X V I) was named ‘On St. Vitus dance’ . He recognised the 
disorder as separate to the hysterical dancing, however used the terminology ‘chorea’ 
and ‘St Vitus dance’ (Sydenham T, 1848). Subsequently, to aid differentiation and in 
respect to Sydenham, physicians preferred to use the term ‘Sydenham’s chorea’ . 
Sydenham’s original description was remarkably accurate. He described a childhood 
disorder ( ‘ from the tenth year to the time o f puberty’ ) presenting with a constellation 
o f involuntary purposeless, rapid movements o f the limbs, in addition to muscular 
weakness and emotional lability (Sydenham T, 1848). Sydenham initia lly thought 
chorea was due to ‘ some humour falling on the nerves’ or ‘such irritation causes the 
spasm’ and suggested purging and bleeding o f the victim to restore strength.
However, Sydenham did not note the association with rheumatic fever (RhF). Indeed 
it was not until the 19th Century when the association with RhF was made. Etienne 
Michel Bouteille was the first to note an association between Sydenham’s chorea and 
rheumatism in 1810. He noted that four o f his patients had arthritic rheumatism before 
the onset o f chorea, and one o f his patients had chorea before rheumatism (Bouteille 
EM, 1810). In 1831, Sydenham’s chorea was classified under the heading o f 
rheumatism by Richard Bright (Bright R, 1831). After this, Germain See noted the
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association, stating: ‘chorea is the result o f a rheumatic diathesis.' and ‘ for every two 
rheumatic children there is at least one who is choreic' (See G, 1850). The association 
o f chorea with carditis and rheumatism was made by Henri Roger in 1866. He thought 
they shared a common source and suggested a condition o f the blood or blood vessels 
was the cause, possibly secondary to thromboses and embolism (Straton CR, 1885; 
Greenfield JG and Wolfsohn JM, 1922). Straton was the first to associate chorea with 
infection and therefore a communicable disease in 1885 (Straton SC, 1885). A 
bacterial coccus was considered increasingly important in the late 19th century and 
Osier noted that ‘Scarlet fever with arthritis may be a direct antecedent’ (Osier W, 
1894). In 1889, Westphal, Wassermann and M alkoff (Wesphal P et al., 1899) isolated 
a diplococcus from the pericardium and CSF o f a child who died from chorea (with 
rheumatic pericarditis). Subsequently, others isolated an infectious coccus. Then in 
1901-3, Poynton, Pane and Holmes produced an animal model o f disease by injecting 
the diplococcus isolated from RhF patients into rabbits and producing a chorea-like 
disease, carditis and arthritis. They called it Diplococcus rheumaticus (Poynton F and 
Paine A, 1913).
By the mid 20th Century, chorea was thought to be part o f an immuno-allergic 
response between the streptococcal toxin and host, with vulnerability o f the synovial 
membrane, heart or nervous tissue.
1.5.2.Epidemiology of Sydenham’s chorea
Most o f the epidemiological features o f Sydenham’s chorea can be gleaned from large 
case series published towards the end o f the I9 lh century.
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1.5.2.1.Sex
All o f the literature agrees that females are more likely to develop Sydenham’s 
chorea. Charles West reported his experience at Great Ormond Street Hospital, 
London in 300 females to 122 males (West C, 1865). Mackenzie similarly reported 
322 females to 114 males (Mackenzie S, 1887) (Figure 1.5).
Figure 1.5. Age and sex distribution o f Mackenzie's SC data (Mackenzie S, 1887).
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This sex differential was manifest throughout all ages (Figure 1.5.). In US, Osier 
reported (in his Philadelphia series) 390 females to 161 males and reported that the 
predominance o f females was much greater after puberty than in childhood (Osier W,
1894). West attributed the female vulnerability to a ‘special excitability o f the nervous 
tissue’ in females. In the 20th century, Nausieda also reported a female predominance 
that was most manifest between the ages o f 11-17 years (Table I.e.) (Nausieda PA, 
1980).
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Table I.e. Percentage o f girls and boys with SC according to age (Nausieda PA, 
1980).
Age Total 3-10 years 11-17 years
Girls 57% 51% 65%
Boys 43% 49% 35%
1.5.2.2. Age
Most o f the early series agree that Sydenham’s chorea predominantly affects school 
age children. However this is not exclusively true as very young children and adults 
were also affected. Mackenzie found that 93% o f cases occurred between 6-20 years 
o f age, and 77% between 6-15 years (Mackenzie S, 1887) (table l.d).
Table l.d. Age ofpatients expressed as percentage o f  total (Mackenzie S, 1887).
Age
(yrs)
0-5 6-10 11-15 16-20 21-25 26-30 31-35 36-40 >40
% 1.4 34 43 16 2 0.5 0.5 0.5 1.4
Very similar age distribution was described by West (GOSH), Osier (USA) and 
Nausieda (20,h century cohort) with a peak around 9-10 years. However, Mackenzie 
described a number o f cases presenting with first attacks aged in the 60’s and 70’s 
(Mackenzie S, 1887). The association o f these cases with a carditis and the self-
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limiting disease course makes the diagnosis o f SC likely in these old-onset cases, 
rather than an undiagnosed hereditary or degenerative cause o f chorea.
1.5.2.3.Seasonality
Before an association with streptococcal infection was made a number o f observers 
had noted the association o f SC with a seasonal distribution. A summary o f Lewis’s 
data reviewed by Osier is made in Figure 1.6 (Osier W, 1894). As can be seen more 
cases present during the colder months.
Figure 1.6. Seasonality o f SC reported by Lewis (data from Jun-Oct are extrapolated 
from text). Percentage o f cases plotted against months o f year (Osier W, 1894).
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1.5.2.4.Y ear fluctuations
It has been noted for over a century that the cases o f SC fluctuate every few years. A 
review o f the Great Ormond Street hospital cases by Davide Martino demonstrated 
this fluctuation that approximately had a 3-4 yearly pattern (Figure 1.7) (Martino D, 
with permission). As seen in Figure 1.7 not only does the number o f RF patients 
fluctuate on a yearly basis, but the proportion o f RF patients that get SC also 
fluctuates yearly.
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Figure 1.7. Early fluctuations in SC cases seen at Great Ormond Street Hospital 
between 1S52 and 1931 (Martino D, with permission). SC cases unbroken line, 
rheumatic fever cases broken line.
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Likewise, Nausieda (Chicago) showed fluctuations in cases between 1951-1968, 
followed by a dramatic decline in cases thereafter (Nausieda PA, 1980). Another 
interesting finding is the fluctuant association o f the number o f rheumatic fever cases 
complicated by SC (Goldenberg J et al., 1992). The number o f RF cases complicated 
by chorea fluctuated on a yearly basis. These findings may be due to changes in the 
rheumatogenic strains in the community.
1.5.2.5. Socio-economic class and race.
t hReports from the 19 Century noted that, although children from all grades o f society 
were susceptible to SC, children from lower classes were most likely to get the 
disease. Mackenzie reported that 70.5% o f his cases were from the lower classes, data 
supported by Osier (USA) (although no epidemiological data was available for
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comparison) (Mackenzie S, 1887; Osier W, 1894). In the 20th Century, the 
vulnerability o f the lower classes was attributed to overcrowded homes (Coburn AF, 
1931). Studies o f army recruits showed that the incidence o f positive streptococcal 
pharyngitis was inversely proportional to the distance between beds in army barracks 
(Wannamker LW, 1953), and subsequent antibiotic use in these populations reduced 
the incidence o f rheumatic fever (Frank PF et al., 1965 ).
Although initial reports by Osier in the 20th Century proposed that black and Indian 
races were less likely to develop SC, the clear endemic status o f SC and rheumatic 
fever around the World (South America, Africa, Asia, Aborigine populations o f 
Australia) makes this statement less tenable. It appears all races are vulnerable to SC, 
and other criteria (overcrowding, antibiotic use, genetic vulnerability) are more 
important risk factors.
1.5.3.Precipitants
Early reports throughout the 19‘ Century described a psychological fright was the 
most likely precipitant o f chorea. Indeed ‘ fright chorea’ was considered the cause in 
~ l 5% o f cases such as ‘over work at school’ or ‘events at home’ (Osier W, 1894;
West C, 1865). Also when multiple cases occurred on hospital wards at the same 
time, these cases were often attributed to hysteria (Osier W, 1894). Other proposed 
precipitants included trauma and blows to the head, and even eye-strain secondary to 
hypermetropism or myopia (Osier W, 1894). However, by the 1880’s reports were 
noting the association with ‘erosions o f the mucous membranes o f the nose and throat 
(Straton CR, 1885). Straton postulated that these erosions could afford portals o f entry 
for micro-organisms which might be the indirect cause o f chorea. Thereafter the
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association with tonsillitis became more apparent. In 1889, Cheadle reported that 
tonsillitis ‘ushered in ' acute rheumatism in -24%  o f cases, and was often very closely 
associated with the onset o f arthritis (Cheadle WB, 1889). Likewise, Scarlet fever was 
an antecedent illness in 129 o f 432 cases by Mackenzie (Mackenzie S, 1887). Cheadle 
also noted the association o f chorea with scarlet fever, and stated by contrast ‘we 
never see a measles chorea, or whooping cough chorea, or mumps chorea (Cheadle 
WB, 1889). Cheadle’s report also highlighted the clear association o f preceding 
rheumatic arthritis. Shortly after these reports, Group A streptococcus (GAS) was 
directly linked to SC and rheumatic fever pathogenesis. As the association o f 
rheumatic fever/SC with GAS infection became manifest in the 20th Century, few 
investigators have subsequently reported the antecedent illnesses in SC.
1.6.Clinical spectrum of post-streptococcal neuropsychiatric 
syndromes
1.6.1.Movement disorders- Sydenham’s chorea
The best described o f all movement disorders after GAS infection remains chorea.
Chorea is Greek for dance, and Sydenham described a constellation o f involuntary, 
purposeless rapid movements o f the limbs. The early characteristics o f SC described 
by West included the child being ‘awkward and fidgety’ , followed by stumbling 
whilst walking and involvement o f the face with the ‘strangest grimaces’ (West C,
1865). Like most extrapyramidal movement disorders, the movements are 
exacerbated by excitement, and cease during sleep. Extra movements o f the hands 
associated with hypotonia results in the ‘m ilkmaid’s grip’ (inability to sustain the grip 
resulting in intermittent squeezing contractions). Involvement o f the tongue results in 
hurried and unsustained tongue movements, with frequently affected oropharyngeal
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involvement and consequent stammering, impaired swallowing and dysarthria (West 
C, 1865).
The chorea is usually generalised: Mackenzie reported that in only 30 o f 429 cases 
were the movements entirely one sided or predominantly one sided (hemichorea) 
(Mackenzie S, 1887). Other more recent reports describe hemichorea in 19% 
(Nausieda PA, 1980). Other features include hypometric saccades, and occasionally 
oculogyric crises (Cardoso F et al., 1997). Other co-morbid movement disorders in 
SC in addition to chorea have been described. Indeed myoclonus and tics have been 
described since the 19th Century (Creak M and Guttman E, 1935; Osier W, 1894). 
Recently tics have been described in SC, sometimes rarely (Cardoso F et al., 1997) 
and sometimes very frequently (Mercadante M T et al., 2000). Mercadante described 
motor tics in 73% o f a Brazilian cohort o f SC (n=22). This has particular relevance to 
the later discussion on the PANDAS hypothesis (Mercadante MT et al., 2000).
1.6.2.0ther movement disorders other than chorea- the PANDAS 
hypothesis
Basal ganglia disorders rarely conform to one extrapyramidal phenotype alone. For 
example, in Huntington’s disease, tics, dystonia and Parkinsonism may occur, 
although chorea remains the most characteristic phenomenon (Jankovic J et al., 1995; 
van D ijk JG et al., 1985). As mentioned in the previous section, myoclonus has been 
described in SC, and differentiating myoclonus from chorea may sometimes be 
d ifficu lt. A recent report with videotape described a case o f myoclonus after 
streptococcal infection (DiFazio MP et al., 1998). However, most recent interest has 
focussed on the description o f motor tics after streptococcal infections. A number o f 
groups had previously described isolated cases o f tics and Tourette’s syndrome after
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streptococcal infections (Creak M and Guttman E, 1935, Kerbeshian J et al., 1990; 
Kiessling LS et al., 1993). Then in the 1980's, an outbreak o f Group A streptococcal 
tonsillitis in Rhode Island was associated with a 10-fold increase in the incidence o f 
motor tics (without chorea): the concept o f post-streptococcal tics was bom (Kiessling 
LS et al., 1993). A separate group o f children were followed in the late 1980’s and 
1990’s with neuropsychiatric disorders (defined by tics and obsessive-compulsive 
disorder) who had exacerbations following streptococcal infections. They had a 
relatively unique course because o f the abrupt onset o f symptoms or dramatic 
exacerbations that ‘came on overnight’ (Allen AJ et al., 1995; Swedo SE et al., 1998; 
Leonard HL and Swedo SE, 2001). The important and defining nature o f these 
patients was the temporal association between exacerbations and further streptococcal 
infections. It was thought that the children would exhibit tics or OCD i f  the ‘dose’ o f 
the aetiological agent were insufficient to cause frank chorea (Swedo SE, 1994). Sue 
Swedo from National Institute o f Mental Health (USA) coined the term PANDAS 
(Pediatric autoimmune neuropsychiatric disorders associated with streptococcal 
infections). This group established working criteria for a diagnosis o f PANDAS as 
follows (Swedo SE et al., 98):
1. Presence o f OCD and/ or tics (DSM -IV)
2. Paediatric onset (pre-pubertal)
3. Episodic course with abrupt onset and dramatic exacerbations (frequently 
explosive)
4. Association with GAS infection (either throat culture or elevated anti-GAS 
antibodies). The authors noted that although there may be significant lag 
between GAS infection and the onset o f the 1st episode, the lag o f days 
between infection and subsequent relapses or exacerbations is much shorter,
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often just days. Swedo noted that when GAS serology is used, not only must 
seropositivity be associated with symptom exacerbations, but also that 
seronegativity (or falling titres) is associated with symptom remission 
(Swedo SE et al., 1998).
5. Association with neurological abnormalities. They defined these as
adventitious movements or motoric hyperactivity. They also used the term 
‘choreiform movements’ which is a confusing terminology but basically 
means chorea-like but not frank chorea.
An important criteria was the absence o f systemic features (carditis, arthritis). In 
1998, Swedo et al. published their findings o f 50 children conforming to the 
PANDAS criteria (Swedo SE et al., 1998). O f these, 80% had motor tics and there 
was a male:female predominance o f 2.6:1. Both the tics and choreiform movements 
waxed and waned in severity over time, and exacerbations were temporally linked to 
streptococcal infections. The children had significant associated co-morbid 
psychiatric disturbance that w ill be described in detail later. The defining GAS 
infection was present at symptom onset in 42% o f the 50 children. Every child had at 
least one symptom exacerbation that was preceded (w ithin 6 weeks) by a documented 
GAS infection. In total there were 144 exacerbations in 50 children where the 
association with GAS infection was known. 23% o f these exacerbations were not 
associated with any sign o f GAS infection in the previous month. The possibility that 
viral or other infections may be causing exacerbations was proposed (Swedo SE et al., 
1998).
Clearly there are a number o f weaknesses with the current PANDAS criteria 
including (Kurlan R, 2004):
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•  GAS infection is extremely common in paediatric populations and may be 
incidental (particularly in winter) (Kaplan EL and Gerber MA, 1998)
•  Tic disorders tend to wax and wane naturally. Sudden deteriorations are also 
possible: 53% o f unselected tic patients had a history o f sudden or explosive 
onset or worsening o f tic symptoms (Goetz CG et al., 1992).
• Most tics have onset pre-pubertally. Therefore this is unlikely to be a 
discriminating marker o f PANDAS.
• The terminology o f choreiform movements is ambiguous and some 
commentators assumed that these cases were just Sydenham’s chorea 
(Kurlan R, 2004). Swedo defends this by defining choreiform movements as 
fine piano playing movements that are absent at rest and only elicited in 
stressed postures, whereas choreatic movements are present continuously and 
associated with failure to sustain tetanic contractures (m ilk maid’s grip) and 
muscle weakness (Swedo SE et al., 2004).
•  Why do PANDAS patients not have systemic involvement (arthritis, carditis) 
i f  the immune mechanism is similar to SC/rheumatic fever? This important 
question has not been adequately examined.
• The latency between GAS infection and SC onset is often 3-5 months. A 
similar latency in PANDAS would make a temporal association between 
GAS infection and neuropsychiatric disease onset difficult.
•  Swedo herself warned o f the pitfalls o f using a single anti-streptococcal 
serodiagnosis at the time o f tic exacerbations (Swedo SE et al., 1998).
Instead longitudinal laboratory data is required with rising titres associated 
with symptom exacerbation, and falling titres on symptom remission.
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Likewise culture o f GAS may occur in asymptomatic carriers and could lead 
to misdiagnosis.
Despite these criticisms, the concept o f PANDAS has generated broad interest 
amongst physicians and lay people alike.
1.6.3.Psychiatric disorders 
1.6.3.1.Sydenhams’ chorea
The high incidence o f emotional factors in Sydenham’s chorea has been recognised 
for over a century, and was initia lly referred to as a ‘choreic temperament’ . However, 
further evaluation o f the psychiatric sequelae o f Sydenham’s chorea demonstrated that 
diagnosable emotional and disruptive disorders were common accompaniments. A 
follow-up study showed high prevalence o f psychiatric syndromes in 75% o f patients 
(Freeman JM et al., 1965). Specifically, the study followed up patients with 
unequivocal SC (n=40) after a mean o f 29 years (22-34 years) and compared the 
follow-up psychiatric morbidity with a control group o f patients from the same era 
with glomerulonephritis, osteomyelitis and rheumatic fever (n=30). A summary o f the 
findings is presented in table 1 .e. As can be seen, there was a significantly higher rate 
o f psychiatric problems in the SC patients compared to controls.
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Table I.e. Psychiatric disorders in SC and controls (Freeman). Definitions by 
Freeman (Freeman JM et al., 1965).
Psychiatric disturbance SC (n=40) Controls (n=30)
No psychiatric disturbance 7/40(17% ) 22/30 (73%)
Personality disorder (passive dependency, passive 
aggressive, compulsive, inadequate personality, 
sexual deviant, others with marked depressive, 
anxiety or hysterical features)
26/40 (65%) 8/30 (27%)
Definite psychoneurosis (phobia, obsessive- 
compulsive disorder, conversion, anxiety)
7/40(17%) 0/30 (0%)
More importantly, this study demonstrated that the behavioural consequences often 
remained for decades after the resolution o f childhood chorea (Freeman JM et al., 
1965). More recent examination o f SC cohorts revealed a high incidence o f obsessive- 
compulsive behaviours (Swedo SE et al., 1989; Asbahr FR et al., 1998). Swedo 
compared obsessive-compulsive symptoms (OCS -using the Leyton Inventory) in SC 
patients (n=23) compared to rheumatic fever without chorea (n=14). The SC patients 
had significantly higher obsessionality scoring than the rheumatic fever patients and 
higher interference scores (impairment). Three o f the SC patients (13%) had clinically 
diagnosable obsessive-compulsive disorder. Notably, the SC patients also had 
significantly higher depression and anxiety scores than the rheumatic fever patients 
(Swedo SE et al., 1989). A separate study by Swedo (Swedo SE et al., 1993) 
examined the psychological features o f 11 children with acute SC. She described an
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abrupt onset o f severe nightmares, decreased attention span and emotional lability 
(described as ‘moody, clingy, crying and tantrums’ ). During their illness, nine o f 
11(82%) met diagnostic criteria for OCD, although most symptoms resolved at 
follow-up after resolution o f the chorea. Although not all studies have documented a 
high rate o f OCS in acute SC (Faustino PC et al., 2003), a subsequent study further 
established a link between SC and obsessive-compulsive symptoms (OCS) (Asbahr 
FR et al., 1998). This study examined the prevalence o f OCS during the acute phase 
o f SC (n=30) compared with rheumatic fever without chorea (n=20). 70% o f the SC 
patients had OCS peaking during the 2nd month o f whom 16.7% met criteria for OCD 
at that time (Asbahr FR et al., 1998). The OCS presented before the chorea in 28.6%, 
although waned and disappeared in the majority. By contrast, 0% o f the rheumatic 
fever patients without chorea had OCS at any time. Furthermore, the incidence o f 
OCD appeared to be increasingly common in children who had relapses o f SC 
(Asbahr FR et al., 1999). Subsequent analysis o f cohorts o f SC has demonstrated that 
psychiatric comorbidity is not limited to OCD, but includes other emotional disorders 
such as generalised anxiety, separation anxiety and major depression (Mercadante MT 
et al., 2000). The prevalence o f psychiatric diseases reported by Mercadante is 
presented in table 1 .f.
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Table l . f  Psychiatric disorders in SC and controls reported by Mercadante 
(Mercadante MTet  al., 2000).
Psychiatric disorder Control group 
(various medical 
problems) (n=20)
Rheumatic fever 
(n=20)
SC (n=22)
OCD 0% 10% 14%
OCS 0% 25% 32%
ADHD (combined) 0% 0% 46% *
Major depression 0% 0% 41%*
Separation anxiety 10% 5% 14%
Generalised anxiety 0% 5% 9%
* SIGNIFICANT DIFFERENCE
OCD: obsessive-compulsive disorder 
OCS: obsessive-compulsive symptoms 
ADHD: attention deficit hyperactivity disorder
In addition, this group showed that the presence or absence o f preceding ADHD 
symptoms was a predictor for the risk o f developing SC. I f  a child had an antecedent 
history o f ADHD (combined type) they had a significantly higher risk o f developing 
SC (85%) than the rheumatic fever controls (36%) (Mercadante MT et al., 2000). 
Swedo (Swedo SE et al., 1993) also described a broader psychiatric phenotype in SC 
with separation anxiety, oppositional disorders and ADHD all over-expressed in her 
11 SC patients. Likewise Faustino found attentional problems and aggressive 
behaviour in their SC patients (n=19) (Faustino PC et al., 2003).
There had been a number o f reports o f schizophrenia as an outcome o f SC 
(Wertheimer N. 1961), although recent literature has not repeated this observation 
(Swedo SE et al, 1989, Swedo SE et al., 1993, Swedo SE et al., 1998).
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1.6.3.2.PANDAS
The psychiatric morbidity o f PANDAS is similar to ( i f  not identical to) Sydenham’s 
chorea. In the acute stages, there is typically a rapid alteration in behaviours and 
emotional lability (Swedo et al., 1998). Indeed Swedo pointed out the explosive onset 
and dramatic deteriorations should be required for diagnosis. PANDAS was defined 
as post-streptococcal emergence o f OCD and/or tics. Indeed OCD and/or tics were 
required for a diagnosis o f PANDAS, therefore it is not possible to directly compare 
the incidence o f OCD in PANDAS cohorts with SC cohorts. There was a broad range 
o f obsessions (contamination, harm, hoarding, somatic, religious) and compulsions 
(washing, checking, repeating, counting, ordering, hoarding) as seen in idiopathic 
OCD. However analysis o f 50 patients with PANDAS demonstrated a high incidence 
o f other emotional disorders (major depression 36%, separation anxiety 20%), 
conduct disorders (oppositional defiant disorder 40%) and attention deficit 
hyperactivity disorder (40%) (Swedo et al., 1998). By contrast mania, psychosis and 
somatization disorders were not present. In summary, a broad range o f emotional, 
attentional and conduct disorders are seen in both SC and PANDAS, although the 
classic psychiatric syndrome o f both remains OCD.
1.6.4. Other CNS features
1.6.4.1. Sydenham’s chorea
The clinical outcomes would appear to be relatively specific to extrapyramidal 
movement and psychiatric disorders. Dysarthria and hypotonia are common 
accompaniments, and would be considered characteristic o f SC. Indeed dysarthria 
occurs in 15-100% o f series and is considered to be extrapyramidal in origin 
(Nausieda PA et al., 1980, Swedo SE et al., 1993, Cardoso F et al., 1997). The
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hypotonia is often mild, although occasionally it can be profound with apparent 
paralysis, sometimes known as chorea paralytic or chorea mollis (Marques-Dias MJ et 
al., 1997). A more disseminated encephalomyelitis with confusion, disorientation and 
rarely delerium is reported in 10% o f cases (Nausieda PA et al., 1980). Occasional 
reports o f  acute disseminated encephalomyelitis have been reported after 
streptococcal infection (Jorens PG et al., 2000). Seizures are rarely reported 0.4-0.5% 
(Nausieda PA et al., 1980; Mackenzie S, 1887), likewise cranial nerve palsy in 0.4% 
only (Mackenzie S, 1887). Cerebellar or sensory abnormalities, mutism, dementia and 
visual impairments are rarely or never seen (Cardoso F et al., 1997).
Neuropsychology has not revealed any significant cognitive disturbance although one 
study highlighted some equivocal impairment o f frontal lobe functioning (Swedo SE 
et al., 1993).
1.6.4.1. PANDAS
In PANDAS, other features described by Swedo included enuresis (12%), encoporesis 
(10%) and deterioration in math skills (26%) (Swedo SE et al., 1998).
1.7. Clinical outcome
The standard medical texts describe that SC is a benign monophasic disorder that self- 
terminates in the majority. Review o f the literature finds that this statement is mainly 
true. Mackenzie found that the usual duration o f attacks is 2-3 months, a finding 
confirmed by Nausieda in 1980 (Figure l . 8) (Mackenzie S, 1887; Nausieda PA et al.,
1980). However a recent study o f SC from Brazil found that SC persisted longer than 
2 years in half o f patients (n=32) (Cardoso F et al., 1999). In this Brazilian report, 
some patients were not aware o f the chorea (Cardoso F et al., 1999).
52
53
Figure 1.8. Nausieda data on the duration o f chorea (Nausieda PA et al., 1980).
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When present, relapses o f SC are usually isolated and occur most commonly in the 
first year after onset, or during pregnancy (chorea gravidarum) (Mackenzie S, 1887). 
The fact that pregnancy and the oral contraceptive pill can precipitate relapses 
suggests a role o f oestrogen in SC expression (Cardoso F, 2002). It should be noted 
that persistent psychiatric sequealae are common, even after the apparent resolution o f 
chorea as previously discussed (Freeman JM et al., 1965).
SC is rarely fatal, in one large report (n=439) from the late 19th Century, 2% o f cases 
were fatal, almost all attributable to co-existing heart disease (Mackenzie S, 1887).
By definition, PANDAS has a relapsing remitting course with temporal association 
after further infections (Swedo SE et al., 1998). Although streptococcal infections 
appear to be the initiators o f disease, other infective triggers may be responsible for 
relapses (Allen AJ et al., 1995; Berrios X et al., 1985).
Although there are few longitudinal studies examining the natural history o f disease, 
it is likely that the outcome o f both SC and PANDAS is variable, varying from
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monophasic self-lim iting disease, to a persistent relapsing remitting course over many 
decades.
1.8.Systemic features in post-streptococcal CNS disease 
1.8.1.Sydenham’s chorea
SC is by definition part o f rheumatic fever (RhF), and other systemic features are 
common. Major criteria o f RhF (other than SC) are carditis, arthritis, subcutaneous 
nodules and erythema marginatum (Jones criteria). SC occurs in isolation in 53- 74% 
o f SC patients (Faustino PC et al., 2003; Goldenberg J et al., 1992). In the large 
Brazilian cohort o f 187 SC patients, 99 had isolated SC whereas 88 had associated 
symptoms (carditis and arthritis in n=32, arthritis alone in n=30, carditis alone n=26) 
(Goldenberg J et al., 1992). Notably this group demonstrated an elevated ASOT more 
commonly in the SC patients with systemic features, than those with isolated SC (83 
v. 43% p<0.01). Also a positive throat culture for Group A streptococcus was 
uncommon in the isolated SC group ( l l% ) suggesting that the isolated SC group had 
a longer latency after infection, by which time the host had frequently cleared the 
organism.
1.8.2.PANDAS
By definition, PANDAS patients should not have any evidence o f rheumatic fever 
(Swedo SE et al., 1998). However this definition was produced to improve diagnostic 
differentiation o f PANDAS from SC, rather than a proven pathological distinction. 
One study to address this issue has been published only in abstract form: a group 
performed echocardiography in PANDAS patients (n=36). They found a high 
incidence o f asymptomatic mild or minimal mitral regurgitation (the commonest 
cardiac lesion seen in rheumatic fever) in 47% o f PANDAS patients, persisting at l
54
55
year (Cardona F et al., 2003). This suggests that asymptomatic systemic disease may 
occur in PANDAS, and indicates that PANDAS may be associated with rheumatic 
fever.
1.9. Genetic predisposition 
1.9.1.Sydenham’s chorea
A high incidence o f ‘nervous affections’ has been reported in families o f patients with 
SC for over a century. Indeed Mackenzie reported that 46% o f SC family members 
had a nervous affection o f some kind (Mackenzie S, 1887) (particularly the parents or 
siblings). However, the definition o f nervous affections was very broad and 
encompassing, including idiocy, epilepsy, drunkenness and paralysis. Notably 
nervousness and excitability occurred most commonly in family members (Mackenzie 
S, 1887). Osier reported chorea in the fam ily members o f 80 o f 554 families (14%) 
(Osier W, 1894). Likewise, a family history o f SC occurred in 13% in Nausieda’s 
series (n=162), and 26-36% had a fam ily history o f rheumatic fever (Aron AM  et al., 
1965; Nausieda PA et al., 1980).
1.9.2.PANDAS
In PANDAS, the incidence o f rheumatic fever has not been evaluated, and therefore 
comparisons with the SC data cannot be made. However, one study examined the 
incidence o f movement and psychiatric disorders in parents and siblings o f PANDAS 
patients: 39% had at least one first-degree relative with a history o f motor or vocal 
tics, and 26% had at least one first degree relative with OCD (Lougee L et al., 2000).
In summary, there is a positive family history o f psychiatric, movement and rheumatic 
fever in a significant proportion o f patients with SC and PANDAS. This supports the
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hypothesis that post-streptococcal C'NS disorders are multifactorial involving a 
genetic predisposition plus exposure to streptococcal infections.
1.10. Other 'post-infectious9 movement disorders
1.10.1.Encephalitis lethargica
‘ Lethargic encephalitis’ has been described for many centuries by physicians such as 
Hippocrates and Sydenham. The most recent epidemic ravaged the World between 
19 16 -1927, and was named ‘ Encephalitis lethargica’-EL by the clinician most 
associated with this disorder- von Economo (von Economo C, 1931). The classic 
phenotype in EL was Parkinsonism, although dystonia, tics and chorea were also 
common and co-existed. The disorder was often preceded by pharyngitis. In addition 
to the extrapyramidal movement disorders, von Economo noted a sleep disorder, 
lethargy and neuropsychiatric disorders were common in the survivors (e.g. catatonia, 
obsessive-compulsive disorder, depression and mutism). Additional common features 
included oculogyric crises, ocular features (ophthalmoplegia and ptosis) and central 
cardiorespiratory features (particularly hiccough). Von Economo felt that the clinical 
phenomenology localised the disease to the basal ganglia and brainstem. Pathological 
findings, like the clinical characteristics, demonstrated an encephalitis with particular 
involvement o f the basal ganglia and midbrain structures.
Because EL was epidemic during the same time period as the 19 18 influenza 
pandemic, an association between the two diseases has been proposed (Ravenholt and 
Foege, 1982). However, von Economo and other workers during the EL epidemic 
thought that influenza was not the cause. In addition, patients with EL rarely had 
influenza before neurological onset; in one early report o f 76 EL cases, only 4 had 
influenza in the 6 months preceding onset (Stallybrass CO, 1923).
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Recent discovery and identification o f the 1918 influenza virus genome by 
Taubenberger (Taubenberger JK et a/., 1997) allowed this group the opportunity to 
examine archived EL brain specimens for 1918 influenza virus RNA. They failed to 
find influenza RNA in EL brains, and furthermore determined that the 1918 influenza 
virus was genetically incapable o f neurotropic disease and only capable o f 
reproduction in the respiratory tree. The authors concluded that EL was unlikely to 
have been directly due the 1918 influenza virus (McCall et al., 2001). A further group 
also failed to demonstrate the 1918 influenza virus in archived EL brains (Lo KC et 
al., 2003).
There have been no further epidemics o f EL since the 1920’s although sporadic cases 
have continued to be reported (Rail et al., 1981; Howard and Lees, 1987; Blunt et al., 
1997; Kiley and Esiri, 2001). Contemporary reports have consistently failed to 
demonstrate evidence o f neurotropic viral particles, and the cause o f EL remains 
unknown. However, a common finding on CSF examination includes the presence o f 
IgG oligoclonal bands (Williams et a/., 1979; Howard and Lees, 1987; Kiley and Esiri, 
2001). In addition, some recent cases have been successfully treated with steroids 
(Blunt et al., 1997). These features have lead investigators to propose that this 
phenotype may be a post-infectious immune-mediated CNS disorder. Interestingly, 
during the epidemic attention had focused on streptococcus as a possible etiological 
agent. A number o f investigators had detected streptococcus in the throats o f patients 
suffering from EL (Wilson, 1918; Harris, 1918; von Economo, 1931). In addition, 
they were able to induce an encephalitis lethargica-like illness in dogs after 
vaccination with streptococcal organisms (von Economo, 1931). However, as gram 
positive organisms were never isolated from the brain, the authors concluded that it
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was unlikely to have been the primary etiological agent. The description o f an EL 
phenotype after streptococcal infection is reported in this thesis.
1.10.2.Tourette syndrome and obsessive-compulsive disorder
Tic disorders, Tourette’s syndrome and obsessive-compulsive disorder are considered
to be variable phenotypic expressions o f the same brain disorder. The 
pathophysiology is thought to be secondary to dysfunction o f cortico-striatal circuits, 
although the exact pathology is unknown (Stein DJ, 2003). It is likely that a variety o f 
processes can disrupt this circuit and result in these clinical phenotypes. The 
recognition o f PANDAS has lead to speculation that subgroups o f ‘ idiopathic’ tic 
disorders, Tourette’s syndrome (TS) and OCD have a (post-streptococcal) immune 
mediated pathophysiology. Using streptococcal serology, a number o f researchers 
have attempted to investigate a possible association o f streptococcal infection w ith tic 
disorders and TS. The studies have generally measured streptococcal serology in 
cohorts and compared them to control groups. The studies are reviewed in table 1 .h.
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Table l.h. Studies investigating streptococcal serology in Tourette’s syndrome (TS) cohorts compared to controls.
Reference Cohort (number o f patients) Control group (number o f controls) Comment
Singer HS et al., 1998 Tourette (n=41) Hospital and community tic-free No difference in ASOT and anti-
(US)* (n=39) DNAse B titres.
Kiessling LS et al., Movement disorder (MD), tics, TS, ADHD, learning difficulties but no MD cohort significantly elevated
1993 (US) choreiform (n=24) movement disorder (n=26) ASOT and antiDNAse B.
Muller N et al., 2000 Child TS (n=13) Healthy children (n=12) ASOT and anti-DNAse B
(Germany) Adult TS (n=23) Healthy adult (n=24) 
Adult schizophrenia (n=l 7)
elevated in TS.
Muller N et al., 2001 
(Germany)
Adult TS (n=25) Adult healthy (n=25) M 12 and M 19 streptococcal 
antibodies elevated in TS.
Cardona F et al., 2001 
(Italy)
Childhood tics (n=150) Phenylketonuria and epilepsy, no tics 
(n=150)
Elevated ASOT in tic cohort.
Church AJ et al., 2003 Childhood TS (n=56) Child streptococcal infection (n=40) Significantly elevated ASOT in
(UK) Adult TS (n=44) Child neurology (n=50) 
Adult healthy (n=50) 
Adult neurology (n=50)
child and adult TS cohorts.
Loiselle CR et al., 2003 
(US) *
Child TS (n=41) Healthy children (n=38) No difference in whole cohort. 
Significantly higher ASOT in TS 
with comorbid ADHD.
Morshed SA et al., 2001 TS (n=81) SC (n=27) ASOT significantly higher in TS
(US) Autoimmune disorders (n=52) 
Normal (n=67)
and SC compared to controls.
Singer HS et al., 1999 
(US)*
TS (n=41) Controls no tics (n=39) No difference in ASOT and anti- 
DNAse B titres.
These cohorts were all Singer (US) and may be the same samples from the same cohorts.
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As can be seen, a number o f the studies demonstrated elevated streptococcal 
serology in tic and TS cohorts compared to controls, although not all o f the cohorts 
demonstrated this association. In fact, the negative studies tended to be from 
Singer’s group in the US, unlike studies from Germany, Italy, Britain and other US 
groups. Indeed, the studies from Singer 1998 and 1999 appear to have used the same 
cohorts in both studies (and possibly also Loiselle 2003). One study demonstrated a 
positive correlation between ASOT and the severity o f tics (Cardona F et al., 2001). 
A t present, it is d ifficu lt to know the exact proportion o f TS who may have an 
association with streptococcal infections. Furthermore, due to the natural tendency for 
TS to wax and wane, longitudinal studies are required.
1.11.Neuroimaging in post-streptococcal CNS syndromes
Neuroimaging often provides insight into the localisation o f CNS disease, although it 
rarely provides detailed biological insight into the pathogenesis. Imaging o f the brain 
using conventional CT and MRI is commonly normal in post-streptococcal CNS 
disease (Giedd JN et al., 1995; Swedo SE et al., 1993). In Giedd’s SC study only 2/24 
had an abnormality on conventional MR imaging (Giedd JN et al., 1995), and 5/11 in 
Swedo’s SC study had any abnormality (although most o f these were likely to be 
incidental and o f no clinical significance) (Swedo SE et al., 1993). One study reported 
a higher incidence o f MRI abnormalities (42%) in 19 SC patients, although the 
majority o f these were probably incidental non-specific abnormalities such as small 
white matter signal changes or arachnoid cysts (Faustino PC et al., 2003).
Occasionally, inflammatory changes have been described in SC, which are 
predominantly (but not exclusively) localised to the basal ganglia (Kienzle GD et al., 
1991; Castillo M et al., 1999; Traill Z et al., 1995; Robertson W et al., 2002). Only
62
63
rarely has enhancement after contrast been described, suggesting that disruption o f the 
blood brain barrier is not typical (Kienzle GD et al., 1991). More sophisticated 
techniques including volumetric studies have shown that the caudate and putamen are 
specifically enlarged during the acute phase o f Sydenham's chorea and PANDAS 
(Peterson BS et al., 2000; Giedd JN et al., 1995; Giedd JN et al., 2000). By contrast, 
there were no differences in the volume o f the total hemispheres, prefrontal or 
midfrontal regions, or thalamus. Furthermore, anecdotal evidence has shown that 
basal ganglia size correlates with the disease course; a longitudinal case study 
demonstrated striatal enlargement during acute presentation with normalisation during 
remission (Giedd JN et al., 1996). SPECT studies have shown hypermetabolism and 
increased glucose consumption in the basal ganglia during acute SC (Goldman S et 
al., 1993; Weindl A et al., 1993; Lee PH et al., 1999). Furthermore, a case report o f 
SC using MR proton spectroscopy has shown reduction o f n-acetyl aspartate in the 
striatum, which was interpreted as indicative o f neuronal dysfunction or loss (Castillo 
M et al., 1999). Although the majority o f imaging findings are reversible, occasionally 
irreversible striatal changes have been described suggesting permanent damage is 
possible (Emery ES et al., 1997; Ikuta N et al., 1998). Although the majority o f 
imaging studies have localised disease to the basal ganglia, imaging is rarely useful as 
a diagnostic tool alone, and is more commonly used to exclude other causes o f 
movement disorders. The imaging studies also suggest that there is a spectrum o f 
immune mediated brain pathology, ranging from mild swelling to gross irreversible 
inflammatory damage and cell death.
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1.12. Treatment of post-streptococcal CNS disease
1.12.1. Penicillin prophylaxis
There are two potential treatment approaches to post-infectious autoimmune 
disorders: either to prevent further exacerbating infections or to modulate the 
autoimmune process. Antibiotic prophylaxis is an accepted treatment o f RhF and SC, 
and should be continued throughout childhood (Dajani AS et al., 1989). It should be 
noted that large studies were required to establish a benefit o f penicillin prophylaxis 
in SC. Initial attempts to replicate these findings in PANDAS using a double blind 
placebo controlled trial were unsuccessful, although this may have been due to a 
failure to achieve acceptable levels o f prophylaxis (Garvey M A et al., 1999). A 
prospective study o f antibiotic treatments for acute tonsillitis in PANDAS showed 
prompt improvements in obsessive-compulsive behaviours, although this was an 
uncontrolled descriptive study (Murphy M L et al., 2002).
A recent double-blind randomised controlled study examining penicillin and 
azithromycin prophylaxis in PANDAS patients (total n=33) demonstrated significant 
reduction in GAS infections in both penicillin and azithromycin groups, therefore 
demonstrating effective prophylaxis. More importantly, the treatment arms had 
significant reduction in neuropsychiatric exacerbations compared to the prior 
untreated year (Snider LA et al., 2005).
1.12.2. Immunomodulation therapies
1.12.2.1. Sydenham’s chorea
There have been no formal studies o f intravenous immunoglobulin (IVIG) or plasma 
exchange in SC. One study with few numbers (n=9: five plasma exchange, four IVIG) 
was published as a preliminary paper (Garvey M A et al., 1996). Both treatment arms 
improved although the plasma exchange group improved very rapidly, whereas three 
o f the four IVIG treated children relapsed within four months o f completing
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treatment. Plasma exchange was held as the superior therapy. Small studies have 
examined the effectiveness o f steroids in the treatment o f SC. One retrospective study 
o f eight patients showed rapid improvements in their treated patients (Green LN,
1978). A further study described SC cases refractory to routine therapy (valproate and 
neuroleptics) who were treated with intravenous methyl-prednisolone and then oral 
prednisolone. Five patients were treated and the authors concluded that these 
treatments were effective in refractory SC (Cardoso F et al., 2003). A study published 
only in abstract form from Utah in the mid-1980’s (Thompson JA et al., 1999) 
compared 36 prednisolone treated patients with 22 untreated childrem. The median 
time to recovery was 2.75 weeks in the prednisolone group compared to 10 weeks in 
the untreated group.
1.12.2.2. PANDAS
The only placebo controlled trial examining the benefit o f immunomodulation 
(plasma exchange and intravenous immunoglobulin) in PANDAS demonstrated 
improvements in the patients treated with active agents compared to patients treated 
with sham (saline) infusions. Importantly, the treatment improvements were 
maintained at one year (Perlmutter SJ et al., 1999). Interestingly, the same finding 
was not reproduced in OCD patients who did not have PANDAS, suggesting that the 
benefit o f immune modulation is restricted to the PANDAS subgroup o f 
neuropsychiatric disorders (Nicolson R et al., 2000).
1.12.3. Conventional therapies and summary of treatments
Currently, immune treatments should not be given routinely to SC or PANDAS 
patients until further controlled trials confirm their benefit. Carbamazepine and
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sodium valproate have been proposed to be useful symptomatic treatments o f SC, and 
are probably preferable to haloperidol, which can cause unacceptable side effects 
(Pena J et al., 2002).
In summary, at present it is probably best to recommend symptomatic treatment in the 
active phase rather than potentially toxic immune modulating therapies. Penicillin or 
azithromycin prophylaxis is recommended in SC and looks promising in PANDAS, 
particularly given the good side effect profile o f antibiotic prophylaxis.
1.13.Clinical aims of this thesis
The clinical aims o f this thesis are to:
1. Define the spectrum o f post-streptococcal extrapyramidal movement disorders 
in a tertiary referral sample in the UK.
2. To define the psychiatric co-morbidity in post-streptococcal extrapyramidal 
movement disorders.
3. Review the neuroimaging in post-streptococcal neuropsychiatric syndromes.
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Chapter 2. Methods- Patient recruitment of post­
streptococcal neuropsychiatric disease
2.1 Movement disorders
2.1.1 Movement disorders: characteristics and terminology
Movement disorders describe abnormal or extra involuntary movements. The term 
‘movement disorders’ usually infer extrapyramidal movements, although cerebellar 
ataxia has sometimes been included in the ‘movement disorder’ spectrum. However, 
in the context o f this work the term ‘movement disorders’ w ill infer extrapyramidal 
movement disorders alone. Extrapyramidal movement disorders are classified broadly 
into two main groups;
1. hypokinetic-rigid syndromes (paucity o f movements)
2. hyperkinetic movement disorders or dyskinesias (extra or excessive 
movements)
The hypokinetic-rigid syndromes (commonly referred to as Parkinsonism) require 
little further classification. Hypokinetic-rigid syndromes describe bradykinetic 
movements and/or akinesia, tremor (classically at rest) and rigidity. However, the 
dyskinetic movement disorders require further classification according to a number o f 
characteristics, namely:
I. Rhythmicity o f extra movements
II. Speed o f movements 
III. Stereotypical nature o f movements
Using these further criteria, it is possible to characterise the dyskinesias into the 
follow ing terminologies:
A. Chorea and ballismus
B. Dystonia
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C. Tremor
D. Myoclonus
E. Tics
The following table describes the different dyskinetic movement disorders according 
to their characteristics:
TABLE 2.A. CHARACTERISTICS OF DIFFERENT MOVEMENT DISORDER
PHENOTYPES
Characteristic Chorea Dystonia Tremor Myoclonus Tics
Rhythmicity No No Yes Either No
Speed Fast Slow and 
sustained
Fast Fast Fast
Stereotypical Variable Stereotypical Stereotypical Stereotypical Stereotypical
or variable
Suppressible No No No No Yes
Other ‘Dance- Twisting Repetitive Often Preceded by
features like ’ regional an urge or 
sensation
Ballismus is related to chorea, but typically involves high velocity displacement, often 
involving the limbs.
It is has been recognised for years that different clinicians may classify the same 
movement disorder in different ways. Being aware o f this, I videoed movement 
disorders o f 16 patients, some o f which were d ifficu lt to classify. I then performed an 
inter-rater comparison o f movement disorder classification.
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2.1.2. Movement disorder classification: Inter-rater assessment 
Method
I aimed to examine possible differences in classification between raters. The 16 
videos featured a range o f extrapyramidal movement disorders in patients with post- 
streptococccal neuropsychiatric disease. The videos were presented in digital form on 
computer. The raters filled in the forms independently and simultaneously. They were 
asked to classify the primary movement disorder and secondary movement disorder 
where two or more movement disorders co-existed.
The raters were:
1. Dr Russell Dale, Primary investigator (RCD)
2. Professor Robert Surtees, Professor o f Paediatric neurology (RAHS)
3. Professor Brian Neville, Professor o f Paediatric neurology (BGRN).
Results
As can be seen in table 2.b, there was general agreement on the classification o f these 
16 videos. Where total agreement was absent, the three raters agreed upon a final 
movement disorder classification for each patient that was used in the clinical results.
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Table 2.h. Videos o f 16 patients with movement disorders rated by 3 physicians.
Video (initials) RCD BGRN RAHS
JW Paroxysmal dystonia Chorea and dystonia Paroxysmal
and chorea dystonia and chorea
CN Hemiballsimus Hemiballismus Hemiballismus,
Hemidystonia Parkinsonism and
hemidystonia
GH Rest tremor Coarse tremor, Dystonic or rubral
extrapyramidal tremor
MO Dystonia Dystonia, Parkinsonism and
Blepharoclonus Parkinsonism blepharospasm
TT Parkinsonism Parkinsonism Parkinsonism
LW Dystonia and chorea Dystonia and chorea Dystonia and
chorea
AA Chorea Dystonia and chorea Choreiform
SB Chorea Chorea Chorea
CR Chorea Tics Complex tics
Complex tics
FA Stereotypies Stereotypies Tics
JG Tics Complex tics Tics
SK Chorea Chorea Chorea (distal)
Cl Myoclonic tics Myoclonic dystonia Chorea and
dystonia
HS Chorea Opsoclonus, ataxia Dystonia
Opsoclonus and Opsoclonus and
myoclonus myoclonus
HT Dystonia and chorea Dystonia Dystonia and ataxia
JT Tremor, Tremor, Dystonia
Parkinsonism Parkinsonism
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2.2 Psychiatric assessments
As a paediatric neurologist, despite a lack o f formal training in psychiatry, I needed to 
be able to produce internationally acceptable psychiatric diagnoses in patients with 
post-streptococcal neuropsychiatric syndromes. After discussion with Professor 
Robert Goodman, Professor o f Child Psychiatry, Institute o f Psychiatry, London, it 
was suggested that the Development and Well Being Assessment (DAW BA) would 
be the most appropriate interview.
2.2.1 The Development and Well Being Assessment
The DAW BA is an integrated package o f measures for child psychiatry that has been 
validated in clinic and community samples for 5-16 year olds. It is performed with the 
parent or individual (over 11 years old). The interview can be performed by non- 
clinical interviewers using a structured interview in a computer-assisted diagnostic 
rating package. The DAW BA interviews and questionnaires were provided by Robert 
Goodman in a Microsoft Access package (Goodman R et al., 2000). The interview 
covers specific areas in detail: separation anxiety, generalised anxiety, obsessive- 
compulsive disorder, major depression, specific and social phobias, post-traumatic 
stress disorder, hyperkinesis/ADHD, and conduct-oppositional disorders. The 
interview asks about all symptoms required for operationalised diagnoses using both 
DSM-IV (American Psychiatric Association, 1994) and ICD-10 (World Health 
Organisation, 1994). Certain disorders are only asked about briefly, namely panic 
disorder, agoraphobia, autistic disorders, tic disorders and eating disorders, and would 
depend upon the open-ended transcript (discussed shortly). The symptoms relate to 
present and recent past. Importantly, the interview focuses upon the impact o f these
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symptoms and associated morbidity, an essential part o f making an internationally 
acceptable psychiatric diagnosis. The computer-generated diagnoses are based upon 
computerised diagnostic algorithms. These diagnoses are not definitive, but provide a 
useful start for the expert clinical raters. To improve validity and check that the 
questions were fu lly  understood, the problems are described in the patient’s own 
words. The expert clinical rater reviews this open text. In addition, for further 
validation, a separate questionnaire is performed, namely the Strengths and 
Difficulties questionnaire (SDQ). The SDQ can generate emotional, conduct and 
hyperactivity scores to support the DAW BA generated diagnoses. The SDQ presents 
a brie f measure o f the adjustment and psychopathology o f children and adolescents 
(Goodman R, 2001). Once the information has been added to the computer package 
(DAW BA, SDQ and written text), the data was saved and given to the clinical rater. 
For this study, the clinical rater was Dr Isobel Heyman, Consultant child psychiatrist, 
Institute o f Psychiatry, London. Dr Heyman is an experienced child psychiatrist, who 
has received training in order to evaluate these interviews. The raters check whether 
the respondents have fu lly  understood the questions, and ensure that the computer­
generated diagnoses conform to the written text and SDQ scores. In borderline cases, 
consensus diagnoses where made with the help o f Robert Goodman. The DAW BA 
has been validated by comparing the usefulness o f the interview in clinic and 
community cohorts. The DAW BA diagnoses correlated well with the clinical case 
note diagnoses (Goodman R et al., 2000). In addition, the DAW BA was used in an 
extremely large population-based study o f psychiatric (DSM-IV) diagnoses in British 
children. In this study, 10,438 children were assessed using the DAWBA. The 
findings o f this study are summarised in table 2.c, and provided an important control 
group to compare with the post-streptococcal neuropsychiatric patients. In table 2.c,
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the ICD-1Q criteria are listed (Meltzer H et al., 2000), although there is a strong 
correlation between ICD-10 and DSM-IV criteria (Ford T et al., 2003).
Table 2.c. The ICD-10 diagnoses o f 10,438 children from a population-based sample.
Diagnosis  Point prevalence
ICD-10
Any psychiatric diagnosis 8.9%
Emotional disorder 4.3%
Obsessive-compulsive 0.2%
disorder
Generalised anxiety 0.6%
Depressive episode 0.7%
Separation anxiety 0.8%
Specific phobia 1.0%
Social phobia 0.3%
Panic attacks 0.1%
Conduct disorders 4.7%
Oppositional defiant disorder 2.5%
Other conduct disorders 2.2%
Hyperkinetic disorders 1.3%
Hyperkinesis 1.1%
Other hyperkinetic disorder 0.2%
Less common disorders 0.5%
2.3 Clinical and laboratory diagnosis of Streptococcal 
infection
Group A streptococcus (GAS) infections are common in children. Most commonly 
they cause pharyngeal infections, presenting as sore throat, lymphadenopathy and
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occassionally systemic symptoms. It is also recognised that GAS can reside in the 
pharynx without producing local inflammation (i.e. carriers).
As GAS infections are common, markers o f GAS infection are frequently elevated in 
paediatric populations, more so than adult populations. In view o f this, I needed to use 
clear clinical and laboratory criteria for including patients into the post-streptococcal 
neuropsychiatric cohort.
Method
To make a diagnosis o f post-streptococcal neuropsychiatric disease, I based the 
criteria upon previously described diagnostic criteria from Sydenham’s chorea 
(Special writing group o f the committee on rheumatic fever, 1992) and PANDAS 
(Swedo SE et al., 1998).
1. The patient is a previously well child with acute or subacute onset o f 
neurological or psychiatric disease occurring shortly (within 2 months) o f a 
pharyngeal infection compatible w ith GAS. Alternatively, i f  the patient 
already has a neuropsychiatric syndrome, there must be two or more relapses 
or deteriorations associated with GAS infection.
2. The infection should be compatible with GAS pharyngeal infection. This 
should include the following symptoms: sore throat, cervical 
lymphadenopathy, fever, and abdominal pain (at least 2 o f these).
3. A ll patients had evidence o f recent or current GAS infection. Laboratory 
evidence o f GAS should be either:
a. Microbiological culture o f GAS or beta haemolytic streptococcus 
species from the throat.
b. Positive streptococcal serology (ASOT or anti-DNase B) acutely with 
a reduction in titre on convalescent testing (3-6 months).
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4. No other explanation for the neurological or psychiatric syndrome.
Other markers o f a post-infectious immune mediated syndrome were also measured, 
and the results are reported in the results including:
•  Erythrocyte sedimentation rate
• Cerebrospinal fluid cells, protein, oligoclonal bands when performed
• MRI brain. A ll MRI brain scans were performed on a 1.5 Tesla magnetic 
resonance scanner. The standard T1 and T2 weighted images were acquired in 
the coronal and sagital planes. A ll images were reported by consultant 
neuroradiologists.
•  Echocardiography and electrocardiography
These further investigations were performed according to the discretion o f the 
consulting physician and were not performed in all patients.
2.4 Patient recruitment
The patients were all recruited via Great Ormond Street hospital NHS trust 
neurosciences unit. The patients presented with movement disorders or neurological 
syndromes after streptococcal infection. Some patients were recruited through the 
routine neurology service. Others were referred directly to RCD from other centres, 
and were subsequently seen as in-patients or out-patients at Great Ormond Street 
hospital NHS trust. A ll patients were interviewed as follows:
1. Past medical history and family history o f neurological, psychiatric and 
autoimmune disorders.
2. History o f preceding infection.
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3. History o f neurological syndrome. Atypical or unusual movement disorders 
were videoed for further analysis as described before. Movement disorders 
were classified according to accepted criteria.
4. Psychiatric interview as described above: DAWBA, SDQ and written text.
5. Symptom review for other symptoms.
6. Clinical examination for neurological and systemic signs.
7. Laboratory investigation as described above. Additional investigation to 
exclude other causes o f the neuropsychiatric syndrome.
2.5 Statistics used in clinical characteristics and control 
groups
Clinical differences between patient groups and controls/ normative data were 
examined using chi-squared test, Fisher’s test or the Mann Whitney test as 
appropriate. Anti-streptolysin-O and anti-DNase B titres in patients and controls were 
analysed using the non-parametric Mann Whitney test.
Control groups used in this thesis were all recruited from Great Ormond Street 
hospital NHS Trust, or the National Hospital for Neurology and Neurosurgery. A ll 
were consented for this investigation. The follow ing control groups were recruited:
•  Child neurology control group (n=100, mean age 8.2, range 1-16 yrs)
•  Child Streptococcal control group- all had recent infection compatible with 
streptococcal infection but no neurological disease, plus positive streptococcal 
serology (n=40, mean age 9.8, range 2-15 yrs).
•  Child autoimmune control group (n=50, mean age 9.2, range 2-16 yrs)
•  Adult neurology group- random neurological controls (n=50, mean age 41, 
range 19-70 yrs)
• Adult healthy group (n=50, mean age 35.6, range 19-57 yrs)
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Chapter 3. Results- the clinical spectrum of post­
streptococcal neuropsychiatric disease
3.11ntroduction
The patients in this chapter w ill be presented as follows:
• Post-streptococcal CNS patients
1. Dyskinesia
2. Acute disseminated encephalomyelitis (ADEM)
3. Parkinsonism
• Encephalitis lethargica, o f whom a proportion were post-streptococcal.
3.2 Post-streptococcal dyskinesias (n=40)
3.2.1. Definition of patients
Patients were referred between 1999-2002 by their general practitioner or 
paediatrician for investigation and management o f an acute onset or relapsing 
dyskinetic movement disorder. A ll patients included had disease onset shortly after 
streptococcal pharyngeal infection, or suffered two or more relapses after 
streptococcal pharyngeal infections (Swedo SE et al., 1998). Evidence o f Group A 
streptococcal (GAS) infection was evident in all patients, and was diagnosed when a 
clinical episode o f pharyngitis occurred with laboratory evidence o f GAS infection 
(growth o f GAS organism on pharyngeal swab, or elevated acute streptococcal 
serology with reduction in serology 3-6 months later). Investigations for an alternative 
cause o f chorea, dystonia and myoclonus (copper, caeruloplasmin, anti-nuclear 
antibody, thyroid function tests, lactate, plasma amino acids and urine organic acids) 
were normal in all patients.
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3.2.2 Demographics
3.2.2.1. Age
The age range o f movement disorder onset was 1.2 -16 years (mean 7.3 years, median
7 years). The breakdown o f patient age according to the movement disorder
phenotype is presented in figure 3.1 .a. As can be seen, the total cohort is distributed
widely over the whole o f the paediatric range, with a peak in the 5-10 year age group. 
The chorea patients were more likely to be older (Figure 3.1 .b. (mean 7.85 yr, median 
8 yr) than the tic patients (Figure 3.I.e. (tic group mean age 6.75 yr, median 7 yr), 
although this difference did not reach statistical significance.
Figure 3.1. Age distribution o f total dyskinesia cohort (A), the chorea subgroup (B) 
and the tic subgroup (C).
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3.2.2.2. Sex
The sex distribution o f the total dyskinesia cohort did not demonstrate clear sex 
predominance. There were 21 male and 19 female dyskinesia patients. However, 
when comparing the chorea with the tic patients, there were some differences in the 
sex distribution (Figure 3.2.). Notably, 35% o f the chorea patients were male, whereas 
69% o f the tic patients were male (p=0.04 using the chi squared test).
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Figure 3.2. Comparison o f sex distribution in the tic and chorea subgroups.
chorea
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3.2.3. Preceding medical and psychiatric history
Psychiatric symptoms were present before movement disorder onset in seven patients 
(17.5%): attention deficit hyperactivity disorder n=6 (one with co-morbid OCD and 
generalised anxiety), and post-traumatic stress disorder n = l. Other past medical 
history included cows milk protein allergy (n=l), asthma (n=l) and moya-moya 
disease (n=l).
3.2.4 Precipitating infectious illness
Thirty-four patients (85%) had an infectious illness compatible with GAS shortly 
before movement disorder onset. The remaining six patients did not have a clinical 
history o f GAS infection at movement disorder onset, but subsequently had two or 
more relapses associated with streptococcal infections. GAS organisms were grown
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from pharyngeal cultures in six patients (three with chorea, three with tics). 
Streptococcal serology (ASOT and anti-DNAse B) was elevated in all other patients 
and therefore provided evidence o f GAS infection. Some patients (Figures 3.3.a and
3.3.b) had normal ASOT but elevated anti-DNAse B (or visa versa). The normal 
range in over 3 year old children is <200 IU/ml (ASOT) and <300 IU/ml (anti-DNAse 
B). The normal range in under 3 year old children is <100 IU/ml (ASOT), and <200 
IU/ml (anti-DNAse B). The mean ASOT values were elevated in the dyskinesia 
cohort (n=40, median 453 IU/ml, mean 529 IU/ml) compared to the neurology
y
controls (median 100 IU/ml, mean 151 IU/ml). Likewise, anti-DNase B was elevated 
in the dyskinesia cohort (median 373 IU/ml, mean 566 IU/ml) compared to the 
neurology control groups (median 196 IU/ml, mean 213 IU/ml) (Figures 3.3.a and
3.3.b). The mean latency between infection and movement disorder onset was 18.9 
days (range 1 -67 days).
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Figure 3.3.a. ASOT in post-streptococcal dyskinesia group and neurological controls. 
Bars presented are 0th, 25th, 5(f , 75th and 100th centiles. Dotted line represents 
internationally defined significant cut-off (ASOT>200IU/ml).
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Figure 3.3.b. Anti-DNase B in post-streptococcal dyskinesia group and neurological 
controls. Bars presented are ( f\  25th, 50th, 75th and I0(fh centiles. Dotted line 
represents internationally defined significant cut-off (anti-DNAse B>300IU/ml).
3.2.5 Spectrum of dyskinesias
The dyskinesias are described for each patient in appendix 1 (chapter 13). The 
movement disorder onset was often abrupt, regardless o f the dyskinesia phenotype. 
The most frequent dyskinesias were chorea (n=20) and motor tics (n=16). The first 
recorded motor tics were eye blinking/eye deviation (n=4), head flicks (n=3), assorted 
facial tics (n=4), shoulder or upper limb tics (n=3) and truncal tics (n=2). Other 
dyskinesias were dystonia (n=5), tremor (n=3), stereotypies (n=2), opsoclonus (n=2) 
and myoclonus (n=l). The dyskinesia patients can be summarised with the following 
pie chart (Figure 3.4).
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Figure 3.4. Column chart o f dyskinetic movement disorders.
dystonia tremor stereotypies myoclonuschorea
Seventeen patients had one or more vocal tics; 13 associated with motor tics, two with 
chorea, one with myoclonus and one with stereotypies.
3.2.5.1. Notable cases o f post-streptococcal dyskinetic movement 
disorders
There were a few cases that were notable because o f their presentation:
Case 1
An eight year old boy had been previously well other than recurrent upper respiratory 
tract infections. There was no personal or family history o f neuropsychiatric disease 
or movement disorder. One week after a sore throat, he presented with an acute onset 
behavioural disturbance and abnormal ‘jumpy’ movements. The episode lasted two 
hours and resolved completely. From this time, he suffered between 1-4 paroxysmal 
attacks per day. Each attack would start suddenly. Attacks were not precipitated by
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movement nor exercise, although stress and anxiety increased the attack frequency. 
Each episode was similar, and characterised by a sudden onset o f behavioural 
disturbance and abnormal movements. His behaviour would become immature, 
anxious and ‘baby-like’ . In addition, he would become inappropriately animated, or 
alternatively inappropriately tearful or angry. Neuropsychiatric profde revealed 
symptoms o f separation anxiety, generalised anxiety and depression (DSM-IV) during 
attacks, which were not present in between attacks. There was no obsessive- 
compulsive behaviour. During some episodes, he would have visual hallucinations o f 
colourful lights or frightening objects. During early attacks, involuntary dystonic 
posturing o f his hands was observed. As the events evolved there was dystonic 
posturing o f the face, head, limbs and trunk, w ith choreoathetosis becoming evident 
towards the end o f an attack. During an event, he would be unable to walk unaided, 
and attempts to weight bear resulted in continuous dancing movements o f the legs 
resembling St Vitus dance. These movements were not evident when he was lying 
supine on the bed. Each attack would last between 10 minutes and 4 hours, and there 
would be 1-4 attacks per day. In between attacks, his behaviour and neurological 
examination was normal.
MRI brain imaging and EEG during an attack was normal. The following 
investigations were normal or negative: fu ll blood count, erythrocyte sedimentation 
rate, c-reactive protein, antinuclear antibody, autoantibody profile, thyroid function, 
urate, lactate, caeruloplasmin, copper, plasma amino acids, urine toxicology and 
echocardiogram. Anti-streptolysin-O titre was elevated to 406 IU/ml (normal <200 
IU/ml) and anti-DNase B titre 256 IU/ml (normal <300 IU/ml). Convalescent 
serology showed a reduction in titres.
A post-streptococcal neuropsychiatric syndrome was suspected and penicillin 
prophylaxis was commenced. Over the following 2 months, he continued to have
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paroxysmal events, occurring up to 4 times per day as described. His gait was so 
impaired he needed to use a wheelchair. A trial o f chlorpromazine therapy had no 
impact on the attacks, and caused unacceptable drowsiness. By the 3rd month, the 
paroxysmal attacks became less frequent, occurring only on alternate days. He only 
had 2 events in the 4th month o f his illness. In the 5th month, he had an exacerbation in 
attack frequency associated with the onset o f hayfever. In the 6th month he was started 
on carbamazepine in an attempt to reduce paroxysmal events, which has halved the 
number o f attacks in the first month o f therapy. He remains on penicillin prophylaxis.
Case 2
A male infant bom at term by uncomplicated delivery had achieved normal 
developmental milestones. At 14 months o f age, he could walk unaided, feed himself 
and was vocalising keenly. There was no fam ily history o f neurological disease. A t 14 
months, he suffered a seven day febrile illness with signs o f upper respiratory tract 
infection. He recovered uneventfully but 10 days later had an acute neurological 
illness. Examination at this time demonstrated asymmetric motor weakness (left more 
than right), truncal ataxia and dystonic posturing. W ithin 3 days, he was 
spontaneously improving and returned back to normal within one week. However, 
seven days later he suffered a further episode o f pharyngitis. This was immediately 
followed by a rapid decline in his function. Over the following two weeks, he lost the 
ability to walk, crawl and sit. Examination demonstrated an upper limb resting tremor, 
rig id ity and dystonic posturing o f the arms and legs. He had oro-pharyngeal 
incoordination resulting in drooling and feeding difficulties. His condition stabilised 
for four weeks, but then deteriorated further associated with another upper respiratory 
tract infection. At this stage symmetrical dystonia persisted with new oro-facial
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grimacing and generalised chorea. His behaviour, sleep pattern and alertness remained 
normal throughout.
MRI brain revealed abnormalities that were restricted to the basal ganglia. There was 
bilateral caudate and putaminal enhancement on T2 weighted sequences. Anti­
streptolysin O titres were 197 IU/ml acutely and 57 IU/ml on convalescent testing 
(normal range in this age group <100 IU/ml). These findings were consistent with 
previous streptococcal infection. The following investigations were normal or 
negative; full blood count, c-reactive protein, CSF microscopy and culture, CSF 
polymerase chain reaction for herpes simplex virus, varicella zoster virus, 
cytomegalovirus, enterovirus, echovirus, human herpes virus 6 and human herpes 
virus 7. Blood serology was also negative for mycoplasma, adenovirus, influenza A 
and B, enterovirus and chlamydia. Urine, throat and blood cultures were negative. The 
follow ing metabolic investigations were negative or normal; copper, caeruloplasmin, 
lactate (blood and CSF), CSF glucose, liver function tests, very long chain fatty acids, 
lysosomal enzymes, acylcamitines, amino acids, urinary organic acids, ammonia, 
creatine kinase, transferrin isoforms and lip id  electropheresis. Ophthalmology, EEG, 
electroretinogram and visual evoked potential were all normal. CSF protein was 
elevated at 0.8 g/dl.
A post-streptococcal autoimmune neuropsychiatric disease was suspected. He was 
started on Penicillin V prophylaxis. Two mg/kg oral prednisolone was also 
commenced for two weeks followed by a six week weaning regimen. Over the 
follow ing two months, in conjunction with physiotherapy and occupational therapies, 
he made significant functional improvements. The rigidity reduced, and his dystonia 
was less pronounced. Involuntary writhing movements o f the upper limbs and trunk 
persisted but were less impairing. Assessment at 10 months (aged two years) showed
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residual dystonia and chorea. Functionally, he was able to sit unsupported but still 
unable to walk.
These two cases were notable for the following reasons. Case 1 presented as 
paroxysmal dystonic choreathetosis, a previously undescribed phenotype o f post­
streptococcal neuropsychiatric disease. Case 2 presented with acute onset dystonia 
and basal ganglia lesions, in a manner previously termed ‘ infantile bilateral striatal 
necrosis’ . Both o f these cases were subsequently reported in the medical literature, 
being examples o f the expanding spectrum o f post-streptococcal neuropsychiatric 
disease (Dale RC et al., 2002; Dale RC et al., 2002).
3.2.6 Psychiatric comorbidity
The psychiatric comorbidity is described for each patient in appendix 1 (chapter 13). 
Acute emotional and/or behavioural alteration occurred in 33 patients (82.5%). Most 
frequently reported acute changes were emotional lability (n=13, 32.5%), anxiety 
(n= l 1, 27.5%), obsessions and/ or compulsions (n=9, 22.5%), and depression (n=7, 
17.5%). Other common behavioural changes included aggressive, oppositional or 
disruptive behaviours (n=14, 35%) and attention deficit (n=l 1, 27.5%). Less common 
psychiatric manifestations included echolalia (n=4), visual hallucinations (n=2), and 
social disinterest (n=2). Formal psychiatric assessments were carried out at least two 
weeks after the acute presentation. One or more ICD-10 diagnoses were made in 25 
patients (62.5%). Thirteen patients (32.5%) had 2 or more psychiatric diagnoses. The 
IC D -10 diagnoses are presented in Table 3.1 .with comparison to previously derived 
normative data (Meltzer FI et al., 2000). As can be seen, emotional disorders were the 
most frequent psychiatric phenotype, o f which obsessive-compulsive disorder was the
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most common, followed by other anxiety disorders and major depression. Conduct 
and hyperkinetic disorders occurred less frequently than emotional disorders, although 
significantly more commonly than would be expected in a normal population (Table 
3.a.). Due to low numbers in some psychiatric comorbidity groups, statistical analysis 
was only applied when the number o f patients with the psychiatric disorder was 
greater than, or equal to 5 (12.5%).
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Table 3.a. Psychiatric diagnoses in post-streptococcal dyskinesia cohort (n=40) and 
national comparison group ( n - 10,438) (Meltzer H et al., 2000).
ICD-10 diagnosis  Point prevalence_______  P
Dyskinesia Normative (continuity
group data -adjusted
chi-square)
Any ICD-10 diagnosis 62.5% 8.9% .000
Emotional disorder 47.5% 4.3% .000
Obsessive-compulsive disorder 27.5% 0.2% .000
Generalised anxiety 25.0% 0.6% .000
Depressive episode 17.5% 0.7% .000
Separation anxiety 7.5% 0.8%
Specific phobia 7.5% 1.0%
Social phobia 5.0% 0.3%
Panic attacks 2.5% 0.1%
Conduct disorders 27.5% 4.7% .000
Oppositional defiant disorder 15.0% 2.5% .000
Other conduct disorders 12.5% 2.2% .000
Hyperkinetic disorders 15.0% 1.3% .000
Hyperkinesis 12.5% 1.1% .000
Other hyperkinetic disorder 2.5% 0.2%
Less common disorders 10% 0.5%
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3.2.7 Other clinical features
3.2.7.1. Other neurological features
Hypotonia and bulbar dysfunction were common in the chorea subgroup (dysarthria 
occurred in half o f the chorea patients). Sleep disorder occurred in nine patients 
(22. 5%), particularly insomnia during the acute phases. Less common features 
included reduced consciousness (n=2), epileptic seizures (n=2), and mutism (n=2).
3.2.7.2. Systemic features
Systemic complications occurred in nine patients (22.5%), and affected the chorea 
patients only (47.5% o f chorea patients had systemic features); five had carditis 
defined using echocardiography (four w ith mitral regurgitation). Two patients had 
arthritis, and three other patients had arthralgia. One further patient had a vasculitic 
rash, but no patients had erythema marginatum. Systemic complications always 
preceded the neurological syndrome.
3.2.8 Family history
Sixteen patients (40%) had a family history o f psychiatric or movement disorders in 
1st degree family members. Ten patients (25%) had at least one family member with a 
history o f movement disorders; motor tics in childhood (n=7), Sydenham’s chorea 
(n=2) and Tourette’s syndrome (n = l). Family history o f psychiatric disorders (ICD- 
10) was present in eleven patients (27.5%); obsessive-compulsive disorder (n=5), 
depression (n=4), hyperactivity (n=3), anxiety, conduct disorder and chronic fatigue 
syndrome (all n= l) (some family members had more than one psychiatric diagnosis).
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A family history o f post-streptococcal autoimmune complications in 1st or 2nd degree 
family members was present in eight patients (20%); Sydenham’s chorea (n=3), 
PANDAS (n=3) and rheumatic carditis (n=2). Some families exhibited very strong 
family histories o f autoimmune, movement and psychiatric disorders as demonstrated 
in figures 3.5..
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Figure 3.5. Family trees. Post-streptococcal diagnosis is listed in brackets (when 
present). OCD: Obsessive-compulsive disorder. ODD: Oppositional defiant disorder.
Family 1
Suicide
Chorea
(Sydenham's chorea) 
onset 7 yrs
Onset 10 yr 
Motor tics 
Anxiety
Depression Depression
Tourette syndrome (PANDAS) 
OCD, anxiety, ODD.
Onset 5 yrs
Chronic motor tic disorder (PANDAS) 
Onset 3 yrs.
KEY:
Affected patient Not interviewed
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Fam ily 2
Rheumatic fever 
Schizophrenia
Depression
Suicide
Chorea
Depression, anxiety (Sydenham’s chorea) 
Onset 8 yrs
Transient tic disorder
OCD, anxiety, depression (PANDAS)
Onset 13 yrs
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Fam ily  3
Rheumatic fever
Motor tics Rheumatic fever 
Depression
Schizophrenia
Motor tics 
OCD
Onset 7 yrs
Chorea (Sydenham’s chorea)
Depression
Onset 10 yrs
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3.2.9 Clinical outcome
Patients with persistent disease are still under medical care. The mean duration o f 
disease in this cohort is currently 2.7 years (2 months-13 years). Eleven (27.5%) 
patients have had a monophasic disorder with complete resolution. O f the 29 patients 
(72.5%) with continuing symptoms, 15 (37.5%) have persistent static disease and 14 
(35%) have a relapsing remitting course associated with further infections. A ll o f the 
patients with tics fulfilled a diagnosis o f PANDAS (Swedo SE et al., 1998). Although 
there was evidence o f streptococcal infections during the majority o f exacerbations, 
two patients had relapses after apparent viral infections, and one patient had an 
exacerbation after a routine vaccination. Nine o f the 16 patients with motor tics (56%) 
fu lfil a diagnosis o f Tourette’s syndrome ICD-10.
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3.2.10. Clinical differences between tic and chorea subgroups
Comparisons between the clinical features are presented in table 3.b.
Table 3.b. Clinical comparison o f tic and chorea subgroups. Psychiatric diagnoses 
according to ICD-10 criteria.
Characteristic Tic (n=16) Chorea (n=20) P
Median age o f presentation (range) 8(2-13) 10(1.5-13) NS
Proportion male 69% 35% 0.04
Median length o f follow-up (range) 2.5(0.2-13) 0.45 (0.2-17) 0.001
Continuing movement disorder 94% 55% 0.01
Any psychiatric disorder 69% 50% NS
Emotional disorder 50% 40% NS
Obsessive-compulsive disorder 50% 10% .02
Generalised anxiety 19% 25% NS
Major depression 12.5% 20% NS
Conduct disorders (all types) 25% 20% NS
Hyperkinetic disorders (all types) 19% 15% NS
As can be seen, chorea was more common in females than males. The converse was 
true in the tic subgroup. There were no other clear differences between the subgroups, 
although persistence o f movement disorder and the presence o f obsessive-compulsive 
disorder were more common in the tic subgroups. This however could at least partly 
be explained by the prolonged disease duration in the tic subgroup compared to the 
chorea subgroup.
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3.3. Post-streptococcal acute disseminated encephalomyelitis 
(n=10)
3.3.1. Introduction
Although GAS classically causes CNS syndromes characterised by extrapyramidal 
movement and psychiatric disorders, it has been previously recognised that GAS can 
induce a broader spectrum o f immune mediated CNS disorders, including 
disseminated inflammatory CNS disorders such as acute disseminated 
encephalomyelitis (ADEM) (Jorens PG et al., 2000). As part o f my previous research 
into ADEM, I was able to recognise a number o f cases with ADEM after GAS 
infection. The ADEM cases were notable because o f the high incidence o f basal 
ganglia lesions. In addition, the ADEM cases were clinically notable because o f the 
high incidence o f extrapyramidal movement and psychiatric disorders. I now present 
10 cases o f post-streptococcal ADEM seen at Great Ormond Street hospital between 
1995 and 2000.
3.3.2. Demographics, past medical history and family history
There were eight males and two females, w ith a mean age o f 6.8 years (range 3-14 
years). None o f the patients had any significant past medical history. One patient’s 
father had Tourette’s syndrome.
3.3.3. Precipitating infectious illness
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A ll 10 patients had a preceding clinical pharyngitis before presentation. A ll had 
laboratory evidence o f GAS infection. The average latency between pharyngitis and 
the onset o f neurological symptoms was 11.5 days (range 4-18 days). Nine post­
streptococcal ADEM (PSADEM) patients had elevated streptococcal titres in the 
acute phase, with a reduction in the convalescent period. In 1 patient the streptococcal 
serology was within the normal range, although serology performed 1 week later 
demonstrated a significantly elevated anti-DNase B level supporting recent infection. 
Serological ASOT was significantly elevated in the PSADEM patients (mean 424 
IU/ml, SD 292, range 53-1060 IU/ml) compared to the neurological control group 
(mean 148 IU/ml, SD 139, range 53-655 IU/ml, p=0.002) but were not significantly 
different from the streptococcal infection control group (mean 562 IU/ml, SD 593, 
range 53-3210 IU/ml, p=0.1).
Similarly, anti-DNase B titre was also significantly elevated in the PSADEM patients 
(mean 1090 IU/ml, SD 1475, range 134 to 5100 IU/m l) compared to the neurological 
control group (mean 205 IU/ml, SD 238, range 68 to 1330 IU/ml, p<0.001) but not 
compared with the streptococcal infection group (mean 525 IU/ml, SD 346, range 76 
to 1530 IU/ml, p=0.2).
3.3.4. Movement disorders
The clinical features o f the 10 patients are presented in appendix 2 (chapter 13). In 
summary, an extrapyramidal movement disorder occurred in five patients; three had 
axial rigidity, four had limb rigidity (one with cogwheeling), two had dystonic 
posturing, two had rest tremor, one hemidystonia, and one paroxysmal hemidystonia. 
No patient had chorea or tics.
3.3.5. Behavioural alteration
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Behavioural disturbance was common during presentation (n=7) and was 
characterised by emotional lability (n=3), inappropriate laughter (n=3), echolalia and 
pallilalia (n= l), attention deficit (n = l), separation anxiety (n= l) and confusion (n=3).
3.3.6. Other clinical features
Somnolence, stupor, and coma occurred in five patients. Three patients required 
ventilation because o f the depth o f coma. Pyramidal weakness was also common 
(n-6).
3.3.7. Clinical outcome
Nine children were treated with intravenous methylprednisolone for three days.
Clinical improvement was often rapid. Eight children had a monophasic illness 
(ADEM), although two (patients 7 and 10) had relapses two and 13 months after 
initial presentation. Both relapses were triggered by pharyngitis (in patient 7, GAS 
serotype M77 was cultured by throat swab during the relapse). They have both 
subsequently been treated with penicillin prophylaxis in an attempt to minimise the 
occurrence o f further relapses.
Eight patients have made a complete recovery. One child has developed an obsessive- 
compulsive disorder (patient 3) and one hemidystonia (patient 6). There have been no 
other reported episodes o f acute neurological dysfunction in a mean follow-up o f 1.9 
years. No patients had clinical carditis during their acute illness (echocardiogram was 
performed in 4, and all were normal).
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3.4 Post-streptococcal Parkinsonism
3.4.1. Introduction
The spectrum o f post-streptococcal neuropsychiatric disorders has generally 
conformed to hyperkinetic and dyskinetic movement disorders, associated with 
psychiatric (mainly emotional) disorders. However, I was involved in the follow ing 
two cases that raised the possibility that the spectrum o f post-streptococcal movement 
disorders was broader than dyskinetic movements alone, but also included akinetic- 
rigid syndromes akin to Parkinsonism. Case one was seen by myself in London in 
2000, case two was seen and reported in the literature by Israeli colleagues and myself 
in 2003.
3.4.2. Case histories
3.4.2.1. Case one
A 15 year old boy presented with an acute personality change 10 days after an upper 
respiratory tract infection. He became extremely anxious and worried about his safety. 
One week later he had an oculogyric crisis and developed upper limb resting tremor 
and bradykinesia. This was followed by extreme daytime somnolence, lethargy and 
intractable hiccough. On examination, he would fall asleep i f  not stimulated and 
yawned continuously. Pupillary responses were poorly reactive to light and 
accommodation. There was tongue tremor, a positive glabellar tap and slow speech. 
Limb examination revealed rigidity with cogwheeling, bradykinesia and freezing. He 
had a stooped gait with poor arm swing. Positive results included an elevated ASOT 
(350 IU/ml), and a mirrored pattern o f oligoclonal bands in both CSF and serum. CSF 
PCR for neurotropic viruses was negative. MRI brain showed enhancement o f the
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basal ganglia seen on T2-weighted imaging. He was treated with 50mg o f levodopa 
twice a day (with carbidopa), which improved his sleep disorder and Parkinsonian 
signs, although he complained o f insomnia. His abnormal clinical signs remained for 
2 months following which the levodopa was withdrawn. He has made a complete 
recovery with no neurological or psychiatric sequelae at one year follow-up. In 
summary, this patient presented with a post-infectious (streptococcal) Parkinsonian 
syndrome with psychiatric and brainstem features.
3.4.2.2. Case 2
A 10-year-old girl was referred for evaluation o f chorea five weeks after having had a 
sore throat for which she had not received antibiotic treatment. During the five week 
interim, she developed small, rapid, involuntary finger movements described as 
“ piano playing”  and her behaviour was quieter and more introverted than usual. She 
also manifested a stereotypy during which she would repeatedly stop what she was 
doing, stand on one foot “ like a stork”  and freeze in this position for several moments. 
Her physician diagnosed the former irregular hyperkinetic movements as chorea and 
he prescribed penicillin treatment. Neuroleptics were not recommended and the child 
was referred for neurological assessment.
The patient is the sixth o f eight children o f unrelated Ashkenazi parents. Her perinatal 
and developmental histories were normal; she had enjoyed good health and was not 
on any medications. There had been no other febrile illnesses, medical or emotional 
problems in the months prior to referral. Her maternal uncle suffered from rheumatic 
heart disease. There was no familial history o f a psychiatric or movement disorder 
(e.g. Parkinson’s disease, dystonia or Huntington’s disease) and no neuroleptics or 
psychotropic medications were found during a house visit.
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On examination, five weeks after the onset o f the hyperkinetic movement disorder, 
her chorea and “ stork posture”  had resolved. However, signs o f hypomimia were 
strikingly apparent. She had a “ poker face” , lips slightly apart without facial mimicry. 
Bradykinesia and increased limbs muscle tone were more noticeable on her left side 
with cogwheel rigidity. Her posture was stooped; hands and arms slightly flexed. Her 
gait was remarkable for absence o f arm swing and presence o f foot shuffling. She had 
no chorea, tremor, dystonia or cerebellar signs. Otherwise her physical examination 
was within normal limits. We evaluated the movement disorders with the motor 
section o f the Unified Parkinson’s Disease Rating Scale (UPDRS). Her movements 
were similar to those o f Parkinson’s disease and her total motor score was 28 [normal 
value 0] (Table 1).
Initial blood tests, including complete blood count, sedimentation rate, serum 
electrolytes, liver and kidney functions, were all w ithin normal limits. Throat swab at 
the time o f examination was positive for streptococci-non-group-A. Anti-streptolysin 
O titer was elevated, 585 IU/ml [normal < 200 IU/m l]. Further laboratory evaluation 
demonstrated normal level o f thyroid stimulating hormone, anti-nuclear antibody, C3, 
C4, copper and caeruloplasmin. Brain MRI including basal ganglia imaging, EEG and 
echocardiogram were normal. DYT1 mutation for torsion dystonia was negative. 
Neurological examinations three and six months after her initial referral revealed 
gradual fading o f the parkinsonian signs with residual movement abnormalities in gait 
and posture at three months follow-up (figure 1). The total UPDRS preformed in her 
follow up visits after three and six months was 18 and 15 respectively (Table 3.c).
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Table 3.c. Motor UPDRS (Unified Parkinson 's Disease Rating Scale) evaluation on 
presentation and follow up
u Motor Examination At presentation 3 months follow up 6 months follow up
18 Speech 1 1 1
19 Facial expression 3 I 1
20 Tremor at rest 0 0 0
21 Action or postural tremor- Right hand 0 0 0
- Left hand 0 0 0
22 Rigidity - Right arm 3 0 0
-Left arm 3 2 1
-Right leg 2 0 0
-Left leg 2 1 0
23 Finger taps-Right 1 1 0
-Left 1 1 1
24 Hand movement -Right 2 2 2
-Left 2 2 2
25 Rapid alternating movements -Right hand 1 1 1
-Left hand 1 2 2
26 Leg agility -Right 1 0 0
-Left 1 1 1
27 Rising from chair 0 0 0
28 Posture 1 0 0
29 Gait 1 1 1
30 Postural stability 1 1 1
31 Body bradykinesia and hypokinesia 1 1 1
Total score 28 18 15
Each task is graded on a scale from 0-4:
0= normal; 4= severe impairment, can barely perform the task.
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3.4.3. Hypotheses on post-encephalitic Parkinsonism
These descriptions o f post-infectious Parkinsonism (both cases after streptococcal 
infection) suggest that the spectrum o f post-streptococcal movement disorders is 
broader than previously described and includes an akinetic-rigid syndrome. The cases 
(particularly case one) were reminiscent o f encephalitis lethargica, an infection- 
associated syndrome o f encephalitis, Parkinsonism, psychiatric disturbance, sleep 
disturbance and brainstem features. The novel finding that streptococcus may induce 
an immune mediated Parkinsonian syndrome required further study, and patient 
ascertainment.
3.5. Encephalitis lethargica (n=20)
3.5.1. Patient recruitment of encephalitis lethargica
In view o f the two cases described in the previous section, I recruited further patients 
presenting with a similar syndrome o f acute onset, post-infectious or immune 
mediated Parkinsonism. This became possible after I presented the index cases at 
regional and national conferences. Cases were subsequently referred to Great Ormond 
Street Hospital or the National Hospital for Neurology and Neurosurgery for further 
assessment.
A ll included patients were referred between April 1999 and May 2002 with a new 
onset CNS dysfunction resulting in an encephalitis lethargica-like syndrome (sleep 
disorder and associated lethargy, Parkinsonism and neuropsychiatric disorders).
3.5.2. Demographics and past medical history
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The demographics and clinical characteristics o f the patients with the EL phenotype 
are presented in appendix 3 (chapter 13). Other than ‘high functioning’ autism (n = l) 
and Down’s syndrome (n=l), there was no past medical history o f note.
3.5.3. Preceding infectious illness and aetiological investigations
Eleven patients (55%) had an infection shortly before disease onset. The infections 
were described as upper respiratory tract infection (n=6) and tonsillitis (n=5). Patient 
presentation was described as acute, subacute or insidious in 35%, 50% and 15% 
respectively. Investigations were tailored according the age o f the patient and 
presentation characteristics. Negative investigations are presented in appendix 4 
(chapter 13).
Two patients had concomitant tonsillitis at assessment; Group A streptococcus was 
grown from the throat in both patients. ASO titres were performed in all patients and 
controls. The data is presented in table 3.d. The mean ASOT in the EL-like cohort 
was significantly elevated compared to the child dystonia (p<0.005), adult neurology 
(p<0.0001) and adult healthy controls (p<0.0001). ASOT was elevated in 65% o f EL 
patients, but normal in 35%. There was no statistical difference between the EL group 
and the child streptococcal group (p= 0.17)
Table 3.d. Streptococcal serology in encephalitis lethargica (EL) cohort compared to 
control groups
Group EL Child Child Adult Adult
streptococcus dystonia neurology healthy
__________ controls______controls controls_____ controls
301 332 151 133 122
(198-404) (269-395) (99-203) (98-168) (101-143)
ASOT IU/ml 
mean
(95% confidence 
intervals)
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3.5.4. Movement disorders
3.5.4.1. Parkinsonism
A ll patients had signs consistent with Parkinsonism. Twelve o f 20 patients had a 
Parkinson’s syndrome according to UKPDS Brain bank criteria; six had all three 
cardinal features (bradykinesia, rigidity and rest tremor), two had bradykinesia with 
postural instability, two had bradykinesia with rigidity, and two bradykinesia with rest 
tremor. The other eight patients had isolated features o f the Parkinsonian phenotype; 
bradykinesia / akinesia (n=6), rest tremor (n = l) and rigidity with rest tremor (n = l).
3.5.4.2. Dyskinesias
In addition to Parkinsonism, 11 patients had evidence o f concomitant dyskinetic 
movement disorders; dystonia (n=6) o f whom 5 had a generalized dystonia, 
chorea/hemiballismus (n=2), motor tics (n=2), stereotypies (n=2), facial grimacing 
and blepharospasm (n=l each). Three patients had oculogyric crises.
3.5.5. Behavioural alteration and psychiatric disorders
The psychiatric manifestations are described in appendix 3 (chapter 13). Seventeen o f 
20 patients had psychiatric disturbance. Mutism occurred in 10 patients. Emotional 
disorders were also common and included depression DSM-IV (n=6), obsessive- 
compulsive disorder DSM-IV (n=3) and anxiety (n=2). Apathy and catatonia occurred 
in four and three patients respectively.
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3.5.6. Other clinical features
3.5.6.1. Sleep disturbance and lethargy
19 o f 20 (95%) patients had sleep disturbance; hypersomnolence (n=12), insomnia 
(n=2) and sleep inversion (n=5). It was usually possible to rouse the somnolent 
patients without difficulty, but they would fall asleep i f  not stimulated. Other sleep 
abnormalities included vivid nightmares (n=2) and sleep walking (n=l). 10 patients 
had lethargy, which was in excess o f what would be expected for the degree o f motor 
weakness.
3.5.6.2. Other features
Five patients had profound reduction in consciousness and required ventilation. Eight 
patients had ocular abnormalities (4 ophthalmoplegia, 3 pupillary disturbance, 1 
ptosis, 1 optic neuritis). Hyperventilation and nocturnal bradycardia were also 
observed (appendix 3). Seizures and memory loss occurred in 3 patients each. 
Symptoms o f intracranial pathology were common, including headache (n=6), 
photophobia (n=3) and meningism (n=2). Other features included incontinence (n=3) 
and limb pains (n=2).
3.5.7 Clinical outcome
10 patients had a monophasic illness, seven a relapsing polyphasic course, two static 
disease and one had progressive disease until death. After a mean follow-up o f five 
months (range 2 months-14 months), only five patients have made a complete 
recovery to date; O f the 15 patients with continuing impairments, six have a persisting
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movement disorder and ten have disabling neuropsychiatric disturbance (one patient 
has both movement and psychiatric disorders).
3.5.8. Histopathology of encephalitis lethargica
One patient died o f the acute encephalitis lethargica illness. The case and 
histopathological findings are now presented.
3.5.8.1. Case history
A 69 year old male with a history o f chronic obstructive airways disease presented 
following a febrile illness with profound somnolence and confusion. He became 
withdrawn, apathetic and stopped caring for himself. He subsequently developed 
bradykinesia, bilateral rigidity with cogwheeling. There were no pyramidal, cerebellar 
or sensory signs. MR neuroimaging revealed bilateral enhancement o f the basal 
ganglia with associated swelling o f the striatum and globus pallidus. CSF revealed no 
cells but intrathecal oligoclonal bands. CSF per for Herpes simplex virus, varicella 
zoster virus and human herpes virus 6 and 7 were negative. His neurological 
syndrome progressed over 3 weeks and was complicated by a lower respiratory tract 
infection, subsequent respiratory failure and the patient died.
3.5.8.2. Histopathological findings
Histological examination revealed perivascular lymphocytic cuffing that was best 
developed in the basal ganglia, but also seen to a lesser extent in the cerebral cortex 
and cerebellum (Figure 3.6a). Changes were most extensive in the putamen, globus 
pallidus and the amygdala. There was no neuronophagia and no viral inclusions. 
Staining o f striatal sections identified the infiltrating cell populations as T and B
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Figure 3.6.a. Perivascular cuffing 
Figure 3.6.b. T-lymphocyte staining. 
Figure 3.6.C. B-lymphocyte staining.
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lymphocytes (Figure 3.6b+c). Staining for amyloid and complement was negative. 
There were reactive astrocytes and activated macrophages in the striatal parenchyma.
3.6. Investigation of post-streptococcal neuropsychiatric 
syndromes
3.6.1. Routine blood and CSF investigations
The mean erythrocyte sedimentation rate (ESR) was elevated in all phenotypes, 
although not all patients had an elevated ESR (>20 mm/hr). The mean ESR was 26.5 
mm/hr in the dyskinesia cohort, 38 mm/hr in the PSADEM cohort, and 30 mm/hr in 
the EL cohort.
The CSF investigations in the different post-streptococcal neuropsychiatric syndromes 
are presented in table 3.e below.
Table 3.e. CSF findings in the different post-streptococcal neuropsychiatric 
syndromes (number tested in brackets).
Syndrome CSF white cell CSF protein- % CSF oligoclonal
count- % elevated ** bands- % intrathecal
elevated * or mirrored pattern
Dyskinesias 11% (n=9) 67% (n=9) 33% (n=9)
(n=40)
PSADEM (n=10) 40% (n=10) 70% (n=10) 100% (n=3)
Encephalitis 12% (n=16) 60% (n=20) 69% (n=l 3)
lethargica (n=20)
* A ll CSF white cells were lymphocytes
**  CSF protein elevated over 0.4 g/l
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As can be seen, there is non-specific evidence o f inflammation and immune activation 
in one third o f the main dyskinesia group and the majority o f EL and ADEM patients. 
There is frequently evidence o f mirrored IgG clones in the CSF and serum (consistent 
with a systemic clonal expansion o f IgG with cross over into the CSF). Occasionally, 
mainly in the EL phenotype, there is intrathecal synthesis o f IgG clones. However, 
sometimes there is no evidence o f IgG clones in CSF or serum using isoelectric 
focussing. However, it should be noted that the sample timings were not all during the 
acute phase.
3.6.2. Neuroimaging
Magnetic resonance neuroimaging is an important part o f any neurological syndrome 
investigation. MR neuroimaging is often done to exclude important aetiological 
causes such as space occupying lesions. Most o f the post-streptococcal 
neuropsychiatric patients underwent MR neuroimaging, and the results are reported 
here. Clearly, the MR neuroimaging is very important in the classification o f some o f 
the syndromes such as acute disseminated encephalomyelitis where disseminated 
inflammatory CNS lesions are characteristic and required for diagnosis. The MR 
neuroimaging results are summarised in table 3.f  below.
I l l
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Table 3 .f Abnormal imaging (inflammatory lesions) in the different clinical 
phenotypes, including presence o f basal ganglia lesions.
Syndrome (patients Percentage Percentage with Percentage with
with MR abnormal basal ganglia inflammatory changes
neuroimaging) inflammatory
changes
elsewhere in CNS
Dyskinesia (n=26) 12% 12% 0%
PSADEM (n=10) 100% 80% 70%
EL (n=20) 40% 40% 10%
As can be seen, in the dyskinesia cohort, the MR imaging was usually normal. By 
contrast, in PSADEM and EL, imaging was often abnormal and is described in detail:
3.6.3.I. Post-streptococcal acute disseminated encephalomyelitis
The inflammatory lesions were specifically localised to the following sub-regions in 
the PSADEM patients: Basal ganglia lesions were identified in 8 o f 10 patients (80%) 
This involved the caudate (50%), putamen (60%), and globus pallidus (40%). Other 
deep grey structures involved included the thalamus (60%), subthalamus (30%), and 
substantia nigra (50%). Lesions were also seen in the supratentorial white matter 
(70%), brainstem (40%), cerebellum (20%), and spinal cord (10%). Only 2 patients 
had no reported basal ganglia lesions, although one o f these had a thalamic lesion. In 
comparison, basal ganglia lesions were reported in only 18% (4/22) o f control ADEM 
(non-streptococcal) patients during the same time period (Dale et al., 2001). Using 
Fisher’s exact test, MR1 basal ganglia lesions were statistically more prevalent in the 
PSADEM group compared to non-streptococcal ADEM (p=0.0002). A ll lesions were
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T2 hyperintense, whereas T1 sequences were normal. Gadolinium was not routinely 
given. Examples o f the MR neuroimaging are given in figures 3.7 and 3.8.
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Figure 3.7. MR neuroimaging o f PSADEM patient. Brain T2-weighted (coronal 
section) demonstrating lesions involving the left caudate (short arrow) and bilateral 
putamen nuclei (long arrow).
Figure 3.8. MR neuroimaging o f two separate PSADEM patients showing 
predominant basal ganglia lesions in both patients (arrows).
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3.6.3.2. Encephalitis lethargica
Magnetic resonance neuroimaging was performed in all patients and was abnormal in 
8 (40%). A ll abnormal images had high signal lesions on T2 imaging. The 
abnormalities were present in basal ganglia (n=8), midbrain/tegmentum (n=5), 
thalamus (n=2), cerebral peduncle (n=l) and temporal lobe (n=l) (Figure 3.9). Three 
patients had convalescent imaging during the recovery phase o f the illness, which 
showed resolution o f the abnormalities (Figure 3.9).
Figure 3.9. MRI brain in a somnolent EL patient, showing inflammatory lesions in the 
midbrain and periaqueductal grey matter (Figure 3.9a), right putamen (Figure 3.9b) 
and bilateral thalami and midbrain (Figure 3.9c). Convalescent imaging showing 
resolution o f the inflammatory changes in the thalami and midbrain (Figure 3.9d).
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3.7 Summary of proposed post-streptococcal 
neuropsychiatric disorders
This series is not epidemiological in design, but is a selected patient population. Also 
the patients were recruited due to the presence o f extrapyramidal movement disorders. 
For these reasons, this description cannot truly represent the true spectrum o f post­
streptococcal neuropsychiatric disorders in the childhood population. However, this 
data has highlighted new and important post-streptococcal neuropsychiatric 
phenotypes. The findings o f the clinical part o f this thesis can be summarised by the 
following simple (Figure 3.10) and detailed (Figure 3.11) figures:
Figure 3.10. Summary o f the common clinical features ofpost-streptococcal 
neuropsychiatric syndromes.
Extrapyramidal Movement 
disorders Psychiatric disorders
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Figure 3.11. Detailed summary o f the clinical features o f poststreptococcal 
neuropsychiatric syndromes.
Dyskinetic movement disorders
• Chorea
• Tics
• Dystonia 
Akinetic-rigid movement disorders
• Parkinsonism
Psychiatric disorders
• Emotional disorders (OCD, 
anxiety, depression)
• Conduct disorders 
I • ADHD
The clinical features can also be summarised according to the clinical syndrome 
(Table 3.g):
Table 3.g. Summary o f proposed post-streptococcal neuropsychiatric phenotypes
Phenotype Movement
disorder
Psychiatry Other features Neuroimaging
SC Chorea Emotional 
disorders plus
Insomnia Normal
PANDAS Tics Emotional 
disorders plus
- Normal
PSADEM Dystonia- Emotional Encephalopathy, Basal ganglia
Parkinsonism disorders plus pyramidal signs and other CNS 
lesions
EL Parkinsonism Emotional Somnolence, Basal ganglia
plus disorders lethargy leisons
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In addition, the post-streptococcal neuropsychiatric phenotype includes the presence 
o f sleep disorders. Notably, in the dyskinetic phenotype, the patients were more like ly 
to suffer from insomnia or reduced sleep. In contrast, the Parkinsonian patients were 
more likely to suffer from somnolence or increased sleep.
3.8. Anti-neuronal antibody findings in the post-streptococcal 
neuropsychiatric syndromes
The thesis by Andrew J Church (findings to be discussed in chapter 4) examined the 
prevalence o f anti-neuronal antibodies (against basal ganglia antigens) in the patients 
w ith post-streptococcal neuropsychiatric syndromes. A  summary o f the anti-neuronal 
antibody results is presented in Table 3.h.
As can be seen, there were common autoantibodies in the serum o f patients with post­
streptococcal dyskinesia, ADEM and Parkinsonism. These findings have been 
published (Church et al., 2002; Dale et al., 2004). The autoantibodies bound to 
autoantigens o f molecular weight 40, 45 and 60 kDa. In addition, in the encephalitis 
lethargica group, a 98 kDa autoantigen was recognised more frequently in patients 
than controls. Identifying these autoantigens w ill be the immunological aim o f this 
thesis.
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Table 3.h Anti-basal ganglia antibodies (ABGA) in post-streptococcal 
neuropsychiatric syndromes and controls as measured by Andrew J  Church (Church 
et al., 2004; Dale RC et al., 2004; Dale RC et al., 2001). There were other bands seen 
in some patients or controls, thought to be o f lesser significance and not reported in 
this table.
Group
Post-streptococcal 
dyskinesia (n=40) 
Post-streptococcal 
ADEM (n=10) 
Encephalitis 
lethargica (n=20) 
Child neurology 
controls (n=100) 
Child 
streptococcal 
controls (n=40) 
Child autoimmune 
controls (n=50) 
Adult neurology 
controls (n=50) 
Adult healthy 
controls (n=50)
Percentage with 
positive ABGA 
(Western blotting)
92.5%
100%
95%
4%
2%
10%
2%
4%
Autoantigen (kDa) 
binding (percentage) 
40 45 60
47.5% 40% 42.5% 
10% 0% 80%
55% 30% 55%
1% 0% 1%
0% 0% 2%
4% 0% 2%
2% 0% 0%
0% 0% 0%
Reference
Church AJ et al., 
2004 
Dale RC et al., 
2001 
Dale RC et al., 
2004 
Church AJ et al., 
2004 
Church AJ et al., 
2004
Church AJ et al., 
2004 
Dale RC et al., 
2004 
Dale RC et al., 
2004
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Chapter 4. Introduction- immunopathogenesis of post­
streptococcal neuropsychiatric disease
4.1. Concepts of CNS autoimmunity
4.1.1. Blood brain barrier
4.1.1.1. Composition and integrity
The blood brain barrier (BBB) protects the central nervous system from fluctuations 
in serum constituents and strongly lim its the access o f cells (such as immune cells) to 
the brain. The BBB consists o f the cerebrovascular endothelium, the choroid-plexus 
epithelium and the arachnoid membrane. There are three properties that distinguish 
the brain capillary endothelial cells from their peripheral counterparts, namely:
1. Dedicated tight junctions that are fusion sites between cells on adjacent 
plasma membranes.
2. Low rates o f endocytosis.
3. Specific transport and carrier molecules (Gloor SM et al., 2001). Although 
these characteristics make the BBB a robust barrier from the rest o f the body, 
proteins and cells are still capable o f accessing the brain either by diffusion 
through pores or via active transcellular passage (discussed later). 
Consequently under physiological conditions, CSF protein concentrations are 
normally 0.5% or less o f the respective plasma or serum concentration. The 
proteins diffuse across the BBB according to their size (or radius) with smaller 
proteins diffusing more rapidly. The degree o f diffusion obviously alters 
(increases) when the BBB is damaged. There are other features o f the BBB 
that protect the brain from immune cell access:
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a) Under physiological conditions, the endothelial cells o f the BBB express very 
low levels o f adhesion molecules (required for leucocyte migration) (Bart J, 
2000).
b) Transforming growth factor- (TGF-p) is made in the CNS and is present in the 
CSF. TGF-p suppresses T-lymphocyte proliferation, down-regulates adhesion 
molecules and markedly diminishes leucocyte migration (in contrast to 
Interleukin-1, Interferon-y and lipopolysaccharides). TGF-p therefore 
minimises immunological surveillance o f the brain.
However there are a number o f recent developments regarding the brain and immune 
surveillance that require specific discussion. It used to be thought that there was no 
antigen drainage from the brain. However, it has recently been shown that CSF and 
brain fluid move through the brain via Virchow-Robin spaces to lymphatic-like 
systems beneath the cribriform plate, and subsequently along cranial and spinal nerve 
roots (Kida S et al., 1995). Antigen from the brain can then flow into the cervical 
lymph node system and therefore be seen by the immune system (Cserr HF, Knopf 
PM, 1992). These CNS-derived antigens can provoke a Th2 lymphocyte and B 
lymphocyte response (Harling-Berg CJ et al., 1999).
In conclusion, although the BBB provides the brain with an important barrier, it is by 
no means impenetrable. Indeed proteins gain access into the CNS at a rate dependent 
upon the protein size. Likewise, immune surveillance does occur in the brain, 
although at a very low level, and brain antigens can drain into the cervical lymph 
system resulting in potential immune activation.
4.1.1.2. Blood brain barrier and T-lymphocytes
There is no doubt that T-lymphocytes are capable o f surveilling the CNS parenchyma, 
although this occurs at a low level (Hickey WF, 1999). I f  there is strong
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immunological activity in the body, irrespective o f whether the CNS is involved, there 
w ill be an elevated number o f T-cells in the CNS (Hickey WF and Kimura H, 1987). 
What is clear is that only activated T-cells, particularly secondary to recent antigen 
stimulation (Fritz RB et al., 2000) are capable o f gaining entry into the CNS. Resting 
or naive T-lymphocytes cannot gain access (although this has been partly questioned 
recently). The level o f surveillance is partly related to the low number o f adhesion 
molecules on the brain endothelial membranes, and also to the lower level T- 
lymphocyte migration into the cerebrum compared to the spinal cord (Phillips LM and 
Lampson LA, 1999).
It appears that there are no homing mechanisms for T-cells to find a CNS antigen. 
Rather the T-cells perform ‘antigen-seeking’ in a random manner (Carrithers MD et 
al., 2000). I f  the T-cells do encounter their CNS antigen, they accumulate there and 
cause secondary inflammation (Hickey WF, 1991). Despite the fact that T-cells can 
gain access to the CNS, they do find the CNS environment hostile and rapidly die via 
an apoptotic mechanism (Bauer J et al., 1998). Another interesting fact is that not all 
activated T-cells may have a detrimental effect on the CNS. Indeed some T-cells have 
a protective effect and via T-cell produced neurotrophic factors can result in neuronal 
repair (Hohlfeld R, 2000).
4.1.1.3. Blood brain barrier and antibodies or B-lymphocytes
Antibodies can gain access to the CNS in a number o f ways. Firstly under 
physiological conditions, antibodies (like other proteins) diffuse via pores into the 
CSF and CNS, albeit at low levels (0.1-0.4%) o f serum levels (Eeg-Olofsson O et al., 
1981). Clearly, i f  the BBB is disrupted then antibodies could diffuse more readily into 
the CNS. Practical markers o f demonstrating antibody presence in the CSF include 
performing isoelectric focussing electrophoresis o f CSF and serum. This can
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demonstrate clones o f IgG in the respective compartments and can differentiate 
whether antibodies are in the CSF alone (intrathecal production) or are also 
represented in the serum (mirrored pattern).
Alternatively, antibodies can be synthesised locally in the CNS by B-lymphocytes that 
have entered the CNS, clonally expanded and differentiated into antibody secreting 
plasma cells. A recent study demonstrated that B-lymphocytes, after activation, are 
capable o f traversing the intact BBB, locating their specific antigen within the brain, 
and differentiating into antibody producing plasma cells (Knopf PM et al., 1998). It 
would therefore appear that B-lymphocytes survey the normal CNS as do T- 
lymphocytes. It is not clear whether this process is dependent upon T-cell help.
4.1.2. Molecular mimicry
4.1.2.1. Concepts of molecular mimicry
There are a large number o f ways in which beta-haemolytic Streptococci can induce 
immune mediated neuronal damage, including polyclonal activation o f lymphocytes, 
superantigen activation, cytokine activation or exposure o f previously unexposed 
(cryptic) self-antigens. A  further potential mechanism is termed molecular mimicry. 
The molecular mimicry hypothesis states that a susceptible host encounters a micro­
organism that has antigens that are immunologically similar to the host antigens, but 
differ enough to induce an immune response in the host (Albert LJ and Inman RD, 
1999). This hypothesis has remained popular as a mechanism for autoimmune 
induction despite the paucity o f evidence that is clinically relevant in humans.
4.1.2.2. The host and molecular mimicry
Although the molecular mimicry hypothesis is appealing, there are a number o f 
important issues that have been recognised over the last decade.
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The immune system recognises itself and has developed mechanisms to avoid 
attacking itself (self tolerance). Indeed, self-reactive T-cells are negatively selected in 
the thymus and deleted by apoptosis, or rendered anergic (Ohashi PS et al., 1996; 
Goodnow CC et al., 1996). However, some T-cells are not deleted, sometimes 
because the autoantigens are present peripherally at a very low level (or cryptic, i.e. 
unseen) (Sercarz EE et al., 1993). Also high avidity T-cells are deleted in the thymus, 
whereas low affin ity T-cells may escape deletion and may be subsequently capable o f 
inducing autoimmune disease (Foumeau JM et al., 2004). Loss o f tolerance may 
depend on a number o f sequences such as presentation o f the antigen (e.g. by an 
appropriate antigen presenting cell and major histocompatibility complex) and also by 
a secondary signal such as cytokine secretion (Rose NR, 1998). Similarly, 
autoantibodies are also present in healthy individuals. In one study, 3% o f monoclonal 
antibodies reactive to different virus proteins cross-reacted with normal tissue 
antigens in mice (Srinivasappa J et al., 1986). In other words, autoantibodies 
themselves are not uncommon although are usually o f low levels, low avidity and o f 
little pathogenic relevance.
4.I.2.3. Immunogenic epitopes: sequence versus structural homology
In the early conception o f molecular mimicry, it was proposed that amino acid
sequences were required to be identical between the host and the organism to activate 
T-cell receptors or bind cross-reactive auto-antibodies. Early protein sequence 
database comparisons stipulated that a seven amino acid sequence or more was 
required to be theoretically significant (Karlsen AE and Dyrberg T, 1998). However it 
soon became apparent that immune reactivity (particularly by T-cells) was degenerate 
and did not require such specific interaction. Indeed only a few crucial residues 
(amino acids) were required to result in binding o f T-cell receptors (Kohm AP et al.,
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2003). Subsequently it has become clear that the structure or conformation o f antigens 
is also highly relevant, and this homology may result in proliferation o f T or B cells 
(Kohm AP et al., 2003).
4.1.2.4. Problems in demonstrating molecular mimicry in clinical 
disease.
Autoimmune diseases have been linked to infectious diseases for decades. One 
problem with proving a link is to demonstrate a reliable temporal association between 
a particular organism and disease. This is d ifficu lt because the infection may have 
long resolved before the disease is clinically evident (Albert LJ and Inman RD, 1999). 
Secondly, molecular mimicry may be a secondary phenomenon caused by an 
alteration in host antigens (revealing previously cryptic antigens) and the creation or 
alteration o f neoepitopes. Therefore reactive T-cell or autoantibodies could be formed 
as a consequence of, rather than the cause of, tissue injury.
In summary, although the molecular m im icry hypothesis is tempting, there are a 
number o f critical problems that must be recognised or overcome:
1. Antigenic mimicry alone may not overcome self-tolerance, and may require 
co-stimulation such as cytokines.
2. Antigenic homology or proliferation does not by itself indicate pathogenic 
mimicry.
3. A tissue-specific antibody response does not, by itself, indicate pathogenic 
mimicry, but may be secondary to tissue injury.
4. Antigen mimicry may elicit tolerance o f the host immune response, rather 
than autoimmunity.
5. A genetic vulnerability is likely to be relevant in most autoimmune diseases 
in addition to the environmental trigger. Most genetic vulnerability is related 
to antigen presentation and major histocompatibility complexes (MHC).
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4.1.2.5. Examples of molecular mimicry in humans
A number o f microorganisms have been incriminated in putative autoimmune
diseases as described in table 4.a.
Table 4.a. Proposed molecular mimicry in human diseases (Albert LJ and Inman RD, 
1999)
Autoimmune disease Proposed antigen Proposed
pathogen
Immune cross­
reactivity
Type 1 Diabetes GAD 65 Coxsackievirus T cell
mellitus
Rheumatoid arthritis HLA-DRB1, 
Heat shock protein 
60
Mycobacterium 
tuberculosis, heat 
shock protein 65
T and B cells
Multiple sclerosis Myelin basic 
protein
Multiple viruses T cells
Spondyloarthropathies HLA-B27 Multiple gram 
negative bacteria
B cells
Graves disease Thyrotropin
receptors
Yersinia
enterocolitica
B cell
Although there are a number o f lines o f evidence supporting the role o f molecular
mimicry in these diseases, the evidence is incomplete and remains controversial
(Albert LJ and Inman RD, 1999). Perhaps the best evidence, and pleasingly for the
sake o f this thesis, comes from work in rheumatic fever (RhF). RhF remains the
prototype o f post-infectious immune mediated disorders. The primary advantage in
RhF investigation is that beta-haemolytic Streptococci have been conclusively proven
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to be the cause o f RhF. Most o f the molecular mimicry data has focussed on the 
rheumatic heart disease (the immunological data related to the brain w ill be presented 
shortly). RhF patients have antibodies that bind to the M protein o f Type 5 
streptococci that cross-react with myocardial tissue (Zabriskie JB et al., 1966; Dale JB 
and Beachey EH, 1985; Kaplan MH and Dallenbach FD, 1961) and can result in the 
destruction o f rat heart cells in vitro (Adderson EE et al., 1998). Further studies have 
demonstrated that infdtrating T-lymphocytes from RhF heart lesions are cross­
reactive with immunodominant epitopes o f the streptococcal M protein (Guilherme L 
et al., 1995). This group have specifically shown CD4+ T-cell cross-reactivity 
between the M5 protein and human mitral valve proteins and myosin peptides 
(Guilherme L and Kalil J, 2002).
4.1.3. Autoantibody criteria for pathogenicity
The presence o f antibodies in serum does not necessarily infer pathogenicity. For
example, antibodies could be produced as part o f tissue damage. In order to 
demonstrate that a disorder is antibody mediated autoimmunity, five criteria must be 
fu lfilled (Archelos JJ and Hartung HP, 2000);
1. Presence o f auto-antibodies.
2. Presence o f antibodies in target tissue.
3. Induction o f disease in animal model by passive transfer o f antibody.
4. Induction o f disease in animal model by auto-antigen immunisation.
5. Improvement o f clinical symptoms after removal o f antibodies with plasma 
exchange.
A  number o f proposed autoimmune CNS disorders are summarised in table 4.b., 
including the evidence acquired to date in each condition (Lang B et al., 2003).
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Table 4.b. Criteria for autoantibody pathogenicity in proposed immune mediated CNS disorders
Antibody
specificity
Disorder Ab’s in 
CSF
Response to 
immunotherapy
Pathogenicity o f autoantibodies Associated
condition
Anti-Hu, Yo, 
M al/2, Cv, Tr
Paraneoplastic Neurological 
syndromes
+' Little None Multiple
tumours
Anti-VGCC
Paraneoplastic cerebellar 
degeneration
*
+ Some Anti-VGCC antibodies from LEMS 
down-regulate VGCC
SCLC
Anti-VGKC
Morvan’s syndrome 7 Yes Anti-VGKC antibodies in NMT 
patients suppress K+ currents in human 
neuroblastoma cells
thymoma + 
NMT
Reversible Limbic 
encephalitis
9 Yes thymoma
Anti-GluR3
Rasmussen’s Encephalitis 9 Transient effects in 
some patients
Antibodies produced to GluR3 proteins 
elicit RE symptoms
Nil
Anti-GAD
Stiff-Man Syndrome
---------*-------
+ Good response -
Progressive Cerebellar 
ataxia
+ Antibodies inhibit GABA-mediated 
transmission in Purkinje cells
Batten’s disease 9 NK Deletion in 
CLN3 gene
Anti-DNA
Neuropsychiatric SLE
+ Yes Antibodies mediate apoptopic death of 
neurones SLE
Anti-phopholipid Response to steroids
Anti-basal
ganglia
antibodies
Post-streptococcal CNS 
syndromes
+ Some Antibodies mediate repetitive 
behaviours in rats
Group A 
Streptococcal 
infection.
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4.2. Immunopathogenesis in post-streptococcal CNS disease
4.2.1. Theoretical possibilities of immunopathogenesis
There are a number o f different possible mechanisms by which beta-haemolytic
streptococcus can induce neuronal damage or dysfunction. The different mechanisms 
are summarised below:
Figure 4.1. Possible immune mechanisms in post-streptocococal CNS disease.
Toxin
mediated mediated
Cytokine
of CNS
invasion
Direct
antibody
mediated
B-cell or
antigen
mediated
Super-T-cell
mediated
Beta-haemolytic Streptococcus throat infection
Neuronal dysfunction
Clearly some o f these mechanisms are considered less or un-likely. For example there 
is no evidence that intact streptococci gain access to the CNS in post-streptococcal 
CNS disorders. Furthermore, the fact that a large proportion o f patients make a full 
recovery without any apparent brain damage makes T-cell injury and associated 
cytotoxicity less likely (although not impossible). Although a large number o f
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mechanisms are theoretically possible, most attention has focussed on B-cell / 
antibody theories. It should be mentioned that a number o f different immune 
mechanisms might be occurring concurrently.
4.2.2. Pathology
As post-streptococcal CNS syndromes are rarely fatal, pathological examination has 
been limited to a few case reports and case series. By virtue o f their fatal nature, it is 
possible that these post-mortem descriptions may represent the more severe end o f the 
spectrum. It is also possible that some o f the early reports may have mistakenly 
included cases o f unrecognised genetic or neurodegenerative disorders such as 
Huntington’s disease or metabolic disease.
The histological findings can be separated into three main groups:
1. Inflammatory (encephalitic) features
2. Degenerative features
3. Thromboembolic features (rarely)
Table 4.c reviews the reports and histological features o f SC (there are no 
pathological reports o f PANDAS). In view o f the conflicting features (inflammatory 
or degenerative), some authors have suggested that the inflammatory features are 
typical o f the acute disease, whereas degenerative features are more typical o f 
subacute or chronic disease. Alternatively, some authors have suggested that 
Sydenham’s chorea is a syndrome only, w ith a number o f different pathological 
processes causing the SC syndrome.
In the inflammatory cases, the most consistent finding is o f encephalitis, with 
perivascular small cell infiltration predominantly o f the basal ganglia and to a lesser 
extent the cortex (Greenfield JG and Wolfsohn JM, 1922; Marie P and Tretiakoff C,
1920). The caudate and putamen were usually the most severely involved basal 
ganglia regions (Greenfield JG and Wolfsohn JM, 1922; Marie P and Tretiakoff C,
130
131
1920). Perivascular infiltration by lymphocytes (particularly small round cells- 
probably plasma cells) was characteristic in these descriptions.
Table 4.c. Summary o f pathological reports o f SC.
Reference Predominant feature Detail
Colony HS et al., 1956 Degenerative Cortex and thalamus
Lewy FH, 1923 Degenerative and 
inflammatory
-
Marie P and Tretiakoff C, Inflammatory Perivascular inflmmation
1920 o f basal ganglia
Greenfield JG and Inflammatory Perivascular inflammation
Wolfsohn JM, 1922 o f basal ganglia and 
cortex.
Ziegler LH, 1927 Degenerative -
Gordon RG and Norman 
RM, 1935
Degenerative -
Lhermitte Jand Pagniez P, Inflammatory or -
1930 Degenerative
Van Bogaert L and Inflammatory or -
Bertrand 1, 1932 Degenerative
Von Santha K, 1932 Vascular ‘Rheumatic encephalitis’
Glaser GH, 1952 Vascular Reminiscent o f CNS lupus
LehoczkyaTV, 1941 Inflammatory, 
degenerative or vascular
-
Delcourt and Sand 1908 Inflammatory (16 cases) Perivascular inflammation 
o f basal ganglia and cortex
Guizzetti and Camisa, Inflammatory and vascular Disseminated encephalitis
1911 (n=2) with secondary ischaemia 
o f cortex
Harvier and Levaditi, 1920 Inflammatory Similar to encephalitis 
lethargica. Perivascular 
inflammation o f 
mesencephalon.
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4.2.3. Auto-antibodies in post-streptococcal CNS disease
4.2.3.1. Sydenham’s chorea.
Support for the antibody hypothesis was first demonstrated by Husby who described 
anti-neuronal antibodies using an immunofluorescent technique in 46% o f 
Sydenham’s chorea patients (n=30), compared to 14% o f rheumatic fever (without 
chorea n=50), and only 1.8-4% o f control subjects (n=203) (Husby G et al., 1976).
The antibodies demonstrated a cytoplasmic pattern o f binding to caudate and 
subthalamus neurones, with occasional weaker staining in the cortex and medulla. 
Furthermore, Husby demonstrated a potential correlation between antibody reactivity 
and the clinical status, with antibody disappearance on chorea remission. In addition, 
the antibodies were removed by pre-incubating with a preparation o f isolated caudate 
neurones, but not cerebral cortex or mouse liver, supporting antibody specificity to 
caudate neurones (Husby G et al., 1976). Two further studies have expanded upon 
these findings; both demonstrated antibodies reactive against basal ganglia neurones 
universally in acute Sydenham’s chorea (100%), although less commonly in the 
chronic or persistent stage (63%) (Church AJ et al., 2002; Kotby A  A  et al., 1998; 
Morshed SA et al., 2001). A further study using immunofluorescence showed 
increased IgG to neuronal tissue in SC compared to normal controls (Morshed SA et 
al., 2001). Although antibody assays using immunofluroescence were important in 
establishing a putative antibody hypothesis, Western immunoblotting studies by 
Church have suggested a conserved group o f autoantigens are involved in auto­
antibody binding (Church AJ et al., 2002). Andrew Church developed this method at 
the Department o f Neuroinflammation, Institute o f Neurology. The antigen was post 
mortem human caudate and putamen from the Queen Square brain bank. The antigen 
was homogenised and delipidated before being solubilised with sodium dodecyl 
sulphate. The assay was protein standardised and controls run on each blot (Church
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AJ et al., 2002). The Western blotting suggested that a conserved group o f brain 
proteins were involved in autoantibody binding. 100% o f the acute SC group (n=20) 
had positive Western blotting binding compared to 69% o f the persistent SC group 
(n=l 6), 13% o f the RhF group (n=l 6) and 0% o f the healthy group (n=l 1). In the 
acute SC group there was binding to a 40 kDa protein in 50% o f patients, 45 kDa 
protein in 50% o f patients and 60 kDa protein in 40% o f patients. Only 15% had no 
reactivity to any o f these antigens (Church AJ et al., 2002). The persistent SC group 
had similar autoantigens (Church AJ et al., 2002). Although these were the 
predominant proteins, there were other autoantigens o f 30kDa protein in 20% o f 
patients, 50 kDa protein in 25% o f patients, 80 kDa in 30% o f patients and 95kDa 
protein in 25% o f patients. The two rheumatic fever patients with positive binding had 
autoantibodies to the 40 kDa protein. Church’s conclusions were that the 40, 45 and 
60 kDa brain antigens were discriminating autoantigens and possibily significant in 
the pathogenesis o f post-streptococcal CNS disorders. Using the same methods, but in 
a separate SC cohort, Church found 93% (13/14) o f acute SC patients had auto­
antibodies to brain proteins, again binding predominantly to the 60 kDa protein in 
50% o f patients, 40 kDa protein in 36% o f patients and 45 kDa protein in 21% o f 
patients (Church AJ et al., 2003). The primary immunological aim o f this thesis (as 
discussed later) is to identify these brain antigens using proteomic techniques. A 
further small study by a separate group also proposed that a 45 kDa was found in SC, 
although only during the acute stage (Frucht S et al., 1997).
Singer performed a similar examination for anti-neuronal antibodies in SC again using 
human basal ganglia (Singer HS et al., 2003). He separated supernatant, pellet and 
synaptosomal fractions and found elevation o f the mean optical density (using 
ELISA) in all three fractions in the SC versus control group, although no statistical 
difference was achieved. There was no difference using adult and paediatric brain
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tissue as the autoantigen. Western blotting was also performed although enhanced 
chemiluminescence was used (a notoriously sensitive method) which revealed a 
plethora o f auto-antibody bands in patient and control samples, the majority o f which 
were unlikely to have been relevant. Singer had to use discriminant analysis using 
ScanPack images to detect differences between the SC and control cohorts (Singer HS 
et al., 2003). Although there were clear differences between the SC and control 
cohort, a number o f autoantigen molecular weights were proposed as being significant 
(amongst them a 44 kDa autoantigen) (Singer HS et al., 2003).
4.2.3.2. PANDAS
Church measured anti-neuronal antibodies in 16 patients with post-streptococcal tics 
conforming to PANDAS criteria (Swedo SE et al., 1998). He compared the findings 
with 190 control samples (children with neurological disease, recent uncomplicated 
streptococcal infection, autoimmune diseases). Positive Western blotting was present 
in 15/16 (94%) PANDAS patients, compared to only 8/190 (4%) controls (Church AJ 
et al., 2004). Again, the positive autoantibody binding was to the same as that 
observed in SC, to brain autoantigens o f molecular weight 40, 45 and 60 kDa.
Pavone examined the sera o f 22 Italian patients w ith Swedo’s diagnostic criteria for 
PANDAS (Pavone P et al., 2004). They ranked antibody positivity using an 
immunofluorescent technique as described by Husby, and compared them with 22 
patients with confirmed GABHS tonsillitis but no neuropsychiatric features. Pavone 
found 64% o f the PANDAS patients had positive anti-neuronal antibodies compared 
to 9% o f the GABHS group (p<0.001 Fisher exact test).
Singer performed ELISA and Western blot analysis for anti-neuronal antibodies in 15 
PANDAS patients compared to 15 controls (Singer HS et al., 2004). Again Singer 
used the same methods as used in his SC cohort including ECL development and
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ScanPack interpretation with discriminant analysis (Singer HS et al., 2004). ELISA 
showed no difference in the means between the groups. Western blotting showed 
complex staining patterns with antibodies directed at multiple molecular weight 
regions in patients and controls. Discriminant analysis revealed differences between 
the PANDAS and controls only using the caudate supernatant antigen preparation, the 
difference most noticeable in the tic rather than OCD PANDAS patients. Singer’s 
conclusions, in contrast to Church’s conclusions, were that anti-neuronal antibodies 
are not elevated in PANDAS, nor are there clear autoantigens in PANDAS (Singer 
HS et al., 2004).
4.2.3.3. Other post-streptococcal CNS syndromes.
As part o f this thesis, I describe a broader clinical spectrum o f post-streptococcal CNS 
disorders including post-streptocococal acute disseminated encephalomyelitis (with 
dystonia), post-streptococcal dystonia and post-streptococcal Parkinsonism (Dale RC 
et al., 2001, Dale RC et al., 2002a, Dale RC et al., 2002b; Dale RC et al., 2004). Using 
Church’s methods these patients also had elevated anti-neuronal antibodies compared 
to controls. Again, the anti-neuronal antibodies bound to autoantigens o f molecular 
weight 40, 45 and 60 kDa (Table 3h). In the Parkinsonism cohort, there was an 
additional band to a 98 kDa autoantigen.
4.2.3.4. Anti-neuronal antibodies in Tourette syndrome and 
obsessive-compsulive disorder
As anti-neuronal antibodies are the proposed mediators o f SC and PANDAS, there 
have been cross-sectional studies examining the serum o f patients with Tourette 
syndrome for anti-neuronal antibodies. The results have been mixed and conflicting. 
Although some studies have demonstrated more prevalent anti-neuronal antibodies in 
TS (Singer HS et al., 1998; Church AJ et al., 2003; Wendlandt JT et al., 2001), other
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studies have failed to find an association (Singer HS et al., 1999; Loiselle CR et al., 
2003; Morshed SA et al., 2001). It is o f interest that the three positive studies have 
proposed a basal ganglia protein o f 60 kDa to be the most discriminating antigen in 
TS compared to controls (Singer HS et al., 1998; Church AJ et al., 2003; Wendlandt 
JT et al., 2001). We have reported that this 60 kDa antigen appears to be common to 
both SC and Tourette syndrome (TS), supporting the hypothesis that post­
streptococcal autoimmunity may also be important in TS (Church AJ et al., 2003). 
Hoekstra identified a 60 kDa antigen as heat shock protein 60 (Hoekstra PJ et al., 
2003). This is a ubiquitous heat shock protein, although a homologous protein exists 
on the streptococcal organism. However, the protein purification used by Hoekstra 
was possibly inadequate, as the brain homogenate proteins were only separated using 
1 -dimensional PAGE electrophoresis, and the candidate protein cut from a coumassie 
gel. It is probable that this one stage purification resulted in inaccurate results.
Hoekstra was able to demonstrate increased reactivity in the Tourette patients 
compared to controls (67% in Tourette patients compared to 40-42% reactivity in 
control groups) (Hoekstra PJ et al., 2003). It is acknowledged that longitudinal studies 
comparing clinical, microbiological and immunological markers are essential to 
define whether a true association exists in TS and OCD (Loiselle CR et al., 2003).
4.2.4.Cross-reactivity of antibodies with streptococcal and brain 
proteins
Although streptococcal organisms are the proposed mediators o f SC and PANDAS, 
relatively little attention has focussed on why beta-haemolytic streptococcus is 
capable o f producing immune-mediated brain disease. The favoured hypothesis is that 
antibodies cross-react between streptococcal and brain epitopes (molecular mimicry). 
Immunization o f rats with M6 streptococcal proteins has been shown to induce cross­
reactive anti-brain antibodies (Bronze MS et al., 1992; Bronze MS and Dale JB,
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1993). Furthermore, synthetic epitopes o f M6 protein sequences were capable o f 
inhibiting anti-brain antibodies from a patient with Sydenham’s chorea. Husby’s 
original experiments suggested that the antibodies against caudate neurones cross­
reacted with epitopes o f Group A streptococcal membranes (Husby G et al., 1976). It 
would also appear that the antibody cross-reactivity is specific to certain strains o f 
streptococcus (Dale RC et al., 2001; Husby G et al., 1976; Bronze MS and Dale JB, 
1993).
A  recent and exciting development was the first attempt to directly link antibody 
cross-reactivity between specific streptococcal and neuronal antigens. Kirvan et al. 
took peripheral blood lymphocytes from patients with SC and created hybridomas and 
therefore monoclonal antibodies (Kirvan CA et al., 2003). One monoclonal antibody 
showed strong reactivity with N-acetyl-beta-D-glucosamine (GlcNAc), a Group A 
streptococcus carbohydrate moiety on the streptococcal cell wall. Using competitive 
inhibition assays (ELISA and immunofluroescence), they demonstrated that these 
antibodies also bound to lysoganglioside GM1, a dominant brain ganglioside present 
on the neuronal membrane. This group also showed that the antibodies bound to the 
neuronal membrane resulting in increased intracellular signalling via CaM kinase II 
activation (76% above the basal level). They also showed that acute SC serum and 
CSF could also activate CaM kinase II compared to controls. In summary, this group 
demonstrated a direct link between a streptococcal carbohydrate moiety and neuronal 
proteins resulting in altered neuronal cell signalling (Kirvan CA et al., 2003). The 
relevance to a broad spectrum o f patients with post-streptococcal CNS syndromes 
remains as yet untested.
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4.2.5. Animal model- passive transfer of IgG
The presence o f serum anti-neuronal antibodies does not infer pathogenicity. Indeed 
auto-reactive antibodies against host tissue are common in healthy individuals. For an 
auto-antibody to be pathogenic, it must be possible to demonstrate effector function. 
One important method to establish effector function is the induction o f disease in an 
animal after passive transfer o f antibody. There has been three such animal models 
published in the literature to date that are summarised in table 4.d.
Table 4.d. Passive transfer o f  immunoglobulin to animals.
Paper Animal Infusion Observation Outcome
Hallett JJ 
et al., 
2000
Rat IgG or serum o f TS  
(n=5) or control 
(n=5).
Stereotypical 
movement or 
behaviour
More Utterances in TS 
rats compared to 
controls
Taylor 
JR et al., 
2002
Rat Serum o f TS with 
raised anti-neuronal 
antibodies (N =12), 
TS (n=12), control 
(n=12).
Oral stereotypy Sig. higher oral 
stereotypies in rats 
given TS serum with 
raised anti-neuronal 
antibodies.
Loiselle 
CR et al., 
2004
Rat Serum o fT S  (n=10), 
PANDAS (n=10), 
control (n=14).
Stereotypic
behaviour
No difference
TS: Tourette syndrome
PANDAS: Pediatric autoimmune neuropsychiatric disorders associated with 
streptococcal infections.
A ll three studies infused IgG or serum directly into the striatum using microcannulae. 
Two studies were positive with induction o f stereotypical movements or oral 
stereotypies in the index animals compared to controls. However, these findings were 
not reproduced in the third (Loiselle CR et al., 2004) study. The Hallett study
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performed immunohistochemistry after the infusion that showed IgG binding to 
neurone membrane in the index cases with secondary internalisation o f IgG into the 
cell (Hallett JJ et al., 2000). It should be noted that the papers used different patient 
serum: some used patients with Tourette syndrome, some with PANDAS. Likewise 
the definition o f the presence o f serum anti-neuronal antibodies differed in the three 
studies: Hallett used an ELISA against a neuroblastoma cell line homogenate (Hallett 
JJ et al., 2000), Taylor used an immunofluorescence technique against rat striatum 
(Taylor JR et al., 2002), and Loiselle used ELISA with human putamen synaptosomes 
(Loiselle CR et al., 2004). In summary there is some evidence that patients with 
Tourette syndrome have IgG that can induce brain dysfunction compatible with 
Tourettism in animals. Clearly it would be preferable to repeat these experiments 
using anti-neuronal antibodies against clearly defined neuronal antigens (rather than 
polyclonal serum or IgG) to further examine the pathogenicity o f IgG using animal 
models.
A  further recent animal model used a different approach. Rather than using patient 
IgG, they immunised mice with a homogenate o f Group A  streptococcus (GAS). 
Specifically, an M6 streptococcus was homogenised and immunised serially in mice 
with Freund’s adjuvant (Hoffman KL et al., 2004). The study was controlled with 
mice immunised with Freund’s adjuvant only. The GAS immunised mice had serum 
IgG that bound to neuronal tissue, particularly in the deep cerebellar nuclei (DCN), 
although to a lesser extent in the basal ganglia (in addition, post-mortem 
immunohistochemistry o f the mice brains showed IgG deposits that were present in 
the DCN o f the GAS immunised mice only). The mice with DCN IgG were more 
likely to have behavioural abnormalities, particularly rearing or repetitive behaviours. 
This group also showed that the GAS antibodies cross-reacted with cerebellar proteins 
subsequently identified as complement (C4) and alpha-2 macroglobulin. This study is
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the first animal model showing that GABHS can cause immune-mediated brain 
disturbance. Criticism o f this study would include:
• The failure to control the study with a different micro-organism.
• Mice are not natural hosts for GAS, therefore their immune response may 
differ from humans.
• The cerebellum was primarily involved rather than the basal ganglia.
•  Homogenisation o f the streptococcus may destroy or create immunogenic 
epitopes.
•  Many o f the behavioural disturbances could be induced by cytokines resulting 
in sickness behaviour.
•  Complement C4 and alpha-2 macroglobulin are ubiquitous proteins, not brain 
specific.
4.2.6. Plasmapheresis in post-streptococcal CNS disease
Improvement in clinical symptoms after plasmapheresis is another requirement to
demonstrate antibody pathogenicity. The only controlled trial o f plasmapheresis has 
been presented in the treatment section o f this introduction. This small study 
demonstrated a benefit o f plasmapheresis on clinical symptoms supporting an 
autoantibody pathogenesis (Perlmutter SJ et al., 1999).
4.2.7. Other immune studies
There have been relatively few other immune related investigations in post­
streptococcal CNS syndromes. Related to anti-neuronal antibodies, Church measured 
the presence o f oligoclonal IgG in the CSF. He found 46% (6/13) o f acute SC patients 
had abnormal patterns o f oligoclonal IgG in the CSF (2 intrathecal synthesis, 4 a
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mirrored pattern) (Church AJ et al., 2003). Church also demonstrated that the IgG 
subclass involved in anti-neuronal antibody binding were o f IgG 1 and IgG3, not IgG2 
or IgG4.
Cytokines are important markers o f immune activation. Th l cytokines (interferon- 
gamma etc.) are pro-inflammatory, whereas Th2 cytokines (interleukin-4, interleukin- 
10, etc) are anti-inflammatory cytokines. Interferon-gamma was undetectable in the 
CSF o f acute or persistent SC, whereas IL-4 and IL-10 were modestly elevated in the 
CSF o f some SC patients (Church AJ et al., 2003). These findings support a Th2 
cytokine profile, and the authors concluded that this would support an autoimmune, 
autoantibody mediated hypothesis. The absence o f IFN-gamma makes a cell-mediated 
pathophysiology less likely. Clearly there are a large number o f other immune related 
investigations still required in post-streptococcal CNS disease, including the role o f T- 
cell help and the superantigen mediated hypothesis.
4.2.8. Genetic and disease predisposition.
The mechanism o f the genetic predisposition in post-streptococcal CNS disease is not 
certain; classical HLA class I and II profiles in SC do not appear to predict a genetic 
vulnerability (Donadi EA et al., 2000). Instead, interest has focussed on a B- 
lymphocyte marker (D8/17) that is highly expressed in patients with rheumatic 
fever/SC compared to healthy controls and autoimmune controls (including post­
streptococcal glomerulonephritis) (Gibofsky A et al., 1991; Khanna AK  et al., 1989). 
This same marker is significantly more prevalent in PANDAS (post-streptococcal tics 
and OCD) patients (Swedo SE et al., 1997), supporting immunological similarity 
between SC, rheumatic fever and PANDAS (table 4.e.). As can be seen, D8/17 is not 
only more prevalent in RhF and SC, but also in idiopathic tics and OCD compared to
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controls (Table 4.e.). Despite this intriguing finding, the function o f this lymphocyte 
marker remains unknown.
Table 4.e. D8/17 expression in SC, PANDAS and other neuropsychiatric syndromes. 
Percentage ofB-cell lymphocytes (DR) expressing D8/17 on surface. All studies
yielded statistically significantly differences.
Definition o f 
positive (% o f 
cells staining 
for D8/17
Patient
group
(number)
Percentage 
o f patients 
positive
Control
group
(number)
Percentage 
o f controls 
positive
Reference
>12% SC (n=9) 89% Healthy
(n=24)
17% Swedo SE 
et al., 
1997
>12% PANDAS
(n=27)
85% Healthy
(n=24)
17% Swedo SE 
et al., 
1997
>11.8% RhF
(n=84)
99% Healthy
(n=76)
14% Khanna 
A K  et al., 
1989
>11.8% TS/OCD 
(n=31)
100% Healthy 
(n=21)
5% Murphy 
TK et al., 
1997
95% percentile 
o f controls
Tic
disorders
(n=33)
60.6% Healthy
(n=20)
5% Hoekstra 
PJ et al., 
2001
TS: Tourette syndrome
OCD: obsessive-compulsive disorder
SC: Sydenham’s chorea
PANDAS: pediatric autoimmune neuropsychiatric disorders associated with 
streptococcal infections 
RhF: rheumatic fever
4.3. Immunological aims of this thesis
The immunological aims o f this thesis are as follows:
1. To learn protein purification and immunoblotting techniques.
2. To use these methods to purify candidate autoantigens from brain 
homogenates.
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To use these methods to identify the 40 kDa, 45 kDa and 60 kDa (and 98 kDa) 
autoantigens involved in autoantibody binding in post-streptococcal CNS 
disease.
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Chapter 5. Protein purification and immunology 
methods. 
Protein purification
5.1. Tissue preparation for Western immunoblotting
5.1.1. Human basal ganglia
Human striatum (caudate and putamen) were excised from the donor within 48 hours 
post mortem. The tissue was then frozen at -80°C until use. A ll human brain tissue 
was kindly provided by the Queen Square brain bank.
5.1.2. Rat brain and rat liver, kidney, heart
Adult Wistar male rats were used for all Western immmunoblotting using rat tissue. 
Rats were reared at B&K, Hull, UK. The brains and other organs were removed 
within minutes o f death and snap frozen in liquid nitrogen. The brains and other 
organs were transferred to Institute o f Neurology frozen within 24 hours o f death, and 
stored at -80°C until use.
5.1.3. Tissue homogenisation method
1. The Teflon homogeniser and plunger were cleaned adequately and dried 
before use.
2. The whole procedure was done on ice. The brain was added to the 
homogeniser after cutting into smaller pieces. T-PER (tissue protein extraction
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reagent) was added at 1ml per gram o f tissue. Protease inhibitor cocktail for 
mammalian tissue was added at 1 OOjul per 2g o f tissue.
3. The tissue was homogenised with the plunger for 10 minutes and until the 
tissue was fu lly homogenised.
4. The homogenate was pipetted into tubes and centrifuged at 10,000g for 10 
minutes.
5. The supernatant was pipetted into fresh tubes and re-spun until the supernatant 
was clear. The cell debris was discarded.
6. The homogenate was frozen in fractions until use.
5.2. Polyacrylamide gel electrophoresis
5.2.1. Introduction
Polyacrylamide gels can be purchased pre-cast in plastic housing. Polyacrylamide gels 
are formed by polymerisation o f acrylamide monomers into long chains, followed by 
cross-linking these chains with compounds such as N, N-methylene-bisacrylamide 
(bis). This system creates a porous gel. The ability o f a protein to pass through the 
pores depends upon the size o f the proteins to be separated. I generally used the pre­
cast polyacrylamide gel electrophoresis (PAGE) gels from Invitrogen for protein 
separation and Western blotting. The PAGE gels come in Bis-Tris gels (protein range 
1.5-300 kDa) or the Tris-Acetate gels (30-400 kDa). I have generally used the Bis- 
Tris gels. The Bis-Tris gels come in 4-12%, 10% or 12%. These gels differ in their 
acrylamide concentration that generally influences the gel pore size and therefore 
migration. The higher concentration gels allow better separation o f middle and lower 
molecular weight proteins. The buffers that are used influence the abilities o f proteins
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to migrate (discussed later). Most PAGE systems now use a detergent system for the 
sample such as sodium dodecyl sulphate (SDS). I f  the sample is run in native form, 
the proteins w ill be separated by charge and size. Insoluble proteins also aggregate 
and block the pores o f the electrophoresis system resulting in poor results. For this 
reason, the SDS system is now widely employed. SDS (or lithium dodecyl sulphate- 
LDS) strongly binds to proteins and saturates the protein with approximately 1 SDS 
molecule per 2 amino acids. The SDS denatures the protein and unfolds the protein 
into a polypeptide. In addition, the protein is saturated with a negative charge, thereby 
abolishing the resident charge o f the protein, and instead replacing it with a negative 
charge. The proteins, once loaded onto the top o f the gel (in a vertical system) migrate 
into the gel by creating a vertical charge through the gel (bottom o f the gel has a 
positive charge, top o f the gel has a negative charge). Therefore the protein is then 
separated only by the protein size, and not charge (the charge/size ratio is virtually 
identical for all proteins when in SDS/LDS). This therefore gives a relatively accurate 
guide to the protein’s molecular weight. In addition, a small amount dithiothreitol 
(DDT) 0.05 Molar is added as a reducing agent, that disrupts any disulphide binds.
This results in further denaturing o f the protein, and sometimes separates protein 
subunits.
5.2.2. Polyacrylamide gel electrophoresis method in detail
1. The sample to be run was prepared as follows: 25% LDS sample buffer, 10% 
o f 0.5Molar DDT. The sample, appropriately diluted in double distilled water 
is added and mixed thoroughly. The sample is then placed in the water bath at 
65°C for 15 minutes.
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2. The following running buffers can be used: NuPAGE 2-(N-morpholino) 
ethane sulphonic acid (MES) SDS running buffer. NuPAGE 3-(N-morpholino) 
propane sulphonic acid (MOPS) SDS running buffer. The buffer constituents 
are described in appendix 5. MES buffer was routinely used. MOPS buffer 
allows better separation o f medium to lower molecular weight proteins (30-60 
kDa) and was used when required. The buffer solutions are concentrates and 
were therefore diluted with distilled water before use.
3. The pre-cast PAGE gels were stored in the cold room. The gels were removed 
from their plastic wrapping, and the preservative was poured away. The plastic 
well guard and the tape from the bottom o f the cassette were then removed.
The well was washed with running buffer three times and loaded into the 
Mini-cell. The well should face toward the inner core. I f  two gels were to be 
run, the well o f the second gel also faces into the core o f the Mini-cell (so that 
the wells are open to the inner core). The gel tension wedges were inserted so 
that there is no leak o f buffer from the inner chamber. The running buffer was 
poured into the inner core, and then the surrounding chambers. The buffer 
must be added so that the gel wells were completely covered by buffer.
Bubbles, which congregate around the bottom o f the cassettes, were removed 
by tilting the mini-cell.
4. Next the samples were prepared and loaded into the well. A molecular weight 
marker was loaded (4-5 jllI) into lane 1 (See Blue Plus2 pre-stained standard, 
Invitrogen). The sample (now in SDS, DDT and heated) was loaded into the 
wells. In a 10 well gel, 25 jul was loaded per well. In a 2D well gel, 150 pi was 
pipetted into the well.
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5. The loaded material was allowed to settle, and then the PowerEase 
electrophoresis apparatus was started. The following protocols were used, and 
found to produce good electrophoresis:
Bis-Tris gel with MES running buffer
•  Voltage: 200V
• Anticipated current start 110-125 mA/gel, end 70-80 mA/gel.
•  Run time 39 minutes
Bis-Tris gel with MOPS running buffer
•  Voltage: 200V
• Anticipated current start 100-115 mA/gel, end 60-70 mA/gel.
•  Run time 50 minutes
6. Once the electrophoresis was complete, the mini-cell was disconnected from 
the electrodes, and the running buffer was poured away. The gels were 
removed from the Mini-cell. The gel was then removed from the cassette. The 
cassette was laid onto paper with the well facing upwards. Using a knife to 
open the cassette, the top wall o f the cassette was removed leaving the gel 
attached to the lower wall o f the cassette. Then the cassette was turned over 
and the gel was manipulated o ff the cassette wall using the knife. The gel was 
then placed in a plastic tray for staining, or transferred to nitrocellulose for 
Western blotting.
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5.3. Staining gels for NuPAGE Novex Bis-Tris 4-12% gels
5.3.1. Colloidal blue staining kit (Invitrogen)
1. After electrophoresis the gel was shaken in fixing solution (50% methanol,
10% acetic acid, 40% double distilled water) for 10 minutes.
2. The fixing solution was replaced with stainer A solution (20ml methanol, 55 
ml double distilled water, 20 ml stainer A) and the gel shaken for 10 minutes.
3. Stainer B (5ml) was added to the solution and shaken for a minimum o f 3 
hours, maximum o f 12 hours.
4. The staining solution was replaced w ith double distilled water and washed for 
7 hours.
5. For short term storage, water was used. For longer term storage 20% 
ammonium sulphate solution was used (both at 4°C).
5.3.2. Silver staining (Amersham Biosciences)
1. After electrophoresis the gel was shaken in fixing solution (100ml ethanol, 
25ml glacial acetic acid, 125 ml double distilled water) for 30 minutes.
2. The fixing solution was replaced with sensitising solution (75ml ethanol, 10ml 
sodium thiosulphate, 17g sodium acetate and 165ml double distilled water). 
Glutardialdehyde was not used, as this forms covalent bonds that interfere 
with mass spectrometry. The gel was shaken in solution for 30 minutes.
3. The gel was washed in distilled water for 15 minutes with 3 changes o f water.
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4. The gel was shaken in silver reaction (25ml silver nitrate 2.5% w/v, 225ml 
distilled water, 0.1ml formaldehyde 37% w/v) for 20 minutes.
5. Then the gel was washed in distilled water for 2 minutes with 2 changes.
6. To develop the gel developing solution (6.25g sodium carbonate, 250ml 
distilled water and 0.05ml formaldehyde) was used for 2-10 minutes.
7. To stop the reaction, EDTA (3.65g) in 250ml water was used (for several 
minutes).
8. The gel was then washed for 15 minutes with 3 changes o f water.
5.4. Ammonium sulphate precipitation
5.4.1. Introduction
Ammonium sulphate precipitation is also known as ‘salting out’ . The technique 
separates proteins secondary to their hydrophobicity. Different proteins have varying 
solubilities in salt solution. The ability o f a protein to remain soluble in salt solution 
depends on the amount o f hydrophobic patches on its surface (side chains o f Phe, Tyr, 
Trp, Leu, lie, Met, Val). Water molecules become ordered around the hydrophobic 
side chains. As the salt concentration becomes higher, the freely available water 
molecules become scarce. The water molecules ordered around the hydrophobic side 
chains therefore are pulled off, and the water molecules are integrated into the salt 
solution. This exposes the hydrophobic surfaces, which want to interact with one 
another and therefore aggregate. It is important that the salt does not bind and interact 
directly with the proteins and destablise the protein (defined chaotropic). In this 
regard, ammonium sulphate is considered the most appropriate salt, for technical and 
economic reasons. It is important to keep the pH and temperature o f the solution
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constant so that the procedure is reproducible. In practical terms, ammonium sulphate 
precipitation is quite simple. The sample is added to a known amount o f double 
distilled water and a small amount o f Tris-HCl (to maintain pH). A known amount o f 
ammonium sulphate is added to the solution, mixed thoroughly, and then centrifuged. 
The precipitate is then stored or re-solublised for further use. Further ammonium 
sulphate is then added to the solution and the procedure is repeated for the next 
fraction. The amount o f ammonium sulphate to be added for each step was calculated 
by Scopes (Scopes RK, 1994).
5.4.2. Ammonium sulphate precipitation method in detail
1. A ll o f this method can be scaled up for larger volumes o f sample.
2. The supernatant rat brain fraction was prepared as previously described 
(method 5.1.).
3. 9635 pi o f double distilled water was poured into a clean glass flask.
4. 315 pi o f the sample was added plus 50 pi o f Tris-HCl, making a total volume 
o f 10,000 pi.
5. The solution was mixed thoroughly on the magnetic stirrer without allowing 
the solution to froth.
6. The solution was brought to 20% ammonium sulphate concentration by adding 
ammonium sulphate (in grams) using Stokes ammonium sulphate precipitation 
table (in this case 1.13g). The solution was mixed thoroughly for 1 hour.
7. The solution was pipetted into centrifugation tubes and spun at 10,000g at 
15°C for 20 minutes.
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8. The resulting supernatant was then poured into the cleaned glass flask ready 
for the next addition o f ammonium sulphate. The precipitate at the bottom o f 
the centrifuge tube was stored or re-suspended in buffer ready for the next step 
(proteins are very stable in the precipitate).
9. Further ammonium sulphate was then added to the supernatant in the glass 
flask according the next desired ammonium sulphate fraction.
10. The resulting precipitates (0-20%, 20-40% etc) can be desalted into the buffer 
required for the next purification step, or stored in the precipitated form.
5.5. Fluid phase liquid chromatography: general principles
5.5.1. Introduction
Fluid phase liquid chromatography (FPLC) allows separation and purification o f 
proteins in the liquid phase. A FPLC system requires a pump, detection meter (UV 
meter), fraction collector and computer for analysis.
Figure 5.1. FPLC diagrammatic representation
UV
Buffer B
Buffer A
valve
Sample
Fraction
collector
I have used the AKTA FPLC machine and UNICORN software from Amersham 
Pharmacia Biotech.
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5.5.2. General method
1. In the UNICORN programme, by clicking on manual, it was possible to 
perform different pump instructions. After each alteration, it was necessary to 
click on ‘ insert’ and ‘execute’ in order to fu lfil this instruction. Using this 
programme it was possible to alter the flow rate and gradient (% o f buffer B) 
to be used. In order to load the flow loop with sample, it was necessary to use 
the flowpath-load pathway before loading the sample.
2. The valve received buffers A  and B. When performing a gradient, the buffers 
were mixed before entering the valve. In addition, the valve received input 
from the flow loop. The output o f the valve was to the column.
3. The columns used in FPLC were always Amersham Biosciences columns. The 
majority were HiTrap columns, either 1ml or 5ml columns. The columns were 
filled with preservatives and were washed and cleaned accordingly (20% 
ethanol or starting buffer). To avoid bubbles, the buffer was dripped into the 
top o f the column before screwing the connector into the top o f the column. 
The column stood vertically just above the UV meter.
4. The UV meter performed continuous monitoring for UV adsorption at 280nm 
for protein (Trp + Tyr band). It was possible to set the UV adsorption to a 
more sensitive lower wavelength, such as 220-205 nm.
5. The fraction collector allowed for the fluid to be collected in tubes using an 
automated tube holder. The fraction collector can be programmed according to 
the fraction size and speed. 144 tubes can be used in the collector.
6. The UNICORN programme was used to create a method template including 
the following:
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Characteristic Detail
Flow rate 0.1-5 ml/min
Start buffer cone (%B) % o f buffer B in starting solution
Equilibration Length o f equilibration in column 
volumes
Flow-through fraction size Size (ml) o f fractions in flow-through
Sample injection (empty loop) Volume o f sample to be injected (less 
than volume loaded)
Wash out unbound sample Volume o f buffer to wash away unbound 
proteins from column (in column 
volumes)
Gradient The length o f gradient (in column 
volumes) to linearly increase from 0% to 
x% o f buffer B. It is also possible to 
create a step gradient, as opposed to a 
linear gradient.
Elution fraction size Volume o f fractions to be collected (0.1- 
5ml)
Re-Equilibrate Number o f column volumes (o f %B) to 
re-equilibrate the column
7. Templates were created and used for the following: desalting, IgG
purification, ion exchange, hydrophobic interaction. It was possible to modify 
these templates as required according to screening experiments.
5.6. Desalting and changing the buffer
5.6.1. Introduction
Removing excessive salt from a sample, or changing the buffer is an essential 
procedure when using chromatography or before 2-dimensional electrophoresis. I 
performed all desalting or buffer changing using the HiTrap 5ml Desalting columns 
(Amersham Biosciences) and the FPLC. In essence, these columns are sieves: they 
allow proteins over 5,000 Daltons in size to pass unhindered through the gel, whereas 
the gel withholds small solutes and molecules. The desalting columns are packed with 
the ‘exclusion matrix’ Sephadex G-25 Superfine. The matrix is cross-linked dextran
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beads. The exclusion lim it o f 5,000 Daltons allows easy passage o f proteins through 
the column. The columns can be used with solutions o f a wide range o f pH, alcohols 
and urea. In order to maintain good desalting, it is important to keep the sample 
volume below 1.5ml.
5.6.2. Desalting method in detail:
1. The FPLC was washed thoroughly with 20% ethanol and then equilibrated 
thoroughly with the starting buffer. The flow loop was also washed and 
equilibrated in the same manner.
2. A 5ml HiTrap Desalting column was removed from the cold room and 
attached to the FPLC. To avoid air bubbles, the column was connected with 
the ‘drop-to-drop’ technique, before the column was attached to the FPLC 
machine.
3. The starting buffer was run through the desalting column for at least 3 column 
volume until the UV meter reading was flat.
4. The sample was loaded into the flow  loop. The sample volume should be no 
more than 1.5 ml (in a 2 ml flow loop). In addition, i f  the sample was from 
ammonium sulphate precipitation, the precipitate was first diluted with some 
starting buffer. Too high a salt concentration may impair desalting.
5. Then the FPLC was programmed as follows:
Flow rate lm l/m in
Equilibrate column 5 column volumes
Inject sample <1.5ml
Fraction size 0.5ml
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6. The sample was usually diluted by the procedure, approximately two-fold.
The typical sample chromatogram was as follows:
Figure 5.2. Desalting chromatogram
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As can be seen, the sample was injected (arrow) and approximately 1.5ml later, the 
sample began to leave the column, now in the start buffer.
5.7. Ion exchange chromatography
5.7.1. Introduction
Ion exchange is one o f the classic ways o f separating proteins using chromatography. 
The technique uses ionic charge to separate proteins. The columns have a matrix that 
allows interaction o f proteins with charged chains immobilised to the matrix. The 
matrix is composed o f insoluble compounds such as dextran (Sephadex), cellulose 
(Sephacel) and agarose (Sepharose). Charged groups are covalently and irreversibly
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bound to the matrix that give the column its exchange ability. The charged groups can 
be classified according to the charge (anionic or cationic):
ANION
• Diethylaminoethyl (DEAE)
• Quaternary aminoethyl (QAE)
• Quaternary ammonium (Q)
CATION
• Carboxymethyl (CM)
• Sulphopropyl (SP)
• Methyl sulphonate (S)
The charged groups are associated with ‘counter ions’ that are mobile and 
‘exchangeable’ . Positively charged exchangers (anionic exchangers) have negatively 
charged counter-ions (anions) available for exchange, whereas negatively charged 
exchangers (cationic exchangers) have positively charged counter-ions (cations).
Before interaction with the column, the sample must be desalted into the start buffer. 
The choice o f buffer is important. The protein o f interest can be bound to the column 
and eluted, or alternatively the protein o f interest could ‘ flow-through’ the column 
without binding to the column. The buffer must contain acid or base to create the 
appropriate pH, and also contain an appropriate concentration o f salt. Salts stabilise 
the proteins, and prevent precipitation (usually 10-20mmol). I have used citric acid 
(pH 2.6-3.6) for cation exchange, and Tris (pH 7.6-8.6) for anion exchange. It is
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generally found that improved separations occur when the protein o f interest is bound 
to the column and then eluted using a salt gradient (starting buffer plus 1 Molar 
sodium chloride). This achieves better separation than allowing the protein o f interest 
to ‘ flow-through’ the column without binding. The choice o f column, and therefore 
buffer, depends on the charge (or isoelectric point) o f the protein whilst in buffered 
solution. Using screening experiments, I have found that the following conditions 
have worked best:
Approximate isolectric 
point o f protein (pi)
Column Buffer
4-5 Cation (e.g. SP) Citric acid (pH 3.0)
6-7 Anion (e.g. Q) Tris (pH 8.0)
Using these conditions, the protein o f interest elutes early on the gradient, and results 
in less contamination, although screening experiments are required. In order to ensure 
that the protein o f interest binds to the column, it is important that the pH o f the buffer 
is at least 1 pH unit below the pi o f the substance to be bound (cation exchanger). 
Conversely using an anion exchanger, the buffer should be at least 1 pH unit above 
the pi o f substance to be found e.g. for a protein pi 6.5, an anion exchanger with a 
buffer o f pH 8.0 would allow binding to the column, and relatively early elution o f the 
protein. I have generally found that proteins are more soluble and therefore achieve 
better separation using the anionic exchange system.
Ion exchange chromatography (IEX) can be used at different points in the purification 
procedure. I have used IEX at the following points during purification:
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PAGE electrophoresis
Ion exchange ch.
Ammonium sulphate
precipitation
chromatography
Ion exchange
Ammonium sulphate
precipitation
Hydrophobic
interaction
electrophoresis
PAGE
The decision to use these purification steps is dictated by a number o f factors 
including:
•  The yield o f the protein to be purified
• The properties o f the proteins. For example, a protein with an extreme pi such 
as 8.0 w ill be purified with less steps than a protein with a charge such as 6.0 
(which is much more common).
•  Contaminating protein properties.
5.7.2. Detailed method of ion exchange chromatography:
1. The appropriate buffer was chosen and freshly made. The elution buffer was 
made by pouring half o f the starting buffer into a fresh glass container and 
adding 1 Molar NaCl to the solution. The buffers was thoroughly mixed before 
use.
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2. The sample to be purified was then desalted into starting buffer using the 
desalting columns as previously described.
3. The column and FPLC was washed thoroughly with 20% ethanol.
4. Then the column was washed with 5 column volumes o f start buffer at 
lm l/m in (using the 1ml columns), or 3ml/min for the 5 ml columns. Then the 
column was washed with the elution buffer for 5 column volumes. This 
removed any residual contaminants from the column. Finally, the column was 
re-equilibrated with 5-10 volumes o f the start buffer.
5. Next, the desalted sample was loaded into the flow-loop ready for injection.
6. Using the FPLC template to inject the sample, an elution gradient was 
produced as follows:
Step Detail
Equilibration o f column 5 column volumes
Volume o f sample injected Less than the volume o f loaded sample
Wash after sample injection A t least 4 column volumes
Gradient 0-100% over 10-20 column volumes
Fraction size 0.5-lm l
The length o f gradient, and the size o f the fractions collected depended upon the 
degree o f separation expected. For example, when the IEX was used early in 
purification, the length o f elution was short and the fractions large, as the purification 
at this stage was crude. In comparison, i f  IEX was used as a late polishing step, a 
limited gradient (e.g. 0-40%) over 20 column volumes was employed with smaller
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fraction sizes. Therefore the method varied slightly depending upon the aims o f the 
IEX step.
The following chromatograms demonstrate the purification applications o f IEX:
5.7.3. Screening experiment 1
Column Mono Q 5ml
Sample 45-65% ammonium sulphate fraction o f 
rat brain
Starting buffer Tris (Ph 8.0)
Elution buffer Tris (Ph 8.0) + 1 Molar NaCl
Gradient 0-100% elution buffer over 10 column 
volumes
Figure 5.3. IEX screening experiment I.
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As can be seen, using this system, there was relatively good separation over the length 
o f the gradient (between A and B). The IEX in this case was unlikely to produce 
adequate purification for autoantigen identification, unless further purification 
strategies are employed, such as hydrophobic interaction.
5.7.4. Screening experiment 2
Column Mono Q 5ml
Sample 45-65% ammonium sulphate fraction o f 
rat brain
Starting buffer Tris (pH 8.0)
Elution buffer Tris (pH 8.0)+1 Molar NaCl
Gradient 0-100% elution buffer over 80 column 
volumes
Figure 5.4. IEX Screening experiment 2.
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As can be seen, this time the gradient was lengthened significantly to 80 column 
volumes. By doing this, the column was able to equilibrate steadily, resulting in 
improved separation (sharpening o f the peaks), although the proteins w ill be relatively 
diluted due to the prolonged elution.
5.7.5. Screening experiment 3
Column Mono Q 5ml
Sample 1. 45-65% ammonium sulphate 
fraction o f rat brain
2. Hydrophobic interaction 
chromatography
Starting buffer Tris (Ph 8.0)
Elution buffer Tris (Ph 8.0) + IMoler NaCl
Gradient 0-50% elution buffer over 80 column 
volumes
Figure 5.5. IEX screening experiment 3.
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As can be seen, this time I used IEX after ammonium sulphate precipitation and 
hydrophobic interaction chromatography. There were less contaminating proteins, and 
the protein o f interest (arrowed) came o ff the column early in elution. IEX was used 
here as a polishing step, rather than an early cruder purification step. The gradient was 
long, and the fractions relatively small for the length o f elution. The yield o f the 
proteins (as suggested by the UV measurements) was low however.
5.7.6. Conclusion of Ion exchange chromatography method
In summary, IEX provides a very useful purification method. Indeed, I found IEX the 
most reliable and predictable purification method. The IEX method needed to be 
varied according to the charge o f the protein to be purified.
5.8. Hydrophobic interaction chromatography
5.8.1. Introduction
Proteins differ in their hydrophobicity, i.e. their interaction with a hydrophobic 
surface. This protein property has also been called ‘salt-promoted absorption’ . In the 
second half o f the 20th century, it was shown that proteins could be separated in the 
liquid phase according to a protein’s interaction with a hydrophobic surface such as 
sepharose. The proteins reversibly interact with hydrophobic ligands that are 
irreversibly bound to the Sepharose column. The high salt concentration causes 
displacement o f water molecules, resulting in increased attraction. Reducing the salt 
concentration, either as a gradient or step-wise then elutes the proteins. As the salt 
concentration decreases, there is less ‘shielding’ o f the protein by water molecules
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resulting in increased hydrophobicity o f the protein with its ligand, and elution o f the
proteins from the column.
The following variables effect hydrophobic interaction:
1. Immobilised ligands attached to the sepharose (aryl and alkyl). The preferred 
ligand (octyl, butyl, phenyl, alkyl) cannot be predicted, and screening 
experiments are necessary to determine which ligand w ill be best at separating 
proteins.
2. The salt used w ill alter the hydrophobic interaction. Classically sodium, 
potassium and ammonium salts have good ‘salting-in’ qualities, and are 
commonly used in HIC. The salt concentration needs to be established by 
screening experiments.
3. The pH w ill affect hydrophobic interaction, acidity generally increasing 
hydrophobic interaction. The pH must be maintained to preserve inter-assay 
comparisons.
4. Likewise, the temperature w ill affect hydrophobic interaction (either increase 
or decrease). For practical purposes, it is therefore necessary to maintain a 
consistent temperature to maintain reproducibity.
5.8.2. Method and screening experiments.
1. In the first instance the hydrophobic interaction chromatography (HIC media) 
test kit was purchased for initial screening (Amersham Biosciences). As 
phenyl sepharose has been used by previous investigators in the separation o f
165
166
proteins from crude homogenates, I chose the HIC 1ml phenyl sepharose high 
performance column for initial screening.
2. The sample (30-70% ammonium sulphate fraction) was first desalted into the 
start buffer. The start buffer was sodium phosphate pH 7.0 buffer with added 1 
Molar ammonium sulphate. The elution buffer was sodium phosphate pH 7.0 
alone.
3. The column was attached to the FPLC and first equilibrated with 5 ml o f 
elution buffer to remove any contaminants from the column. I f  this was 
inadequate, the column was eluted with distilled water, or 20% ethanol. After 
washing with the elution buffer, the column was equilibrated with 5-10ml o f 
the start buffer (high salt buffer).
4. The sample (now desalted into the start buffer solution) was loaded onto the 
column.
5. The FPLC was then programmed using an ‘HIC template’ . The following 
programme was found to produce a reasonable chromatogram.
Variable Value
Flow rate 0.25 ml/min
Wash out after sample injection 5 column volumes
Length o f gradient 15 column volumes
Fraction size 1ml
6. After completion o f the gradient, the column was regenerated with 5ml o f
distilled water and stored, or regenerated with the start buffer for a further 
sample.
166
167
5.8.3. Screening experiment 1
HIC was first performed with a l molar solution o f ammonium sulphate in the sodium 
phosphate buffer. As can be seen in the chromatogram (Figure 5.6), this start buffer 
did not allow any proteins to bind to the column (i.e. form hydrophobic binding). A ll 
o f the proteins flowed through the column without binding to the column, therefore 
failing to separate proteins.
Figure 5.6. HIC screening experiment 1 using: Start buffer: Sodium phosphate pH  
7.0, 1 Molar ammonium sulphate. Elution buffer: Sodium phosphate Ph 7.0.
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As can be seen from the chromatogram, all proteins flow through the column without 
binding to the column. I therefore needed to change the HIC conditions.
5.8.4. Screening experiment 2
In order to create a more hydrophobic environment, the salt conditions o f the start 
buffer were increased to 3 molar ammonium sulphate in the sodium phosphate pH 7.0 
buffer. This significantly improved binding to the column, although now the proteins
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were so strongly bound, the proteins were eluted near the end o f the gradient, 
including after completion o f the gradient.
Figure 5.7. HIC screening experiment 2 finding using: Start buffer: Sodium 
phosphate Ph 7.0, 3 Molar ammonium sulphate. Elution buffer: Sodium phosphate Ph 
7.0.
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Proteins now bind to the column, although proteins are all eluted at the end o f the 
gradient.
5.8.5. Screening experiment 3.
To allow proteins to be eluted towards the middle o f the gradient, the salt solution was 
reduced to 1.5 Molar ammonium sulphate solution.
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Figure 5.8. HIC screening experiment 3 using: Start buffer: Sodium phosphate Ph 
7.0, 1.5 Molar ammonium sulphate. Elution buffer: Sodium phosphate Ph 7.0.
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Although still near the end o f the gradient, the proteins were now eluted more 
satisfactorily. It should be possible to improve separation further i f  required.
5.8.6. Screening experiment 4.
Despite alterations in the salt concentrations o f the binding buffer, the chromatogram 
failed to significantly improve using the phenyl sepharose column. It is possible that 
an alternative column would allow improved protein separations. I therefore tried a 
different column from the HiTrap screening column series- the Butryl sepharose fast 
flow column. The FPLC and all o f the variables were otherwise unchanged.
In order to determine the separation abilities o f the butryl sepharose column, I 
Western blotted different fractions on a 4-12% Bis-Tris 10-lane gel. The protein 
fractions were normalised and transferred to nitrocellulose and Western blotted using 
the standard method. Serum from patient MB (anti-40 kDa antibodies) was used as 
the primary antibody. The blot was developed colormetrically (Figure 5.9).
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Figure 5.9. HIC Screening experiment 4. Using this continuous gradient, the butryl 
sepharose column produced better interaction on the column, and improved elution 
over a larger range o f the gradient. The 40kDa protein is present in fraction 4.
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5.8.7. Screening experiment 5.
Using the Butryl sepharose column, I used a step gradient to see i f  the protein o f 
interest could be eluted during a step. The 40 kDa protein eluted after 60% o f the
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gradient, and before 80% o f the gradient. I therefore used the same variables but 
introduced a step in the gradient as follows:
%  buffer B Length of elution
0-60% 10 column volumes
60-80% 0 column volumes
80-80% 10 column volumes
End elution (100%) 5 column volumes
The fractions were Western blotted in the same way as described in screening 
experiment 4.
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Figure 5.10. HIC screening experiment 5. This STEP gradient allowed a large peak 
elution during the 60-80% step, which contained the 40 kDa protein. By introducing a 
step before the 60-80% step, it should be possible to minimise the contamination o f  
the preceding proteins.
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5.8.8. Conclusion
HIC may provide a useful purification step in conjunction with other purification 
strategies. The column and salt concentrations w ill need to be altered according to 
screening experiments (for each protein o f interest).
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5.9. 2-dimensional electrophoresis
5.9.1. Principle
2-dimensional electrophoresis employs a method o f separating proteins according to 
two reproducible properties: mass and charge. This method therefore allows 
separation o f crude or partially purified homogenates, in an attempt to identify 
candidate autoantigens.
5.9.2. Method
I used the Invitrogen mini gel system for all 2-dimensional electrophoresis.
5.9.2.1. Sample
Rather than use whole brain homogenate, I improved resolution and interpretation o f 
2-dimensional electrophoresis by first performing ammonium sulphate precipitation. 
The chosen ammonium sulphate fraction was first desalted into sodium phosphate 
buffer, Ph 7.0. The buffer contained 20 mmol o f salt. Salt concentration significantly 
above or below this level can interfere w ith isoelectric focussing. The sample was 
then concentrated using micropore centrifuge systems.
5.9.2.2. Sample preparation and buffering
The electrophoresis demands that the proteins are soluble and expressing their native 
charge. However, a compromise needs to be met, as some proteins are poorly soluble 
in aqueous solutions and require small amounts o f detergent to improve solubility. For 
this reason, a small amount o f SDS was included in the sample preparation before
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electrophoresis. Too much SDS could conversely impair separation. The sample was 
therefore made up as follows:
•  100 pi sample
• 25 pi 0.5% SDS
• 125 pi IEF sample buffer, Ph 3-10
This results in a 0.05% SDS concentration. The solution was mixed thoroughly, and 
left at room temperature for 20 minutes.
5.9.2.3.1st stage electrophoresis (separation by charge)- isoelectric 
focussing
Using the Invitrogen/ NOVEX Power ease 500 systems, a pH 3-10 isoelectric 
focussing 10 well gel was employed.
The following buffers were required to create an appropriate charge current through 
the gel:
IEF Cathode buffer, pH 3-10 
IEF Anode buffer, pH 3-10
The buffers were prepared and allowed to stand to remove bubbles.
1. The gel was removed from its packet and the preservative discarded. The wells 
were washed 3 times with the cathode buffer, and the gel was loaded onto the 
Mini-cell so that the well faces the buffer core. I completed the mini-cell and 
ensured the system was secure, and did not allow mixing o f the inner and outer 
chambers.
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2. I loaded the cathode buffer into the inner chamber, and ensured the buffer 
covers the well. I ensured the cathode buffer did not leak into the outer 
chamber.
3. I then loaded the anode buffer into the outer chamber.
4. Then I loaded 25 pi o f sample (in sample IEF buffer and SDS) into each well 
(10 wells).
5. The gel was run for the following protocol: 100 V  constant (1 hour), 200 V 
constant-( 1 hour), then 500 V  constant (30 minutes). The approximate current 
is 5 mA/gel at the start, ending on 6 mA/gel. The protocol therefore lasts 2.5 
hours.
6. I then removed the gel from the cast, and fixed the gel with IEF fixing solution 
for 30 minutes. This step fixed the proteins and removed the ampholytes. Then 
the gel was washed for 5 minutes in distilled water.
7. The gel was then stained for 5 minutes in Coomassie R-250 0.1%. This 
allowed visualisation o f the lanes for the 2nd stage.
8. The gel was destained for 30-60 minutes to remove excess Coomassie.
9. After washing briefly, the gel was incubated with 20% methanol for 1 hour. 
This removed the acetic acid (destain solution) and shrunk the gel slightly to 
facilitate the 2nd stage transfer.
10. This completed the 1st stage. The gel was stored at +4° C until use.
5.9.2.4. 2nd stage of 2-dimensional electrophoresis (polyacrylamide 
gel)
The next step separated proteins according to size.
1. I first cut out one lane o f the IEF gel using a sharp straight blade.
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2. The lane was then placed into an LDS solution (1ml LDS buffer, 1ml double 
distilled water, 0.5ml 100% methanol). The lane was incubated in this solution 
for 20 minutes with occasional gentle shaking.
3. The lane was then washed in MES running buffer and excess liquid was 
removed before transfer to 2-D NuPAGE gel.
4. The lane was trimmed slightly before transfer to the trough (pre-filled with 
MES buffer). For comparison between silver stained gel and Western blots, it 
was essential to be consistent in the extent o f the trimming.
5. The lane was transferred with the aid o f blotting paper that was cut to size.
The blotting paper was just shorter than the width o f the trough. The blotting 
paper was placed onto the gel segment, so that just over half the height o f the 
gel segment is covered by blotting paper. This allowed the gel to be 
transferred to the trough. The lane must be inserted in a consistent way. The 
acidic end o f the gel was always put in the lane next to the molecular weight 
marker. The lane was inserted and any bubbles removed before running.
6. 4 pi o f molecular weight marker was loaded into the small chamber, and run 
using a standard PAGE electrophoresis protocol as previously described.
7. The gel was then stained using silver stain, or transferred to nitrocellulose for ‘ 
Western immunoblotting, as required.
5.10. Concentrating proteins
5.10.1. Introduction
For concentration o f proteins in solution, it is possible to use centrifugation o f 
solutions through membranes. Using the Amicon centrifugal filter devices
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(Microcon), the membrane is sealed with a silicone rubber O-ring. The sample is 
placed on top o f the membrane and, using centrifugation, the water and low molecular 
weight proteins pass through the membrane, retaining and therefore concentrating the 
larger molecular weight proteins. The low adsorption characteristic o f the membrane 
means that >95% o f proteins are recovered.
5.10.2. Concentration device method in detail
1. The Amicon centrifugal device (Microcon) to be chosen depended upon the 
molecular weight o f the autoantigen o f interest. The devices are named 
according to the membrane porosity. The following devices are applicable to 
the following autoantigen molecular weight
•  YM-3 (3,000 molecular weight lim it)
•  Y M -10(10,000 molecular weight lim it)
•  YM-30 (30,000 molecular weight lim it)
•  YM-50 (50,000 molecular weight lim it)
•  Y M -100 (100,000 molecular weight lim it)
2. The sample reservoir (with the membrane) was placed in the vial. The sample 
to be concentrated was then loaded into the sample reservoir (5 0 0 jli1  at a time). 
The lid was closed securely and the assembly then placed in a fixed rotor 
centrifuge, with an appropriate counter-balance.
3. The assembly was then centrifuged at 10,000g for between 20-30 minutes.
This allowed concentration to below lOOjil.
4. Next the sample reservoir was removed from the vial, and the sample reservoir
inverted into a new vial. Then the vial was centrifuged at l,000g for 3 minutes,
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propelling the concentrate into the new vial. Then the vial was removed from 
the centrifuge, the reservoir discarded, and the concentrated sample used in the 
next experimental phase.
5.11. Protein measurement
5.11.1. Introduction
Protein normalisation and measurement is an important procedure. I used the Biuret 
method using Biorad reagents.
5.11.2. Method in detail
1. A  Maxisorp 96 well microtitre plate was used. On each run, one well was left
blank. The samples (serum, supernatants etc.) were diluted as appropriate. 
Standards were run on each plate as follows: 400mg/l, 900 mg/1, 1500 mg/1.
2. Reagent A (Biorad) (25 pi per well) was loaded.
3. The sample was then loaded (10 pi per well) and mixed with gentle agitation.
4. Then, Reagent B was loaded (200 pi per well), and the plate was agitated 
briefly to mix.
5. The plate was left for 10 minutes.
6. The plate was read using Wallac plate reader at wavelength 750 nm.
7. The standards were plotted, and the values calculated from the standards.
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5.12. Purifying specific proteins- immunoglobulin G
5.12.1. Introduction
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It is possible to purify immunoglobulin G (IgG) using affinity chromatography. 
A ffin ity  chromatography uses a reversible interaction between a ligand and the 
protein o f interest. The ligand is irreversibly attached to the column matrix. The 
ligand then reversibly interacts with the protein o f interest, whereas the contaminating 
molecules flow through the column. The interaction between the protein and ligand is 
then reversed by altering the column conditions (e.g. changing the pH or salt 
concentration). In the case o f IgG, protein A  is the ligand. Protein A is derived from 
Stapholococcus aureus, and has 5 regions that bind to the Fc part o f IgG molecules. 
Protein A is irreversibly bound to the Sepharose matrix, which allows the protein A  
molecules access to the IgG as they flow through the column. The column mainly 
binds IgG (mainly IgG 1, 2 and 4), although IgA and IgM have occasionally been 
reported to bind.
5.12.2. Protein A chromatography method in detail
1. The binding buffer (0.02M Sodium Phosphate, pH 7.0) and the elution buffer 
(0.1M Citric acid, pH 3.0) were made fresh. The column and flow loop were 
washed thoroughly with 20% ethanol and then washed with binding buffer.
2. The protein A column was connected to the FPLC and bubbles avoided 
entering the column by dripping binding buffer into the column before 
attaching to the FPLC. The column was then eluted with 5 column volumes 
and equilibrated with binding buffer (to remove any residual IgG from 
previous experiments).
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3. The patient serum was then diluted 5-10 fold with binding buffer.
4. The dilute serum was loaded into the flow loop.
5. The FPLC was then programmed as follows:
Flow rate 0.5ml/min
Equilibrate 5 column volumes o f binding buffer
Inject Less than the sample volume
Flow through fraction size 2ml
Re-equilibrate 5 column volumes
Elution fraction size 0.25ml
6. The chromatogram should be as fol ows:
Figure 5.11. Protein A IgG purification
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The sample is injected, and serum constituents other than IgG flow through the 
column (A). Then during the elution, the IgG is purified (B).
7. The IgG was purified in elution buffer (pH 3.0). The acidity can alter IgG 
function, and should be normalised with Tris-HCl (pH 9.0). I found that 60pl 
o f Tris-HCl was required to neutralise 250pl o f eluted IgG. I ensured the pH
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was physiologically normal (pH 7.4) before performing experiments 
involving live neurones.
Immunology- methods
5.13. Western blotting
5.13.1. Introduction
Western blotting, or Western transfer describes the transfer o f proteins from the gel 
onto an absorbent surface such as nitrocellulose. Once immobilised onto 
nitrocellulose, the patient serum can be incubated with the nitrocellose. Human IgG 
that binds to the immobilised proteins can be identified using anti-IgG antibodies. 
Western blotting is a classic method for identifying protein-antibody interactions. 
There are, however, some limitations w ith this method. The primary limitation is 
related to the protein preparation required to solbilise the proteins. The SDS or LDS 
solution unfolds the proteins. The proteins are therefore no longer in their 
physiological state regarding conformation. Likewise, cryptic epitopes are revealed by 
SDS solubilisation that may not be physiologically seen by antibodies in vivo. 
However, Western blotting provides a valuable method o f identifying antibody- 
antigen interaction.
5.13.2. Method in detail
l . The following transfer buffer was made up: For 500ml o f transfer buffer,
25ml o f NuPAGE transfer buffer was added to 100ml methanol and 375ml
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distilled water. The transfer buffer was mixed and allowed to settle to 
minimise air bubbles. Then the following were placed in separate trays and 
incubated w ith transfer buffer: 5-6 blotting pads, 5-6 filter paper per gel, 1 
nitrocellulose paper per gel, cellophane.
2. The gel was processed as for PAGE method. The gel was inserted into the gel 
membrane sandwich as follows. Blotting pads were laid onto the bottom o f 
the membrane cassette first, followed by at least one filter paper. Next the 
cassette was laid onto the bench and opened with the lane facing upwards.
The gel was then laid onto a filte r paper and the gel pushed onto the filter 
paper. The nitrocellulose paper was then laid onto the other gel surface and 
any air bubbles were pushed out. The gel should be completely flush with the 
nitrocellulose paper. The filte r paper-gel-nitrocellulose was then loaded into 
the membrane cassette. Then the cellophane was placed onto the back o f the 
nitrocellulose (to prevent passage o f the proteins through the nitrocellulose). 
Then a further filter paper was added, and the cassette sandwich was 
completed with blotting pads. The lid  was put on the sandwich and I made 
sure that the sandwich contents were tightly packed.
3. The membrane sandwich was placed into the mini-cell tank and the wedges 
inserted into the back o f the tank to tighten the system and prevent leaks.
4. Next the transfer buffer was poured into the cassette and the tank checked that 
there were no leaks. The transfer buffer was added until the buffer covers the 
top o f the sandwich contents. Next tap water was added to the surrounding 
tank as a cooling measure.
5. The tank was then placed onto the platform o f the PowerEase 500 and the lid 
was secured onto the tank.
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6. I used the Gel transfer programme that provided 30 Volts with 170 mA 
current for 1 hr 20 minutes.
7. Once the transfer was complete, the nitrocellulose blot was removed from the 
sandwich and incubated in 2% m ilk protein (in 0.9% saline) for 2 hours to 
block the nitrocellulose. This reduced non-specific interaction o f patient 
serum with the nitrocellulose.
8. The blot was then ready for probing with patient serum. The blot can be 
washed with 0.9% saline and incubated in shallow trays or inserted into a 
manifold. Manifolds allow multiple sample or serums to be run alongside one 
another for comparison.
9. The manifold was washed thoroughly in advance and allowed to dry. The 
manifold was assembled w ith the nitrocellulose blot inserted. The manifold 
was held together with screws and tightened to avoid leakage. The manifold 
lanes were checked for leaks by loading 0.9% saline into each lane.
10. Samples were diluted and prepared shortly before loading onto the manifold.
11. A  clear record o f the loading procedure was kept for later analysis. The 
molecular weight marker was loaded into lane 1, and lane 2 contained the 
negative control (secondary antibody only). Then the patient’s sera were 
loaded into the appropriate lane as per protocol.
12. The manifold was then incubated overnight at 4°C on a rocker.
13. Next the blot was washed before incubation with the secondary antibody.
First the blot is washed with 6 changes o f tap water. The wash solution was
0.9% saline with 0.2% m ilk proteins and 0.025% Tween for colormetric 
development. When using ECL, the wash solution contained 0.05% Tween to 
reduce the background reactivity.
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14. Using this wash solution, the blot was washed every 10 minutes for 10 
changes o f wash solution.
15. Next the secondary antibody was loaded onto the manifold. The secondary 
antibody was diluted 1:1000 for colormetric analysis, or 1:5000 for ECL 
development. The anti-human IgG antibody was conjugated to horseradish 
peroxidase. The secondary antibody was diluted in 0.2% m ilk and 0.9% 
saline. The secondary antibody was incubated for 2 hours.
16. Then the blot was washed exactly as before.
17. At the end o f the washing, the blot was ready for development. The manifold 
was dismantled, and the blot is transferred to a tray. The blot is then 
developed for 15-20 minutes in the developing solution for colormetric 
development or using PIERCE enhanced chemiluminscence method 
(appendix 5).
18. The development was then stopped by washing thoroughly with distilled 
water, and then dried under a hair drier.
19. The blot was then interpreted.
5.14. Enzyme linked immunosorbent assay
5.14.1. Introduction
Enzyme linked immunosorbent assay (ELISA) offers an alternative way o f assessing 
the presence o f antibodies against an antigen. Unlike PAGE with SDS solubilisation, 
proteins can be immobilised to the ELISA plate in the proteins physiological status 
and conformation. The proteins are immobilised onto a solid-phase surface. In the 
case o f ELISA, the solid-phase is polystyrene flat-bottomed plates. These plates allow
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good optical and binding properties (passively adsorbed). I routinely used Nunc
Maxisorp plates.
5.14.2. Method
1. The first variable to be decided was the concentration o f the antigen to be 
used. This varied according to a number o f factors, and could only be 
determined by screening experiments. The protein was pipetted into a vial, and 
diluted to the desired concentration with 0.05 Molar carbonate buffer. The 
solution was mixed thoroughly on the vortex, then lOOpl o f solution was 
pipetted per well. The plate was then agitated on the ELISA plate shaker for
10 minutes. Then the ELISA plate was left in the cold room (4°C) overnight to 
allow adsorption o f proteins to the plate surface.
2. The wash solution was prepared (saline with 0.2% m ilk and 0.05% Tween). 
The plate was washed 6 times w ith the wash solution, and then blocked with 
2% bovine specific albumin (BSA) for 1 hour. The plate was agitated on the 
ELISA plate shaker during this time.
3. Again the plate was washed 6 times w ith the wash solution. A t this time, the 
patient samples were prepared in the appropriate dilution. In addition, one well 
was left blank, and a positive and negative control was run on each plate.
4. 200pl o f diluted serum (or control) was loaded into each well. An ELISA 
template was kept with the details o f which patient/control sample was loaded 
into which well. The plate was incubated at room temperature on the ELISA 
plate shaker for 1 hour. Samples were usually run in duplicate.
5. Again the plate was washed with 6 changes o f wash solution as before.
6. The secondary antibody was then incubated in each well, to allow detection o f 
human IgG that was bound to antigen immobilised on the plate surface. The
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secondary antibody for patient and control serum was rabbit anti-human IgG 
HRP conjugated, at a dilution o f 1:1000. 200pl o f secondary antibody solution 
was incubated in each plate. Obviously for commercial antibodies, the correct 
species o f antibody (e.g. goat, mouse) must be chosen. The secondary 
antibody was incubated for 1 hour.
7. The plate was again washed with wash solution for 6 changes as before.
8. Now the wells were ready to detect the antibody presence. The secondary 
antibody was conjugated with HRP. The peroxidase catalysed the chemical 
reaction resulting in colour production in the ELISA well. The detector 
solution is described in appendix 5 (lOOpl per well).
9. The plate was allowed to develop in the dark for 15 minutes, and then stopped
with 1 M HC1 (50 pi per well).
10. The plate was read using the Wallac plate reader. The reading was set for OPD 
detection at a wavelength o f 492nm.
11. The readings were normalised by subtracting the blank, and the duplicates 
were averaged. The duplicates were compared to ensure reproducibility. I f  
there is poor reproducibility (>10% difference), then the sample was repeated. 
The same positive and negative controls were run on each plate so that inter­
assay comparisons could be made.
5.15. Absorption experiments
5.15.1. Introduction
There are a number o f ways to confirm or refute the identity o f candidate 
autoantigens. One method is to perform absorption experiments. These experiments
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involve pre-incubating the patient IgG with the candidate antigen (or control) to see i f  
the specific antibodies are removed.
5.15.2. Method in detail
1. 10 (il o f patient serum was diluted to 1ml with 0.2% m ilk in 0.9% normal
saline.
2. Next, the antigen to be pre-incubated was added to the serum as required. In 
addition, the same amount o f control antigen was added to a control vial.
3. The vials were secured in a tray and rocked gently at room temperature for 2 
hours. Prolonged incubations could also be considered.
4. Next, the vials were centrifuged at 10,000g for 10 minutes.
5. It was important not to disturb any immune complexes or antigen-antibody 
complexes that may have precipitated. The supernatant (800 |il) was therefore 
pipetted carefully from the vial. This supernatant was then loaded into a 
manifold lane to be Western blotted, or alternatively ran on an ELISA 
(compared with the pre-incubation serum).
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Chapter 6. Proteomic identification of the 45 and 98 
kDa antigens
6.1. General aim
In patients with post-streptococcal movement and psychiatric disorders, it is possible 
to demonstrate serum antibodies that bind to a number o f apparently common brain 
autoantigens, as demonstrated by AJ Church. I aimed to identify these autoantigens 
using protein separation and purification strategies followed by mass spectrometry 
analysis. A number o f different autoantigens have been demonstrated, with varying 
frequencies. I started with the 98 kDa and subsequently the 45 kDa doublet.
The first aim was to determine whether the autoantigens present in human basal 
ganglia are also present in rat brain. I f  this were the case, it would allow me to use 
brain tissue with a readily available supply, which would improve the chance o f 
identifying the autoantigens.
6.2. Choosing the antigen: Rat brain and human basal ganglia.
6.2.1.The 98kDa autoantigen
6.2.1.1. Method
Human basal ganglia and rat brain (without cerebellum) was homogenised and the 
supernatant was prepared as previously described. The total protein was measured in 
the supernatant. The protein was loaded as stated in the table below.
Patients and controls 1 patient with 98 kDa autoantibodies (SN) 
Control: secondary antibody only
Antigen Human basal ganglia homogenate 5pg (lane 1) 
Rat brain homogenate 15(ig (lane 2)
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Western blotting Standard method (4-12% Bis-Tris 10 well gel)
Serum dilution 1/300
Antibody detection Anti-human IgG 1/1000. Colormetric development
6.2.1.2. Results
The 98 kDa autoantigen was present in both human basal ganglia and rat brain (Figure
6.1.). There was secondary antibody reactivity to the human IgG present in the human 
tissue. The secondary antibody alone demonstrated binding to the human IgG, but not 
the 98 kDa autoantigen (not shown).
6.2.1.3. Conclusion
The 98kDa autoantigen was present in both human and rat brain tissue. Rat brain w ill 
hopefully provide a more readily available source o f protein for purification and 
identification.
6.2.2. The 45 kDa doublet
6.2.2.1. Method
Human basal ganglia and rat brain (without cerebellum) was homogenised and the 
supernatant was prepared as previously described. The protein was measured in the 
supernatant and loaded as stated in the table.
Patients and controls 1 patient with 45 kDa autoantibodies (DA) 
Control: secondary antibody only
Antigen Human basal ganglia homogenate 5pg (lane 1) 
Rat brain homogenate 15pg (lane 2)
Western blotting Standard method (4-12% Bis-Tris 10 well gel)
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Serum dilution 1/300
Antibody detection Anti-human IgG 1/1000. Colormetric development
6.2.2.2. Results
The 45 kDa autoantigens were present in both human basal ganglia and rat brain 
(Figure 6.2). There was secondary antibody reactivity to the human IgG present in the 
human tissue only. The secondary antibody alone demonstrated binding to the human 
IgG, but not the 45 kDa autoantigen (not shown). These findings were true o f both the 
proteins in the 45 kDa doublet (upper and lower band).
6.3. Comparing antibody findings in different patients
The 45kDa and 98 kDa autoantigens were present in rat, as well as human brain. I 
next aimed to determine whether different patients w ith post-streptococcal brain 
disorders had antibodies against the 45 and 98 kDa autoantigens. I therefore tested 
different patients with suspected antibodies against the 45 and 98 kDa autoantigens.
6.3.1. The 98kDa autoantigen
6.3.1.1. Method
I therefore tested different patients against rat brain using Western immunoblotting. 
Rat brain homogenate was diluted to achieve the best signal, without compromising 
the background. A dilution o f 1:16 was found to be appropriate.
Patients and controls 7 patients with suspected 98 kDa autoantibodies 
(SN, DL, MH, PW, JW, ZB, TT)
Control: secondary antibody only
Antigen 1:16 rat brain homogenate 150pl
Western blotting Standard method (4-12% Bis-Tris 2D gel)
Serum dilution 1/300
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Antibody detection Anti-human IgG 1/1000. Colormetric development
6.3.1.2. Result
The 98 kDa autoantibodies were common to different patients with post-streptococcal 
brain patients (lane 1-6 and 8). The secondary antibody did not react with any rat 
brain constituents (Lane 7, Figure 6.3.).
6.3.2. The 45kDa doublet autoantigens
6.3.2.I. Method
I tested different patients with suspected 45kDa autoantibodies against rat brain using 
Western immunoblotting.
Patients and controls 5 patients w ith one or both o f the 45 kDa doublet 
autoantibodies (TT, GW, DA, EW, Ta)
Control: secondary antibody only
Antigen 1:16 rat brain homogenate 150jxl
Western blotting Standard method (4-12% Bis-Tris 2D gel)
Serum dilution 1/300
Antibody detection Anti-human IgG 1/1000. Colormetric development
6.3.2.2. Results
A number o f post-streptococcal brain patients had antibodies that react with a doublet 
at 45 kDa. Some patients have both auto-antibodies, some have one only (Figure 6.4.).
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Figure 6.1. Comparison of human basal 
ganglia with rat brain (98 kDa). Patient 
SN has antibody reactivity to the 
98kDa autoantigen in both human basal 
ganglia (lane 1) and rat brain (lane 2). 
Human IgG reactivity (from the 
secondary antibody) is present in the 
human tissue only.
Figure 6.2. Comparison of human 
basal ganglia (lane 1) with rat brain 
(lane 2) (45 kDa). Autoantibodies 
against the 45 kDa autoantigen bind 
to a 45 kDa autoantigen that is 
present in both human basal ganglia 
and rat brain. The secondary antibody 
binds to human IgG, in the human 
tissue only.
Figure 6.3. Different patients with 98 
kDa antigen auto-antibodies. Patients 
(lanes 1 -6 and 8) react with a common 
98 kDa autoantigen. Lanes 4 and 8 also 
have antibodies against a 60 kDa 
autoantigen. Secondary antibody (lane 
7) shows no binding.
Figure 6.4. Different patients with 45 
kDa antigen auto-antibodies. Patients in 
lanes 1-4 have antibodies that bind to 
one or both proteins at 45 kDa. Lane 
l(both proteins), lane 2(lower protein), 
lanes 3 and 4 (both), lane 6 (lower 
protein). Lanes 2-6 also appear to have 
a common antibody to a 60 kDa 
protein.
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6.4. Regional distribution of the 45 kDa and 98 kDa proteins.
6.4.1. Aim
Before attempting to identify the proteins, I tried to learn more about the 
characteristics o f the 45 and 98 kDa proteins (other than the molecular weight). Using 
patient antibodies as a probe, I next aimed to determine the regional localisation o f the 
autoantigens in rat tissues.
6.4.2. Method
The rat organs were from male Wistar rats. The organs were removed immediately 
after death, and snap frozen. The organs were kept whole at -80 °C until use, then 
homogenised and centrifuged as previously detailed. The supernatant was stored in 
alloquots at -80°C until required. In order to make comparisons between tissues, I 
measured the total protein (Biuret method, as previously detailed) for all tissues. The 
total proteins were then normalised and loaded into appropriate lanes in a 10 well gel. 
The total protein required to produce a colormetric signal is stated below (and varied 
between autoantigens).
6.4.2.1. The 98kDa autoantigen
Patient 1 patients with strong signal 98 kDa autoantibodies 
(SN)
Antigen Lane 1. Rat brain (cerebellum removed) 6.25pg. 
Lane 2. Rat cerebellum 6.25|ig.
Lane 3. Rat kidney 6.25pg.
Lane 4. Rat liver 6.25|ig.
Lane 5. Rat heart 6.25jng.
Western blotting Standard method (4-12% Bis-Tris 10 well gel)
Serum dilution 1/300
Antibody detection Anti-human IgG 1/1000. Colormetric development
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6.4.2.2. The 45kDa doublet
Patient 1 patients w ith strong signal 45 kDa doublet 
autoantibodies (EW)
Antigen Lane 1. Rat brain (cerebellum removed) 25jug. 
Lane 2. Rat cerebellum 25(ig.
Lane 3. Rat kidney 25pg.
Lane 4. Rat liver 25pg.
Lane 5. Rat heart 25pg.
Western blotting Standard method (4-12% Bis-Tris 10 well gel)
Serum dilution 1/300
Antibody detection Anti-human IgG 1/1000. Colormetric development
As can be seen, the total proteins needed to be higher using this patient antibody and 
the 45 kDa antigens.
6.4.3. Results
6.4.3.1. The 98 kDa protein
Using the auto-antibodies as a probe, it was possible to establish the regional 
localisation o f the 98kDa protein. The protein was expressed in rat brain and weakly 
in rat heart. There is no apparent difference between whole brain (without cerebellum) 
and cerebellum (Figure 6.5).
6.4.3.2. The 45 kDa doublet
Using the auto-antibodies as a probe, it was possible to establish the regional 
localisation o f the 45 kDa doublet proteins. The lower protein is present in whole 
brain and cerebellum, but not in other organs. By contrast, the upper protein in the 
doublet is ubiquitous, and appears to be equally present in all tissues (Figure 6.6.).
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Figure 6.5. Regional comparison between brain and other organs. The 98 
kDa autoantigen is highly expressed in brain (whole brain, lane 1 and 
cerebellum, lane 2) and weakly in heart (lane 5), but not in rat kidney and 
liver (lanes 3 and 4).
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Figure 6.6. Regional comparison between brain and other organs (45 kDa 
doublet). The lower protein is present only in whole brain and cerebellum 
(lanes 1 and 2). By contrast, the upper 45kDa protein is ubiquitous, and 
equally present in all tissues.
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6.5. Ammonium sulphate precipitation
6.5.1. Aim
I next aimed to purify, or partially purify the autoantigens in order to determine their 
identity. There are thousands o f proteins in each supernatant, and separating the 
proteins by one characteristic (e.g. molecular weight) is inadequate for confident 
protein identification. It is therefore necessary to perform a number o f different 
purification steps, aiming to concentrate the protein o f interest, whilst at the same 
time, remove contaminating proteins. The first step employed by investigators is often 
salt precipitation. Although crude, this provides a useful first step.
6.5.2. Method
The method has been previously described in detail. Again the patient IgG is used as 
the probe. I in itia lly used large ammonium sulphate precipitation fractions as follows:
• A  whole brain fraction was run for comparison.
•  0- 20%
•  20-40%
• 40-60%
• 60-80%
• 80-100%
The precipitated proteins were re-suspended in 1 ml o f sodium phosphate buffer pH 
7.0, and mixed on the vortex. For this experiment the proteins were not desalted. The 
different fractions were then loaded onto a 10 well 4-12% Bis-Tris gel, 
electrophoresed using the standard method and transferred onto nitrocellulose using
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the standard method. The blot was blocked using 2% m ilk for 2 hours. Patient SN was 
used to determine which fraction contained the 98 kDa protein, DA was used for the 
45kDa proteins.
6.5.3. Results
The 98 kDa protein precipitates mostly between 60-80% salt fractionation, although 
also precipitates to a lesser extent in the 40-60% fraction (Figure 6.7.). The 45 kDa 
proteins also precipitated in the 40-60% and 60-80% fraction.
6.6. Ammonium sulphate precipitation with smaller fractions
6.6.1. Aim
I next aimed to see whether I could improve separation further by reducing the size o f 
the fractions, although the yield o f protein decreased as a consequence.
6.6.2. Method
I used the same ammonium sulphate precipitation method, but this time used smaller 
fractions as follows:
• Whole brain as a control
• 50-60%
• 60-65%
• 65-70%
• 70-75%
• 75-80%
• 80-85%
• 85-90%
• 90-100%
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Figure 6.7. Ammonium sulphate 
precipitation. Fractions electrophoresed and 
blotted onto nitrocellulose (1: whole. 2: 0- 
20%. 3: 20-40%. 4: 40-60%. 5:60-80%. 6: 
80-100%). Patient SN with 98 kDa 
antibodies used to probe the blot. The 98kDa 
protein precipitates mainly in the 60-80% 
fraction, although to a lesser extent in the 40- 
60% fraction.
Figure 6.8. Second ammonium 
sulphate precipitation screen. Whole 
fraction is in lane 1. The 98 kDa 
protein is enriched in the 50-60% 
fracion (lane 2), and to a lesser extent 
60-65% fraction (lane 3).
Figure 6.9. Result o f ammonium sulphate precipiation. Western 
blotting (A) of whole rat brain (lane 1) and 50-60% (lane 2). Patient SN 
with 98 kDa antibodies. Silver staining of whole rat brain (B) (lane 3) 
and 50-60% fraction (lane 4). The silver stain demonstrates a reduction 
in the background contamination.
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The gel was processed in the same way, and patient SN was used as before (98 kDa 
autoantigen).
6.6.3. Results
The ammonium sulphate precipitation demonstrated enrichment o f the 98 kDa protein 
in the 50-60% fraction predominantly (Figure 6.8.). Notably, the 45kDa doublet 
proteins also appeared to enrich in this fraction.
6.7. Ammonium sulphate precipitation final fraction
6.7.1. Aim
Finally, I aimed to crudely examine the degree o f purification achieved by ammonium 
sulphate precipitation by staining and Western blotting the 50-60% fraction, with 
comparison to the whole brain fraction.
6.7.2. Method
The whole brain and 50-60% fraction were run in neighbouring lanes as follows:
Antigen The following were loaded onto a 4-12% Bis-Tris 
10 well gel:
Lane 1. Rat whole brain 6.25pg.
Lane 2. Rat 50-60% fraction 6.25pg.
Lane 3. Rat whole brain 6.25pg.
Lane 4. Rat 50-60% fraction 6.25pg.
Silver staining Lanes 3 and 4 were silver stained using the routine 
method
Western blotting Lanes 1 and 2 were used for Western blotting using
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the standard method
Serum dilution for 
Western blotting
1/300
Antibody detection 
for Western blotting
Anti-human IgG 1/1000. Colormetric development
6.7.3. Results
The 98 kDa protein was confirmed to reside in the 50-60% fraction using Western 
blotting. The silver stain showed that there had been a significant reduction in 
contamination. The 98kDa protein now appeared to be more discrete, although further 
purification w ill be necessary (Figure 6.9.). A  similar degree o f purification was 
evident in the 45 kDa doublet proteins.
6.8.2-dimensional electrophoresis
6.8.1. Aim
The first purification step (ammonium sulphate precipitation) allowed partial 
purification o f the protein o f interest. This improved the chances o f adequate 
separation o f proteins. Next I used 2-dimensional electrophoresis to separate the 
proteins. This method allowed proteins to be separated according to mass and charge. 
I f  this method achieved adequate separation, the candidate protein would be cut out o f 
the gel and subjected to mass spectrometry.
6.8.2. Method
6.8.2.1. The 98 kDa protein
The method is previously described in detail in chapter 5.
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Antigen 50-60% fraction, desalted to sodium 
phosphate buffer pH 7.0. 10|ig loaded per 
isoelectric focussing lane.
Isoelectric focussing Standard protocol as previously 
described.
2nd stage: PAGE electrophoresis Standard protocol as previously 
described. MES buffer.
Western blotting o f gel 1 Standard method.
Western blotting patient antibody SN 1:300 dilution
Western blotting secondary antibody Rabbit anti-human IgG HRP conjugated 
1:1000
Western blotting development Colormetric and ECL.
Silver staining o f gel 2 Standard silver staining method.
6.8.2.2. The 45 kDa doublet
Antigen 5 0 - 6 0 %  fraction, desalted to sodium 
phosphate buffer pH 7 .0 .  10|LLg loaded per 
isoelectric focussing lane.
Isoelectric focussing Standard protocol as previously 
described.
2nd stage: PAGE electrophoresis Standard protocol as previously 
described. MES buffer.
Western blotting o f gel 1 Standard method.
Western blotting patient antibody DA 1 :3 0 0  dilution (upper 4 5  kDa band) 
EW 1 :3 0 0  dilution (both 4 5  kDa bands)
Western blotting secondary antibody Rabbit anti-human IgG HRP conjugated 
1 :1 0 0 0
Western blotting development Colormetric and ECL.
Silver staining o f gel 2 Standard method.
6.8.3. Results
6.8.3.1.The 98 kDa autoantigen
Initial attempts were unsuccessful related to the following problems and probable 
causes:
Problem Solution
Very streaky staining pattern Ensure salt at 20mMol or below
(sodium phosphate buffer desalting)
201
Poor resolution o f proteins with 
streaking
Poor visualisation on Western blotting
Correlation between silver stained and 
Western blotting gels
202
Reduced protein load to 1 Opg per IEF 
lane.
Conversion to ECL development (and 
reduction o f secondary antibody to 
1:5000. Increase tween concentration 
to 0.1% to reduce background.
Ensure the IEF lanes are trimmed 
exactly the same way before loading 
onto the PAGE 2D gel for the 2nd stage.
After correcting for the above problems, it enabled me to achieve reasonable 
separation o f proteins and allow the candidate protein to be identified on Western 
blotting. As can be seen from Figure 6.10, there were 2 possible proteins apparent on 
the silver stained gel. I therefore subjected both proteins to mass spectrometry. I was 
able to reproduce the Western blots w ith satisfactory results using a different patient 
(DL).
6.8.3.2. The 45 kDa doublet autoantigens
Patient DA with the upper doublet 45 kDa protein bound to a protein more basic than 
the 98 kDa NSE. The upper 45 kDa protein had a p i o f approximately 6 (Figure
6.11.). The lower 45 kDa protein had a similar p i to the 98 kDa protein. Both the 
upper and lower 45 kDa protein could be localised on the silver stained gels (Figure
6.11. and 6.12).
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Figure 6.10. 2-dimensional 
electrophoresis. The silver stain allowed 
adequate separation of proteins (upper 
figure). Western blotting (lower figure) 
allowed identification of the 98 kDa 
autoantigen using patient SN IgG.
Figure 6.11. 2-dimensional 
electrophoresis using DA serum 
(upper doublet of 45 kDa 
autoantigen). The suspected protein 
o f interest is labelled with an arrow.
45 kDa
\
45 kDa
\
Figure 6.12. Western blotting 
(lower image) using patient EW 
showing binding to the more basic 
upper protein, and the more acidic 
lower protein.
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6.9. Mass spectrometry
6.9.1. Method
Adequate separation o f proteins makes it possible to cut the proteins from the gel and 
digest the proteins using trypsin. The resulting purified proteins were identified by de 
novo sequencing using a Q-TOF tandem mass spectrometer. The resulting spectra and 
amino acid sequences after mass spectrometry were compared with protein databases 
in the public domain. This work was performed by Robin Wait, Kennedy Institute o f 
Rheumatology, Imperial College, London.
6.9.2. Results
6.9.2.1. The 98 kDa autoantigen
As can be seen, a large number o f amino acid sequences in the 98 kDa protein were 
compatible with gamma enolase, neuron-specific enolase (NSE) (Figure 6.13). There 
was 36% coverage and produced a lod score o f 930 with high confidence that this 
result is correct. Importantly, both 98 kDa proteins were digested, analysed separately 
and were both confirmed to be NSE. NSE exists as a monomer or a dimer. The 98 
kDa protein therefore represents the NSE dimer.
6.9.2.2. The 45 kDa doublet autoantigens
The acidic protein (pi approximately 5) was also found to be gamma enolase (NSE), 
presumably the monomeric form (Figure 6.14.). The coverage was 5.3% with a lod 
score o f 198.
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3 5 1 EAIQACKLAQ
4 2 1 RFAGHNFRNP
l d s r g n p t v e  v d l h t a k g l f
L S W E Q E K E D  NLMLELDGTE
VINGGSHAGN KLAMQEFMIL 
EALELVKEAI DKAGYTF.KMV 
IEDPFDQDDW AAWSKFTANV 
ENGWGVMVSH ••SG ETEDTFI
SVL
RAAVPSGAST GIYEALELRD  
NKSKFGANAI LGVSLAVCKA 
PVGAESFRLA MiLGAEVYHT 
IGMDVAASEF YRDGKYDLDF 
GIQ1VGDDLT VTNPKPI ERA 
ADLW GLCTG QIKTGAPCRS
GDKQRYLGKG VLKAVDHINS 
GAAEKDLPLY RHIAQLAGNS 
LKGVIKDKYG KDATNVGDEG 
ftSP A D PSR C I TGDQLGALYQ 
VEEKACNCLL LKVNQIGSVT 
ERLAKYNQLM RIEEELGEEA
Figure 6.13. Mass spectrometry result of 98 kDa protein.
ENOG_RAT
Gamma enolase (EC 4.2.1.11) (2-phospho-D-glyc 
(P07323)
1 SIQKIW AREI LDSRGNPTVE VDLHTAKGLF RAAVPSGAST GIYEALELRD GDKQRYLGKG VLKAVDHINS
M T IA P A L IS S G  LSW EQEKLD NLMLELDGTE NKSKFGANAI LGVSLAVCKA GAAEKDLPLY RHIAQLAGNS
1 4 1  DL1LPVPAFN VINGGSHAGN KLAMQEFMIL PVGAESFRDA MRLGAEVYHT LKGVIKDKYG KDATNVGDEG
2 1 1  G FAPNILENS EALELVKEAI DKAGYTEKMV IGMDVAASEF YRDGKYDLDF KSPADPSRCI TGDQLGALYQ
2 8 1  DFVRNYPW S IEDPFDQDDW AAWSKFTANV' G IQIVGDDLT VTNPKRIERA VEEKACNCLL LKVNQIGSVT
3 5 1  EAIQACKLAQ ENGWGVMVSH RSGETEDTFI ADLW GLCTG QIKTGAPCRS ERLAKYNQLM RIEEELGEEA
4 2 1  RFAGHNFRNP SVL
Figure 6.14. Mass spectrometry result o f 45 kDa lower molecular 
weight protein.
ENOA_RAT
Alpha enolase (EC 4.2.
(P04764)
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FDSRGNPTVE VDLYTAKGLF
l n w e q e k :  r q l m i e m d g t e
VINGGSHAGN KLAMQEFMIL 
EA LE LLK 3A I AKAGYTDQW  
IEDPFDQDDW DAWQKFTATA 
SNGWGVMVSH R S E E T E D T F I 
LAK
RAAVPSGAST GIYEALELRD  
NKSKFGANAI LGVSLAVCKA 
PVGASSFREA MRIGAEVYHN 
IGMDVAASEF YRAGKYDLDF 
G IQ W G D D L T VTNPRRIAKA  
ADLW GLCTG~ Q I KTGA PCRS
NDKTRFMGKG VSKAVEHINK  
GAVEKGVPLY RHIADLAGNP 
LKNvCKEKYG KDATNVGDEG
K SPDDASRYI TPDQLADLYK  
AGEKSCNCLL LKVNQIGSVT 
ERLAKYNQIL RIEEELGSK A
Figure 6.15. Mass spectrometry result o f 45 kDa upper molecular 
weight protein.
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The basic protein (pi approximately 6) was found to be alpha enolase (non-neuronal 
enolase) (Figure 6.15.). The coverage was 9% with a lod score o f 383.
6.10. Conclusion of protein purification
The recognised properties o f the monomeric and dimeric neuron-specific enolase 
(NSE), and human non-neuronal enolase (NNE) are presented below.
Autoantigen Molecular weight, Da PI Regional distribution
45 kDa upper 47,051 6.1 Ubiquitous
45 kDa lower 46,991 5.1 Neuronal specific
98 kDa -87,000 5.1 Neuronal specific
These properties are compatible w ith the regional distribution o f the 98 kDa and 45 
Kda doublet autoantigens.
Enolase is a glycolytic enzyme, but is a multifunctional protein. Interestingly, both 
neuronal and non-neuronal enolase exist on the cell surface o f neurones (Lim L et al., 
1983; Leung TK et al., 1987), and are involved in cell signalling and energy 
metabolism (Nakajima K  et al., 1994a; Nakajima K  et al., 1994b). Also, the glycolytic 
enzyme enolase exists on the Streptococcal cell surface, and has been previously 
incriminated in the post-streptococcal autoimmune disease, rheumatic fever (Fontan 
PA et al., 2000). The enolases would therefore make quite appealing candidate 
autoantigens.
Next, I planned to confirm these conclusions by using commercial antibodies against 
the enolases, and commercial enolase antigens.
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6.11. Testing commercial enolase antigens
6.11.1. Aim
The candidate autoantigens are neuronal and non-neuronal enolases. I next tested 
these findings by buying purified human neuronal and non-neuronal enolases from 
commercial companies.
6.11.2. Method
6.11.2.1. Non-neuronal enolase
Human non-neuronal enolase (NNE) purified from brain was purchased from a 
commercial source (Accurate chemical and scientific corporation, Westbury, New 
York). The human protein was purified using chromatography (ion exchange and gel 
filtration) and was claimed to be at least 96% pure. The human NNE and rat brain 
were loaded as follows:
Patients and controls 1 patient w ith anti-NNE antibodies (DA) 
Control: secondary antibody only
Antigen Rat brain homogenate 1:16 (lane 1) 
Human NNE 2 jig  (lane 2)
Rat brain homogenate 1:16 (lane 3) 
Human NNE 2 jig  (lane 4)
Western blotting Standard method for lanes 3 and 4 (4-12% Bis-Tris 
10 well gel)
Serum dilution for 
Western blotting
1/300
Antibody detection Anti-human IgG 1/1000. Colormetric development
Silver staining Lanes 1 and 2 were stained using the silver stain 
method
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6.11.2.2. Neuronal specific enolase
208
Human neuronal specific enolase (NSE) was purchased from a commercial source 
(appendix). The human protein was purified using chromatography (ion exchange and 
gel filtration) and was claimed to be at least 96% pure. The human NSE and rat brain 
were loaded as follows:
Patients and controls 1 patient w ith anti-NSE antibodies (GW) 
Control: secondary antibody only
Antigen Rat brain homogenate 1:16 (lane 1) 
Human NSE 2 fig (lane 2)
Rat brain homogenate 1:16 (lane 3) 
Human NSE 2 |ig (lane 4)
Western blotting Standard method for lanes 3 and 4 (4-12% Bis-Tris 
10 well gel)
Serum dilution for 
Western blotting
1/300
Antibody detection Anti-human IgG 1/5000. ECL development
Silver staining Lanes 1 and 2 were stained using the silver stain 
method
6.11.3. Results
6.11.3.1. Non-neuronal enolase
Using Western blotting, patient DA reacted with the 45 kDa protein in the whole rat 
brain preparation (lane 3). The patient reacted with the commercial human NNE (lane 
4). The 2 reactive bands lined up on the Western blot (Figure 6.16.). The silver stained 
gel confirmed the relative purity o f the commercial human NNE.
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Figure 6.16.
Confirmation of anti- 
NNE antibodies using 
commercial antigen. 
Silver staining (A) and 
Western blot (B) 
demonstrating that 
patient DA has anti- 
NNE antibodies.
3 4
45 kDa
Figure 6.17.
Confirmation of anti- 
NSE antibodies using 
commercial antigen. 
Silver staining (A) and 
Western blot (B) 
demonstrating that 
patient GW has anti- 
NSE antibodies.
98 kDa
45 kDa M
pi 3
98 kDa 
45 kDa
z1
7 ~
pi 8
Figure 6.18. 2-dimensional 
electrophoresis using 
commercial anti-enolase 
antibody (C-19) at 1:2000 
dilution with colormetric 
development shows binding 
to the monomeric and dimeric 
NSE (long arrows) and NNE 
(short arrow).
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6.11.3.2. Neuronal specific enolase
Using Western blotting, patient GW reacted with the 45 kDa protein in the rat 
preparation, in addition to a 60 kDa protein and another protein below 45 kDa (lane 
3). The patient reacted with the commercial human NSE (lane 4) (Figure 6.17). The 2 
reactive bands lined up on the Western blot. The silver stained gel confirmed the 
relative purity o f the commercial human NSE.
6.12. Testing commercial enolase antibodies
6.12.1. Aim
Commercial enolase antigens have so far supported the hypothesis that the 45 kDa 
antigens are human enolase isoforms. I next aimed to test this hypothesis with 
commercial anti-enolase antibodies. A  polyclonal antibody was used which was 
known to react with both neuronal and non-neuronal enolases o f human and rat origin 
(C-19, Santa Cruz Biotechnology).
6.12.2. Method
I first wanted to use the commercial antibody with a 2-dimensional electrophoresis 
Western blot. I therefore used the same method as previously described during patient 
analysis:
Antigen 50-60% fraction, desalted to sodium
phosphate buffer pH 7.0. 10pg loaded per
isoelectric focussing lane.
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Isoelectric focussing Standard protocol as previously 
described.
2nd stage: PAGE electrophoresis Standard protocol as previously 
described. MES buffer.
Western blotting o f gel 1 Standard method.
Western blotting commercial antibody Goat C-19 1:2000 dilution
Western blotting secondary antibody Rabbit anti-goat IgG HRP conjugated 
1:1000
Western blotting development Colormetric.
Silver staining o f gel 2 Standard silver staining method.
6.12.3. Results
The commercial antibody was overloaded when originally used at a 1:500 dilution. 
Even at 1:2000 dilution, a strong signal was present with colormetric development. 
The C-19 antibody showed binding to the more basic non-neuronal enolase, and to the 
more acidic neuronal specific enolase in the monomeric and dimeric form as 
presented in Figure 6.18.
6.13. Testing both commercial anti-enolase antibody and 
enolase antigens
6.13.1. Aim
I now intended to test a number o f patients who had suspected anti-NNE antibodies 
against the human NNE, using the commercial anti-enolase antibody as a control.
6.13.2. Method
I used commercial human NNE as the antigen, which was loaded onto a 2D gel and 
electrophoresed using the standard method.
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Patients and controls 4 human patients w ith suspected anti-NNE 
antibodies (DA, LD,CR,EW)
2 human healthy controls (AC49, AC50) 
Control: secondary antibody only 
Positive control: C-19 anti-enolase antibody
Antigen Human NNE 4 jig
Western blotting Standard method (4-12% Bis-Tris 2D gel)
Serum dilution for 
Western blotting
1/300 in human patients and controls 
1/2000 for C-19
Antibody detection Anti-human IgG 1/5000. Anti-goat IgG 1/5000 for 
C-19 antibody. ECL development
6.13.3. Results
The post-streptococcal neuropsychiatric patients w ith suspected anti-NNE antibodies 
all reacted with the commercial NNE. The commercial anti-enolase antibody (C-19) 
reacted with enolase at the same level o f the patients. Neither o f the human controls 
reacted with the antigen (Figure 6.19.). The blot showed some background reactivity, 
possibly related to inadequate washing. Unfortunately, the human commercial enolase 
was prohibitive in cost, and alternative NNE sources w ill be necessary for further 
experiments.
6.14. Presence of anti-enolase antibodies in CSF, as well as 
serum.
6.14.1. Aim
The presence o f antibodies reactive with brain proteins in the serum is suggestive that 
a brain disease may be autoantibody mediated. However, presence o f these antibodies 
in the CSF would be a significantly more persuasive argument. I therefore used the 
CSF o f one patient (EW) who had anti-NNE antibodies in the serum to examine for 
CSF anti-NNE antibodies.
212
1 2 3 4 5 6 7 8
Figure 6.19. Western blotting against commercial human NNE 
Secondary antibody only (lane 1) shows no reactivity. Positive 
control (commercial anti-enolase antibody) reacts with human 
NNE (lane 2). Human patients all react with the human NNE 
(lanes 3-6). Human controls (lane 7 and 8) do not show any 
antibody reactivity.
45 kDa
1 2  3 4
Figure 6.20. Comparison of anti-NNE antibodies in CSF and 
serum. CSF 1:10 diltution (lane 1) is compared with serum 
1:4000 dilution (lane 2). Secondary antibody only (lane 3) shows 
no reactivity. Commercial anti-enolase antibody (lane 4) shows 
reactivity with human NNE as anticipated.
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6.14.2. Method
The serum and CSF were loaded in 400 fold dilution for comparison (serum diluted 
400 fold). This is based on well-established differences in total IgG between CSF and 
serum.
Patients and controls CSF and serum o f human patient with anti-NNE 
antibodies (EW)
Control: secondary antibody only 
Positive control: C-19 anti-enolase antibody
Antigen Human NNE 4 jig
Western blotting Standard method (4-12% Bis-Tris 2D gel)
Dilution for Western 
blotting
1/10 CSF dilution (200jil in 2ml) 
1/4000 serum dilution 
1/4000 for C-19
Antibody detection Anti-human IgG 1/5000.
Anti-Goat IgG 1/5000 for C-19 antibody. 
ECL development
6.14.3. Results
The CSF showed clear reactivity against the human NNE band. The serum, as 
anticipated, showed strong reactivity (Figure 6.20). It is not possible to make 
comparisons between the CSF and serum antibody levels using Western blotting due 
to its qualitative, not quantitative assessment. The commercial anti-enolase antibody 
reacted with the human NNE, and lined up with the CSF/serum pair. The secondary 
antibody alone showed no reactivity.
6.15. Anti-NNE antibody ELISA: A cheap available autoantigen 
source?
6.15.1. Aim
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The protein NNE is a relatively conserved protein w ith relative homology between 
species. Human NNE is available by purifying the protein from human tissue but is 
expensive to buy and labour intensive to do, w ith poor yield o f the final protein. 
Recombinant human enolase is one alternative source (discussed later). However, 
there are 2 commercially available enolase antigens available that are cheap (Baker’s 
yeast enolase and rabbit muscle enolase).
I tried to determine whether these commercially available enolase proteins would be 
valid surrogate autoantigens o f human NNE.
6.15.2. Method
Using NCBI Protein FASTA technology and BLAST 2 sequence homology analysis,
I first compared the sequence homology between human NNE and the 2 commercially 
available enolase antigens.
Commercial
antigen
Homology with human NNE
Identities Positives Gaps Chance
homology
Baker’s yeast 
enolase
62% 78% 0% 10-154
Rabbit muscle 
enolase
83% 90% 0% 0.00
As can be seen, there is a high degree o f homology between the human NNE and 
these commercial enolases. It is also conceivable that homology is conformational, 
rather than the linear peptide sequence.
Next, I aimed to determine whether two patients previously identified with anti­
human/rat NNE antibodies reacted with these commercial enolase antigens.
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Patients and controls 2 patients w ith anti-human NNE Abs (DA, EW) 
Control: Commercial C-19 anti-enolase Ab
Antigen Human basal ganglia 5pg homogenate (lane 1) 
Rabbit muscle enolase 5jig (lane 2)
Baker’s yeast enolase 5jug (lane 3)
Western blotting Standard method (4-12% Bis-Tris 10 well gel)
Serum dilution 1/300 (human patients) 
1/1000 (C-19)
Antibody detection Anti-human IgG 1/1000.
Anti-Goat IgG 1/1000 for C-19 antibody 
Colormetric development
6.15.3. Result
One gel was stained with colloidal blue staining. Rabbit enolase had one strong band 
at 45 kDa. Baker’s yeast enolase had one strong band at 43 kDa. There were 2 weaker 
higher bands in both preparations.
C-19 commercial polyclonal anti-enolase antibodies reacted very strongly with all 3 
lanes. DA reacted strongly with all 3 antigens (rabbit>Baker’s>human basal ganglia) 
EW reacted weakly with all 3 antigens (human basal ganglia>rabbit>Baker’s).
6.15.4. Conclusion
There was some evidence that the patients have antibodies that react with Rabbit 
muscle enolase and Baker’s yeast enolase, as well as human alpha enolase. However, 
this did not mean that the anti-human alpha enolase antibodies cross-react with the 
commercial enolase antigens. Even i f  the antibodies do cross-react, the antibodies 
may not have the same affinity to human as they do to other enolases.
I therefore aimed to determine whether the anti-human alpha enolase antibodies do 
cross-react with the commercial enolase antigens using absorption experiments.
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6.16. Cross-reactivity of anti-NNE antibodies with commercial 
enolase antigens: absorption experiments.
6.16.1. Hypothesis and aim
The next aim was to find a useful, cheap surrogate enolase for ELISA development. 
Rabbit and Baker’s yeast enolase appear to be useful candidates. It was now necessary 
to determine whether the patient anti-NNE antibodies truly cross-react with the 
commercial enolase antigens. I therefore performed an absorption experiment, to see 
i f  anti-NNE antibodies were removed by pre-incubation with the commercial 
antigens.
6.16.2. Method
The absorption experiment method is previously described in detail. The following 
tubes were created. Tube A  was a control w ith no antigen incubation. Serum from 1 
patient (DA) was used.
Constituents Tube A Tube B Tube C
Serum 10(0.1 in 1ml 0.2% 
m ilk
lOpl in 1ml 0.2% 
m ilk
lOpl in 1ml 0.2% 
milk
Antigen incubation - 20jig Rabbit 
muscle enolase
20pg Baker’s yeast 
enolase
Incubation 2 hours on rocker at room temperature
Centrifugation 10,000g for 10 minutes
Sample for 
incubation with rat 
brain homogenate
800pl supernatant (do not disturb any precipitate)
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The post-incubation sera were incubated with the rat brain homogenate after Western 
immunoblotting (standard method). C-19 was used as positive control.
6.16.3. Results
The anti-rat NNE antibody signal intensity was significantly reduced by pre­
incubation with rabbit muscle enolase, but not with Baker’s yeast enolase. There was 
still some residual antibody reactivity even with rabbit enolase (Figure 6.21.). A  
higher amount o f rabbit enolase incubation (100 |ig) produced no significant 
difference.
6.16.4. Conclusion
This suggests that the anti-NNE antibodies do cross-react with rabbit muscle enolase 
in this patient (DA). Rabbit muscle enolase may therefore provide a useful surrogate 
enolase source for ELISA development. There are still some residual anti-brain 
enolase antibodies. This may be because the incubated enolase antigen was not 
adequately in excess, or that some o f the anti-NNE antibodies are specific to 
rat/human enolase epitopes, and do not cross-react with the commercial rabbit muscle 
enolase preparations. I therefore used rabbit muscle enolase for further ELISA 
development and assessment with other patients.
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Figure 6.21. Incubation experiment with commercial enolases. Anti-enolase 
antibody (C-19) binds to alpha enolase in brain homogenate. Patient DA serum 
used in all incubation experiments. No antigen incubation (lane A). Pre-incubation 
with rabbit muscle enolase resulted in decreased anti-brain enolase antibodies 
(lane B). Pre-incubation with Baker’s yeast enolase did not bind the anti-brain 
enolase antibodies (lane C).
■
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Figure 6.23. ELISA negative patients used in incubation experiments. JN pre-incubation 
(lane 1), and post-incubation (lane 2). EW pre-incubation (lane 3), and post-incubation 
(lane 4). Other positive patient with anti-brain enolase antibodies (lane 5). There is no 
reduction in anti-enolase antibodies post-incubation.
Figure 6.24. Purification of recombinant 
human alpha enolase. PAGE gel stained with 
comassie blue, showing recombinant human 
enolase after His column chelation and 
elution (lane 1). Lane 2 shows the result of 
gel digestion. There is reduction in the 
contaminating E.Coli proteins.
M w  1 2
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6.17. Development of an ELISA for anti-enolase antibodies 
using commercial rabbit muscle enolase.
6.17.1. Hypothesis
Rabbit enolase appears to be a potentially useful surrogate o f human/rat brain NNE 
from provisional experiments. Therefore, I aimed to develop an ELISA using rabbit 
muscle enolase.
6.17.2. Method
The ELISA method was followed as described in the method section using a 96 well 
plate.
Antigen/antibody Concentration
Antigen- rabbit muscle enolase 1 pg per well
Primary antibody- patient or control serum 1:200 dilution (200 pi per well)
Secondary antibody- anti-human IgG HRP 
conjugated
1:1000 (200 pi per well)
Detection- OPD 100 pi per well
6.17.2.1. Patients and controls
I used five patients with previously described strong anti-NNE antibody binding on 
Western immunoblotting. I used 8 healthy normal child controls for comparison. As a 
positive control, I used the commercial anti-enolase C-19 antibody.
6.17.3. Results
6.17.3.1. Commercial antibody (C-19)
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Using the commercial antibody at different concentrations, I created a standard curve 
with the rabbit enolase antigen.
2.5
1.5ao
0.5
0 2 4 6
C-19 concentration
1. blank
2. 1:4000
3. 1:2000 DILUTIONS
4. 1:1000
5. 1:500
Next, I ran the patients and controls and plotted the patients, controls and blanks as
follows:
Figure 6.22. ELISA against rabbit muscle enolase, comparing patients against
controls and blanks.
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As can be seen, although the Patients appear to have elevated anti-enolase antibodies
compared to controls, 3 o f the patients do not have significantly elevated anti-enolase
Patient □  Control A Blank
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antibodies using this assay, although previous experiments have shown that they do 
have anti-alpha enolase antibodies against human and rat brain. It is possible that not 
all o f the patient’s anti-NNE antibodies cross-react with the rabbit muscle enolase. I 
therefore aimed to examine this possibility by testing the two patients with the lowest 
anti-rabbit muscle enolase antibodies to see whether these patient’s anti-NNE 
antibodies are cross-reactive with rabbit muscle enolase.
6.18. ELISA development: further absorption experiments.
6.18.1.Hypothesis and aim
To perform absorption experiments using patients previously shown to have anti-NNE 
antibodies who were negative using the rabbit muscle enolase ELISA. It is suspected 
that these patient’s anti-NNE antibodies do not cross-react with rabbit muscle enolase
6.18.2. Method
The high protein concentration o f rabbit muscle enolase was used. Tube A  was used 
as a control with no antigen pre-incubation.
Constituents Tube A Tube B
Serum 1 OjliI in 1ml 0.2% m ilk lO jil in 1ml 0.2% m ilk
Antigen incubation - 1 OOpg rabbit enolase
Incubation 2 hours on rocker at room temperature
Centrifugation 10,000g for 10 minutes
Sample for 
incubation with rat 
enolase
800pl supernatant (do not disturb any precipitate)
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Sera from EW and JN were used (2 ELISA negative patients). The post-incubation 
sera were incubated with rat brain antigen (ammonium sulphate precipitation) after 
Western immunoblotting.
6.18.3. Results
There was no alteration in the pre and post incubation anti-brain enolase antibodies o f 
both patients EW and JN (Figure 6.23). This suggests that the anti-NNE antibodies do 
not cross react with rabbit muscle enolase in these patients.
6.18.4. Conclusions
Although anti-NNE antibodies in some patients cross-react with rabbit muscle 
enolase, other patients do not. It therefore appears that rabbit muscle enolase w ill not 
make a useful surrogate antigen for ELISA or Western blotting assays. It w ill 
therefore be necessary to use a brain NNE from rat or human. This w ill require 
purification o f brain enolases from brain homogenates, or production o f a 
recombinant NNE.
6.19. Purified recombinant human non-neuronal enolase
6.19.1. Introduction
Rabbit muscle enolase, although in itia lly  appealing as a measure o f anti-NNE 
antibodies turned out to be a poor surrogate marker. It was therefore necessary to use 
a human form o f NNE. Commercial human NNE purified from human brain is very 
expensive (£450 for 50 |ig) and thus not a practical antigen for using in a diagnostic
223
224
assay. We therefore tried to develop a recombinant form o f human NNE.
Recombinant human NNE was made by Paul Candler (PhD student, Department o f 
Neuroinflammation). He created recombinant human alpha enolase using gene 
specific primers to amplify mRNA from healthy human lymphocytes, and expressed 
the protein in an E.Coli vector. The protein was His tagged and partially purified 
using His chelating columns. Although the human NNE was the dominant protein, 
there were contaminating E.Coli proteins. I therefore tried to reduce the contaminating 
proteins with further protein purification techniques. I tried ion exchange 
chromatography that, although effective, resulted in a poor yield o f protein. I therefore 
simply extracted the NNE protein from PAGE gels as follows:
6.19.2. Method
The His column purifed extract was incubated with SDS and DDT using the standard 
PAGE sample preparation. The SDS sample was then run in a 10 well PAGE gel, w ith 
2 lanes containing the molecular weight marker. Once the gel had been run for 39 
minutes using the standard PAGE method, the gel was removed from the plastic 
housing. Then a section o f gel containing the recombinant human enolase was excised 
from the gel. I excised the section between 40 and 55kDa. The gel was then minced 
and incubated in 1 ml o f sodium phosphate buffer w ith 0.1% SDS for 30 minutes at 
65° C. The gel was then loaded into a microcon concentrator with a membrane cut-off 
o f 100 kDa. The NNE should then flow through the membrane, whereas the gel 
structure remains above the membrane. The supernatant was then collected and 
concentrated using Microcon YM-10 concentrators (10 kDa cut-off). The resulting 
protein was then run in a PAGE gel and compared with the His-purified recombinant 
NNE.
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6.19.3. Results
The gel digestion produced significant improvement in purity, compared to the His 
column fraction (Figure 6.24).
6.20. Anti-NNE antibody screening of patients and controls 
using recombinant human NNE.
6.20.1. Method
I now aimed to test a number o f patients and controls against recombinant human 
NNE using Western blotting. The method was as follows:
Patients and controls 20 patients w ith post-streptococcal CNS disorders 
(10SC, 10 PANDAS)
20 controls (10 w ith neurological disease, 10 
healthy children)
Positive control: commercial anti-enolase 1:2000
Antigen 60 jig recombinant human NNE per 2D gel
Western blotting Standard method (4-12% Bis-Tris 2D gel)
Serum dilution 1/300
Antibody detection Anti-human IgG 1:1000 HRP. Colormetric 
development
Anti-Goat IgG 1:1000 for anti-enolase antibody
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6.20.2. Results
The patients reacted significantly more compared to the controls (Table 6.a.).
Table 6.a. Anti-recombinant human alpha enolase antibodies in patients compared to 
controls.
Group Positive binding (%)
Patients (n=20) 7 o f 20 (35%)
Controls (n=20) 0 o f 20 (0%)
6.20.3. Conclusion
Patients with post-streptococcal CNS disorders have a higher incidence o f antibodies 
against human NNE than controls. However, a significant number o f patients do not 
have these antibodies. This may be partly attributable to the sensitivity o f this assay. 
The recombinant human protein has an advantage over commercially available 
enolases due to being identical to human enolase at the genomic and proteomic level. 
The sensitivity and specificity o f anti-neuron-specific enolase antibodies was 
measured by Andrew Church (as part o f his thesis).
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6.21. Summary of enolase autoantigens.
Table 6.b. Summary o f  45 and 98 kDa proteins
Characteristic 45 kDa upper 
doublet
45 kDa lower 
doublet
98 kDa
Mass spectrometry 
identity
Non-neuronal 
enolase monomer
Neuron-specific
enolase
monomer
Neuron-specific 
enolase dimer
Confirmation with 
commercial human 
antigen
+ +
Confirmation with 
recombinant human 
antigen
+
Confirmation with 
commercial antibody
+ + +
The criticisms and future directions o f this work are detailed in the discussion.
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Chapter 7. Proteomic identification of the 40 kDa 
autoantigen
7.1. Choosing the antigen: Rat brain and human basal ganglia.
7.1.1. Aim
The aim o f this section was to purify and identify the 40 kDa autoantigen. Firstly, it 
was necessary to make sure that I could use rat brain tissue instead o f human brain 
tissue as the brain homogenate.
7.1.2. Method
1. The rat brain supernatant homogenate was used as previously described.
2. Western blotting was performed using 4-12% Bis-Tris PAGE gel. ‘See Blue 
plus T  molecular weight marker was loaded in lane 1. 3 jug o f Human basal 
ganglia was loaded in lane 2. 15 |iG  o f rat brain was loaded in lane 3.
3. The gel was electrophoresed and transferred using the standard method.
4. A patient with strong 40 kDa antibodies (MB) was incubated overnight and 
washed as per standard method.
5. The nitrocellulose was developed colormetrically.
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7.1.3. Results
The 40 kDa autoantigen was present in both rat brain and was the same molecular 
weight as the 40 kDa autoantigen in human basal ganglia (Figure 7.1).
7.2. Regional localisation of 40kDa antigen in rat tissues
7.2.1. Aim
In order to learn more about the 40 kDa antigen, I aimed to determine the regional 
localisation o f the protein in rat tissues. Rat brain (with cerebellum removed), 
cerebellum, kidney, liver and heart were used.
7.2.2. Method
1. One 10-lane 4-12% Bis-Tris gel was used.
2. The rat tissues were homogenised in the same way, and total proteins were 
measured. The proteins were then normalised, and 75jag o f each homogenate 
was loaded into a separate lane.
3. The gel was electrophoresed using the normal method, transferred to 
nitrocellulose and blocked with 2% m ilk for 2 hours.
4. A patient with strong 40 kDa antibodies was incubated 1:300 overnight.
5. The blot was then washed with 10 changes o f 0.025% Tween/0.2% m ilk in 
saline.
6. A secondary antibody (rabbit anti-human IgG with conjugated HRP 1:1000) 
was incubated for 2 hours, and then the blot was washed as before.
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7. The blot was then developed colormetrically for 15 minutes.
230
7.2.3. Results
The 40 kDa protein is present in rat brain and heart. The protein may also be weakly 
present in kidney and liver (Figure 7.2.).
7.3. Ammonium sulphate fractionation
7.3.1. Aim
I aimed to use protein purification methods to purify the 40 kDa autoantigen in order 
to identify the protein using mass spectrometry. In the first instance, I used 
ammonium sulphate fractionation as a first step in protein purification.
7.3.2. Method
1. The ammonium sulphate fractionation method as previously described was 
followed. In summary, rat brain was homogenised as previously described.
2. The following fractions were precipitated, then re-suspended in 1ml o f sodium 
phosphate buffer Ph 7.0: 0-20%
20-40%
40-60%
60-80%
80-100%
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Figure 7.1. Comparison of 
human basal ganglia and rat 
brain (40 kDa antigen). The 
40 kDa antigen was present 
in both rat brain (lane 3) and 
human basal ganglia (lane 
2). Human IgG was present 
in the human basal ganglia 
preparation only.
Figure 7.2. Regional comparison o f 40 kDa antigen. Lane 1: Rat brain (minus 
cerebellum). Lane 2: Rat cerebellum. Lane 3: Rat kidney. Lane 4: Rat liver. 
Lane 5: Rat heart. The 40 kDa antigen was present and enriched in rat brain 
and heart. The protein was possibly weakly present in liver and kidney. There 
was a strong band (38kDa) in both kidney and liver, which may be irrelevant, 
or represent an isoform of the brain protein.
\
38 kDa
Figure 7.3. Ammonium sulphate fractionation. Lane 1: Whole rat brain. Lane 
2: 0-20% fraction. Lane 3: 20-40% fraction. Lane 4: 40-60% fraction. Lane 
5: 60-80% fraction. Lane 6: 80-100% fraction. The 40 kDa protein was most 
abundant in the 40-60% fraction. This patient also had anti-45 kDa 
antibodies (possibly enolase).
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3. The fractions were then solubilised in SDS and reduced with DDT using the 
standard protocol. 25 pi o f each fraction was then loaded onto a 10-lane 4- 
12% Bis-Tris gel, including a molecular weight marker. The samples were not 
desalted for this screening process.
4. The gel was electrophoresed using the standard protocol, transferred, and 
blocked in 2% milk.
5. The serum from patient MB with strong anti-40 kDa antibodies was incubated 
at 1:300 concentration overnight.
6. The blot was washed, secondary antibody was incubated (1:1000) and washed 
again.
7. The blot was developed using colormetric detection.
7.3.3. Results
The 40 kDa antigen was most prevalent in the 40-60% fraction (Figure 7.3). This 
fraction was used for further protein purification strategies.
7.4. 2-dimensional electrophoresis
7.4.1. Aim
The ammonium sulphate precipitation was able to remove some contaminants and 
concentrate the antigen o f interest in the precipitant. However, this method did not 
achieve adequate purification alone. 2-dimensional electrophoresis enabled further 
protein separation by weight and charge.
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7.4.2. Method
1. The 2-dimensional method was employed as previously described.
2. First, the 40-60% ammonium sulphate fraction was desalted (method) into 
sodium phosphate buffer, pH 7.0. This buffer allows proteins to exist in their 
isoelectric form. The 40-60% fraction was then concentrated using micropore 
YM-10 devices. The sample was then made up in IEF buffer and a small 
amount o f SDS to achieve a final SDS concentration o f 0.05% SDS (112.5pl 
sample, 12.5pl 1%SDS, 125^1 IEF buffer).
3. The method was then followed exactly as previously specified.
4. After the second stage, one gel was silver stained as described. A  further gel 
was transferred to nitrocellulose and blotted in the normal way.
5. The blot was incubated with patient serum (MB) at 1:300 dilution overnight. 
The blot was then washed, secondary antibody incubated and washed again as 
per usual Western blotting protocol.
7.4.3. Results
The silver stained gel and Western blot results are presented in figure 7.4. As can be 
seen, it was possible to identify a candidate protein from 2-dimensional 
electrophoresis. This protein was subjected to gel digest and Q-TOF mass 
spectrometry.
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Figure 7.4. 2-
dimensional 
electrophoresis showing 
silver stained gel 
(above), and Western 
blot (below) after 
incubation with MB 
serum. The candidate 
antigen is labelled with 
the arrow.
Protein Score Coverage Molecular weight Pi
Fructose-bisphosphate aldolase C 
(Aldolase C)
2066 40.0% 39134 Da 7.1
ALFC_RAT
Fructose-bisphosphate aldolase C (EC 4.1.2.13) (Br
(P09117)
1 PHSYPALSAE QKKELSDIAL RIVAPG KG IL AADESVGSMA KRLSQIGVEN TEENRRLYRQ VLFSADDRVK
7 1 KCIGGVIFFH ETLYQKDDNG VPFVRTIQEK GILVGIKVDK GVVPLAGTDG ETTTQGLDGL LERCAQYKKD
1 4 1 GADFAKWRCV LK ISDRTPSA LAILENANVL ARYASICQQN G IV PIV E PE I LPDGDHDLKR CQFVTEKVLA
2 1 1 AVYKALSDHH VYLEGTLLKP NMVTPGHACP IKYSPEEIAM ATVTALRRTV PPAVPGVTFL SGGQSEEEAS
2 8 1 LNLNAINRCS LPRPWALTFS YGRALQASAL SAWRGQRDNA GAATEEFIKR AEMNGLAAQG KYEGSGDGGA
3 5 1 AAQSLYVANH AY
Figure 7.5. Mass spectrometry result of 40 kDa protein.
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7.5. Mass spectrometry of candidate protein using Q-TOF.
7.5.1. Results
The candidate protein was cut out o f the gel and digested by Robin Wait (Institute o f 
Rheumatology, Imperial College London). The resulting peptides were then processed 
using the Q-TOF mass spectrometer. The resulting spectrum was compared with 
NCBI databases in the public domain. The tail and head o f the protein were processed 
independently and resulted in the same protein match. The 2-dimensional 
electrophoresis resulted in a candidate protein w ith high mass spectrometry coverage 
(Figure 7.5). The molecular weight and p i were consistent with the 2-dimensional 
electrophoresis migration. However, I aimed to use different protein purification 
methods in addition to 2-dimensional electrophoresis, in order improve confidence 
that aldolase C was indeed the 40 kDa autoantigen.
7.6. Identifying the 40 kDa autoantigen using chromatography
7.6.1. Aim
2-dimensional electrophoresis and mass spectrometry identified aldolase C as the 
candidate 40 kDa autoantigen. Before significant amounts o f time and money in 
creating recombinant aldolase C, I wanted to confirm these findings using different 
purification techniques, namely chromatography. I found that performing ammonium 
sulphate precipitation followed by hydrophobic interaction chromatography then ion 
exchange chromatography produced good separation for identification.
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7.6.2. Method
1. HIC 5ml butryl sepharose FF high performance column was used. Phenyl FF 
columns were less successful in screening.
2. The sample (40-60% ammonium sulphate fraction) was first desalted into the 
start buffer (sodium phosphate pH 7.0 buffer with added 1.5 Molar ammonium 
sulphate). The elution buffer was sodium phosphate pH 7.0 alone.
3. The FPLC was programmed using the‘HIC template’ and followed as 
previously described.
Variable Value
Flow rate 0.25 ml/min
Wash out after sample injection 5 column volumes
Length o f gradient 20 column volumes
Fraction size 1ml
4. I then Western blotted different fractions on a 4-12% Bis-Tris 10-lane gel. The 
proteins were transferred to nitrocellulose and Western blotted using the 
standard method.
5. Serum from patient MB (anti-40 kDa antibodies) was used as the primary 
antibody. Anti-human IgG HRP conjugated 1:1000 was used as the secondary 
antibody.
6. The blot was developed colormetrically.
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7.6.3. Result
The hydrophobic interaction chromatography produced reasonable separation o f 
proteins. This method was performed rapidly and over a short gradient. The aim was 
then to proceed to a further purification step, namely ion exchange chromatography. 
Western blotting showed that the 40 kDa protein was present in lane 4 during HIC 
(Figure 7.6.). This fraction was therefore used in further purification chromatography.
7.7. Further purification of the 40 kDa protein using ion 
exchange chromatography.
7.7.1. Aim
The hydrophobic interaction chromatography provided a useful first stage in the 
purification strategy. I next used this fraction for ion exchange chromatography.
7.7.2. Method
1. I used the 5ml HiTrap Q fast flow  column and connected the column to the 
FPLC using the standard technique. The binding buffer was Tris-HCl buffer 
(pH 8.0), and the elution buffer was Tris-HCl buffer (pH 8.0) with 1.5 Molar 
NaCl.
2. I first desalted the lane 4 fraction from the HIC method into the IEX binding 
buffer.
3. I then loaded the sample onto the FPLC as previously described. I used the 
following variables:
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Figure 7.6. Hydrophobic interaction chromatography (40 kDa 
antigen). The 40 kDa protein was present in lane 4 during Western 
blotting which equated to fraction B5 during hydrophobic interaction 
chromatography.
KiX *  H*2VI l*V
t t tt ft
1 2 34  5 6  1 2 3 4 5 6
Figure 7.7. The ion exchange chromatography produced further 
separation of the 40 kDa proteins. The protein was eluted from the 
column early in the gradient (fractions 2 and 3). Some of the 
protein did not bind and flowed through the column (fraction 1).
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Variable Detail
Flow rate 1 ml/min
Inject sample volume 3.3ml
Wash unbound sample 5 column volumes
Fraction size 1ml
Gradient 0-100% in 15 column volumes
4. The chromatogram shown in Figure 7.7 was produced, and fractions were 
selected for testing as indicated (arrows). The samples were loaded onto a 10- 
well gel and submitted to PAGE electrophoresis as previously described. The 
gel was Western blotted, incubated w ith patient MB (1 GOO), and developed 
using ECL.
7.7.3. Results
The 40 kDa protein was eluted from the IEX column in fractions 2 and 3 as 
demonstrated using Western blotting. The 40 kDa proteins were eluted early in the 
IEX protocol (chromatogram and Figure 7.7)
7.7.4. Conclusion
The 40 kDa protein had been partially purified using ammonium sulphate 
precipitation, hydrophobic interaction chromatography and ion exchange 
chromatography. I therefore performed a silver stain o f the fraction in an attempt to 
identify the protein using mass spectrometry.
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7.8. Identifying the 40 kDa protein after chromatography 
purification using mass spectrometry.
7.8.1. Aim
Next, I silver stained the final fraction in an attempt to identify the 40 kDa protein 
using mass spectrometry.
7.8.2. Method
1. The following fractions were run on a 10-well 4-12% Bis-Tris gel using 
PAGE. One gel was Western blotted and incubated with MB (1:300). The 
other gel was silver stained for identification o f the 40 kDa protein.
•  Ammonium sulphate fraction (40-60%)
• Hydrophobic interaction chromatography fraction (lane 4 fraction from 
HIC)
• Ion exchange chromatography (fraction 3 from IEX)
7.8.3. Results
The Western blot confirmed that the 40 kDa protein was maintained in the 
purification procedure (Figure 7.8). The silver stain showed that the 40 kDa protein is 
partially purified by these methods, with reduction in contaminating proteins. The 40 
kDa protein was submitted to mass spectrometry.
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Figure 7.8. 40 kDa antigen purification after chromatography.Western blot (A) and 
Silver stain (B) o f ammonium sulphate precipitation 40-60% fraction (lane 1), 
hydrophobic interaction chromatography fraction (lane 2), and ion exchange 
chromatography (lane 3). The 40 kDa protein is partially purified by this procedure 
with reduction in contaminating proteins.
Protein Score Coverage Molecular weight Pi
Fructose-bisphosphate aldolase C 
(Aldolase C)
1066 16.8% 39134 Da 7.1
ALFC_RAT
Fructose-bisphosphate aldolase C (EC 4.1.2.13) (Br
(P09117)
1
71
141
211
281
351
PH SYPALSAE Q KK ELSDIAL R IV A PG K G IL  AADESVGSM A KRLSQIGVEN TEENRRLYRQ VLFSADDRVK
KCIG G VIFFH  ETLYQKDDNG V P FV R T IQ E K  G IL V G IK V D K  GW PLAGTDG  ETTTQGLDGL LERCAQYKKD
GADFAKWRCV L K ISD R T P S A  L A ILEN A N V L ARYASICQ QN G IV P IV E P E I  LPDGDHDLKR CQFVTEKVLA
AVYKALSDHH VYLEGTLLKP NMVTPGHACP IK Y SP E E IA M  ATVTALRRTV PPAVPGVTFL SGGQSEEEAS
LN LN AINR CS LPRPW ALTFS YGRALQASAL SAWRGQRDNA G AATEEFIKR AEMNGLAAQG KYEGSGDGGA
AAQSLYVANH AY
Figure 7.9. Mass spectrometry result o f 40 kDa protein.
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Figure 7.10. Other patients 
with anti-aldolase antibodies. 
Lane 1: anti-aldolase 
commercial antibody 1:5000. 
Lane 2-5: Patients. Lanes 6-8: 
Controls. The patients all bind 
to aldolase C and the 
reactivity lines up with the 
commercial antibody. The 
controls show no reactivity.
242
7.8.4. Mass spectrometry results
The 40 kDa protein purified using chromatographic techniques confirmed the protein 
identity as Aldolase C (Figure 7.9.).
7.8.5. Conclusion
Aldolase C was confirmed as the like ly autoantigen in this patient. Aldolase C was 
purified in 2 independent methods (2-dimensional electrophoresis and 
chromatography). Aldolase C is the neuronal isoform o f aldolase. Like enolase, 
aldolase exists in the cytoplasm o f neurones. Like enolase, aldolase also exists on the 
neuronal membrane surface (Knull HR and Fillmore SJ, 1985) and is suspected to be 
involved in redox control o f receptor function and signal transduction (Bulliard C et 
al., 1997).
7.9. Testing the findings using commercial anti-aldolase 
antibodies
7.9.1. Aim
Patient MB has antibodies against aldolase C, the brain isoform o f aldolase. I next 
aimed to test these findings using a commercial anti-aldolase antibody, and also 
determine whether other patients have these antibodies.
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7.9.2. Method
1. Using Western immunoblotting, I used the partially purified aldolase C 
fraction. This fraction had been partially purified by ammonium sulphate 
fractionation, hydrophobic interaction chromatography and ion exchange 
chromatography. This fraction was concentrated using the YM-10 micropore. 
The sample was then loaded onto a 2D 4-12% Bis-Tris gel and 
electrophoresed, transferred to nitrocellulose and blocked using the standard 
method.
2. As a positive control, I used commercial anti-human aldolase antibodies that 
have been previously shown to bind to human brain aldolase C (AbCam, UK).
3. I then ran 4 patients that I have previously identified with probable 40 kDa 
autoantibodies (1:300 dilution). I compared the findings with 3 healthy 
controls.
4. The blot was washed, secondary antibody applied (anti-human 1:5000), and 
washed again using the standard method.
5. The blot was developed using ECL.
7.9.3. Result
The 4 patients all have anti-aldolase C antibodies (lane 5 weakly) (Figure 7.10). The 3 
controls are all negative. This encouraging result needs to be furthered with other 
patients and controls. The commercial anti-aldolase antibody lines up with the 
patients, further confirming the identity o f the 40 kDa protein as Aldolase C.
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7.10. Testing the patients with anti-aldolase C antibodies 
against recombinant human Aldolase C.
7.10.1. Method
I now aimed to test a number o f patients and controls against human aldolase C using 
Western blotting. Recombinant human Aldolase C was made by Paul Candler at the 
Institute o f Neurology. In brief, the protein is made by E.Coli after inserting the 
human aldolase C genome into the E.Coli vector. The protein was His-Tagged, and 
purified using a His column. Despite good purification, there was a low level o f 
contaminating E.Coli proteins. I used a commercial anti-aldolase antibody as a 
positive control. The method was as follows:
Patients and controls 20 patients w ith post-streptococcal CNS disorders 
(10SC, 10 PANDAS)
20 controls (20 healthy children)
positive control: commercial anti-aldolase 1:5000
Antigen 100 jig recombinant human aldolase C per 2D gel
Western blotting Standard method (4-12% Bis-Tris 2D gel)
Serum dilution 1/300
Antibody detection Anti-human IgG 1:1000 HRP. Colormetric 
development
Anti-Goat IgG 1:1000 for anti-aldolase antibody
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7.10.2. Results
The patients reacted significantly more compared to the controls (Table 7.a.). One 
control bound to human aldolase C.
Table 7.a. Anti-human aldolase C antibodies in patients compared to controls.
Group Positive binding (%)
Patients (n=20) 7 o f 20 (35%)
Controls (n=20) 1 o f 20 (5%)
7.10.3. Conclusion
More patients reacted w ith the human aldolase C than the controls, however, most o f 
the patients did not react w ith this protein. This may be at least partly related to the 
sensitivity setting o f this methodology. It is possible that the assay is too insensitive. 
This w ill be discussed in more detail in the discussion.
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Chapter 8. Proteomic identification of the 60 kDa 
protein
8.1. Choosing the antigen: rat brain and human basal ganglia
8.1.1. Aim
The aim o f this section was to purify and identify the 60 kDa autoantigen. Firstly, it 
was necessary to make sure that I could use rat brain tissue rather than human brain 
tissue as the brain homogenate.
8.1.2. Method
1. The rat brain supernatant homogenate was used as previously described.
2. Western blotting was performed using 4-12% Bis-Tris PAGE gel. ‘See Blue 
plus 2’ molecular weight marker was loaded in lane 1. 3 pg o f Human basal 
ganglia was loaded in lane 2. 15 pG o f rat brain was loaded in lane 3.
3. The gel was electrophoresed and transferred using the standard method.
4. A  patient with strong 60 kDa antibodies was incubated overnight and washed 
as per standard method.
5. The nitrocellulose was developed colormetrically.
8.1.3. Results
The 60 kDa autoantigen is present in both rat brain and is the same molecular weight 
as the 60 kDa autoantigen in human basal ganglia (figure 8.1).
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8.2. Regional localisation of 60kDa antigen in rat tissues
8.2.1. Aim
In order to learn more about the 60 kDa antigen, I aimed to determine the regional 
localisation o f the protein in rat tissues. Rat brain (with cerebellum removed), 
cerebellum, kidney, liver and heart were used.
8.2.2. Method
1. One 10-lane 4-12% Bis-Tris gel was used.
2. The rat tissues were homogenised in the same way, and total proteins were 
measured. The proteins were then normalised, and 25pg o f each homogenate 
was loaded into a separate lane. A  molecular weight marker was loaded in lane 
1.
3. The gel was electrophoresed using the normal method, transferred to 
nitrocellulose and blocked w ith 2% m ilk  for 2 hours.
4. A  patient with strong 60 kDa antibodies was incubated 1:300 overnight.
5. The blot was then washed with 10 changes o f 0.025% Tween/0.2% m ilk in 
saline.
6. A secondary antibody 1:1000 (rabbit anti-human IgG with HRP conjugation) 
was incubated for 2 hours, and then the blot was washed as before.
7. The blot was then developed colormetrically for 15 minutes.
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Figure 8.1. Human basal 
ganglia and rat brain 
comparison. The 60 kDa 
antigen is present in both rat 
brain and human basal ganglia 
(arrowed). Human IgG is 
present in the human basal 
ganglia preparation only (IgG 
arrowed). The proteins have 
the same molecular weight.
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Figure 8.2. Regional 
localisation of the 60 kDa 
protein. Lane 1: Rat brain 
(minus cerebellum). Lane 2: 
Rat cerebellum. Lane 3: Rat 
kidney. Lane 4: Rat liver. 
Lane 5: Rat heart. The 60 
kDa antigen is present and 
enriched in rat brain and 
weakly in heart.
1 2 3 4 5 6 7 8
Figure 8.3. Different patients with antibodies to 60 kDa protein. 
Patients in lane 1-5 and 7 appear to have the same 60 kDa autoantigen 
(long arrow). 98 kDa autoantigen antibodies are also common in these 
patients (short arrow).
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8.2.3. Results
The 60 kDa protein is present in rat brain and rat cerebellum, very weakly in heart, 
but not in other rat tissues (Figure 8.2).
8.3. 60 kDa protein. Do other patients react with the same 
autoantigen?
8.3.1. Aim
I wanted to establish that patients other than the index case reacted with the same 
protein. I therefore ran a number o f patients together on a Western blot against whole 
rat brain.
8.3.2. Method
Rat brain homogenate 1:16 was electrophoresed using the standard method and 
Western blotting as previously described.
Patients and controls 8 patients w ith suspected 60 kDa autoantibodies 
(BS, Isr, GW, KE, FH, CH, NM, CM).
Antigen 1:16 rat brain homogenate 150jal
Western blotting Standard method (4-12% Bis-Tris 2D gel)
Serum dilution 1/300
Antibody detection Anti-human IgG 1/1000. Colormetric development
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8.3.3. Results
Different patients reacted with the same 60 kDa autoantigen (lanes 1-8, particularly 1- 
5 and 7 in Figure 8.3).
8.4. Identifying the 60 kDa protein
8.4.1. Aim
To use protein purification methods to purify the 60 kDa autoantigen in order to 
identify the protein using mass spectrometry.
8.4.2. Ammonium sulphate fractionation
8.4.2.1. Method
The ammonium sulphate fractionation method as previously described was followed.
8.4.2.2. Results
Fortuitously, the 60kDa protein was enriched in the 40-60% fraction, as was true o f 
the 40 and 45 kDa proteins. The 40-60% fraction was therefore used for further 
purification strategies.
8.4.3. Chromatography
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8.4.3.1. Aim
I next used the 40-60% fraction for further purification strategies. I suffered a number 
o f false starts with further separation. Ion exchange chromatography lead to co­
precipitation with another protein which caused initial confusion. However, using 
hydrophobic interaction chromatography first proved to be a better and significantly 
purifying step rather than ion exchange chromatography.
8.4.3.2. Method
1. HIC 5ml butryl sepharose FF high performance column was used.
2. The sample (40-60% ammonium sulphate fraction) was first desalted into the 
start buffer (sodium phosphate pH 7.0 buffer with added 1.5 Molar ammonium 
sulphate). The elution buffer was sodium phosphate pH 7.0 alone.
3. The FPLC was programmed using the ‘HIC template’ .
Variable Value
Flow rate 1 ml/min
Wash out after sample injection 5 column volumes
Length o f gradient 30 column volumes
Fraction size 2ml
4. I then Western blotted different fractions on a 4-12% Bis-Tris 10-lane gel 
(Figure 8.4.). The proteins were transferred to nitrocellulose and Western 
blotted using the standard method.
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5. Serum from patient Isr (anti-60 kDa antibodies) was used as the primary 
antibody. Anti-human IgG HRP conjugated 1:5000 was used as the secondary 
antibody.
6. The blot was developed with ECL.
8.4.3.3. Result
The hydrophobic interaction chromatography produced surprisingly good separation 
o f proteins. This method was performed slowly aiming to achieve good separation. 
After Western blotting, it showed that the 60 kDa protein was present in fraction E10 
(lane 2) 
in Figure 8.4.
8.5. Identification of the candidate protein using mass 
spectrometry
8.5.1. Method
The fraction E10 (lane 2) was submitted to PAGE with a control lane (rat brain 
fraction).
8.5.2. Results
The HIC fraction E10 was loaded onto lane 2 o f the PAGE gel (Figure 8.5). The 60 
kDa protein was enriched in this fraction w ith significant reduction in contaminating 
proteins. The protein was cut out by Robin Wait, digested and subjected to Q-TOF 
mass spectrometry and identified as pyruvate kinase M l (Figure 8.6).
Pyruvate kinase is an enzyme involved in energy metabolism that resides both in the 
cytoplasm and on the neuronal surface, and has a molecular mimic in streptococci.
The M l isoezyme is expressed in brain and heart.
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Figure 8.4. HIC chromatography o f 60 kDa protein. HIC produced good 
separation o f proteins. The 60 kDa protein was eluted early (fraction 2).
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Figure 8.5. Purification of 
60 kDa protein. Rat brain 
40-60% fraction (lane 1) 
and HIC fraction ‘ElO’ 
(lane 2) were separated by 
PAGE. The protein was 
labelled with a long arrow.
Protein Score Coverage Molecular weight Pi
Pyruvate kinase, M 1 isoform 2415 20.5% 57668 Da 7.0
K P Y 1R A T
Pyruvate kinase, M1 isozyme (EC 2.7.1.40) (Pyruvat
(P11980)
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4 2 1
4 9 1
PKPDSEAGTA
ARLNFSHGTH
ITLDNAYMEK
PGAAVDLPAV
EILEASDGIM
VLDGADCIML
KCLAAALIVL
LAMNVGKARG
FIQTQQLHAA
EYHAETIKNV
CDENILWLDY
SEKDIQDLKF
VARGDLGIEI
SGETAKGDYP
TESGRSAHQV
FFKKGDVVIV
MADTFLEHMC
RAATESFASD
K NICK W EVG
GVEQDVDMVF
PAEKVFLAQK
LEAVRMQHLI
A R Y R PR A PII
LTGWRPGSGF
R L D ID S A P IT
PILYRPVAVA
SKIYVDDG LI
ASFIRKAADV
MMIGRCNRAG
AREAEAAVFH
AVTRNPQTAR
TNTMRVVPVP
A R N T G IIC T I
LDTKGPEIRT
SLQVKEKGAD
HEVRKVLGEK
KPVICATQML
RLLFEELARA
QAHLYRGIFP
GPASRSVEML
GLIKGSGTAE
YLVTEVENGG
G K N IK TISK I
ESMIKKPRPT
SSQSTDPLEA
VLCKDAVLDA
KEMIKSGMNV
VELKKGATLK
SLGSKKGVNL
ENHEGVRRFD
RAEGSDVANA
MAMGSVEASY
WAEDVDLRVN
Figure 8.6. Mass spectrometry of the 60 kDa protein.
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8.6. Commercial anti-pyruvate kinase antibodies and pyruvate 
kinase antibodies in patients and controls.
8.6.1. Aim
I next aimed to test the patients w ith suspected antibodies against rat pyruvate kinase 
using a commercial anti-pyruvate kinase antibody as a positive control.
8.6.2. Method
I used the fraction E10 from HIC that contained the rat pyruvate kinase. The E10 
fraction was concentrated using the micropore concentrators YM-10 from 1ml to 150 
pi. The sample was made up in SDS, and run on a 4-12% 2D Bis-Tris gel. The gel 
was electrophoresed and transferred using the standard method. The blot was then 
processed as follows:
Patients and controls 4 patients with suspected 60 kDa autoantibodies 
(Isr, GW, KE, TT)
Negative control: secondary antibody only 
Positive control: Goat anti-pyruvate kinase antibody 
(1:2000)
Antigen E10 fraction from HIC 150pl
Western blotting Standard method (4-12% Bis-Tris 2D gel)
Serum dilution 1/300
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Antibody detection Anti-human IgG 1/5000 HRP. ECL development
8.6.3. Results
As can be seen in Figure 8.7, the commercial antibody and patients reacted with the 
pyruvate kinase in the E 10 fraction. The patient with the strongest reactivity on 
screening (KE) reacted strongest on this Western blot (lane 2). The Western blot was 
technically slightly untidy, probably related to the small amount o f antigen loaded 
onto the Western blot, w ith resulting relatively high background reactivity.
8.6.4. Conclusion
I next aimed to test the patients against commercially available pyruvate kinase. The 
only available pyruvate kinase commercially available was rabbit pyruvate kinase.
8.7. Testing homology of human with commercial pyruvate 
kinase antigens.
8.7.1. Aim
I bought rabbit pyruvate kinase hoping that this antigen would make a useful 
surrogate antigen for antigen development. I first compared the homology o f rabbit 
and rat pyruvate kinase with human M l pyruvate kinase (PYK).
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Figure 8.7. The commercial 
anti-pyruvate kinase 
antibody (lane 1) strongly 
reacted with the pyruvate 
kinase- the antibody was 
overloaded. Patients (lanes 
2-5) also reacted with the 
pyruvate kinase. Lane 6 was 
anti-human secondary 
antibody only showing no 
reactivity.
Mw 1
Figure 8.8. Testing the findings with commercial pyruvate kinase antigen. 
Coumassie stained gel (lanes 1 and 2 with molecular weight marker) show a 
strong band at 60 kDa in lane 2, and a weaker band at -100 kDa(presumably 
the dimer of pyruvate kinase). The Western blot shows reactivity against a 60 
kDa protein in the rat brain fraction (lane 3) and to the rabbit PYK (lane 4- 
arrowed).
Figure 8.9. Different patients with anti-pyruvate kinase antibodies. Patients 
(lane 2-5) and controls (lanes 6-8) against rabbit PYK. Commercial antibody 
in lane 1. Three of four patients are positive, whereas all 3 controls are 
negative.
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8.7.2. Method
I performed a BLAST 2 protein search on the NCBI database.
8.7.3. Results
Comparison with human Identity Positive Chance homology
PYK M l
Rat PYK M l 93% 95% 0.0
Rabbit PYK M l 92% 96% 0.0
Although there is similarity in the homology between human and rat/ rabbit tissue, the 
database could not specify whether the reported amino acid sequence was the brain 
isoform. The commercial rabbit PYK is derived from muscle, whereas all work so far 
has used rat brain. The amino acid sequence, conformation and immunogenicity may 
differ in the muscle and brain.
8.8. Provisional assessment o f anti-pyruvate kinase 
antibodies using rabbit pyruvate kinase antigen.
8.8.1. Method
I first compared rat 40-60% fraction with the commercial rabbit pyruvate kinase 
(PYK). I performed the experiment as follows:
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Patients and controls 3 patients w ith suspected 60 kDa autoantibodies 
(Isr, KE, GW)
Antigen Lane 1: Rat brain 40-60% fraction (25 fig)
Lane 2: Rabbit muscle pyruvate kinase (2.5 fig)
Commassie stain Lanes 1 and 2 were commassie stained using the 
standard method.
Western blotting Lanes 3 and 4 were Western blotted using the 
standard method (4-12% Bis-Tris 10 well gel)
Serum dilution 1/300
Antibody detection Anti-human IgG 1/5000 HRP. ECL development
8.8.2. Results
The coummassie stain demonstrated a 60 kDa antigen in lane 2. Western blotting 
showed reactivity o f all 3 patients to a 60 kDa antigen in the rat 40-60% fraction, and 
also to the rabbit pyruvate kinase (Figure 8.8).
8.8.3. Conclusion
With this encouraging initial result, I aimed to test further patients against the rabbit 
PYK.
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8.9. Anti-pyruvate kinase antibody screening of patients and 
controis using rabbit pyruvate kinase.
8.9.1. Method
I now aimed to test a number o f patients and controls against rabbit pyruvate kinase 
using Western blotting. The method was as follows:
Patients and controls 20 patients w ith post-streptococcal CNS disorders 
(10SC, 10 PANDAS)
20 controls (10 w ith neurological disease, 10 
healthy children)
Positive control: commercial anti-PYK 1:5000
Antigen 20 pg rabbit PYK per 2D gel
Western blotting Standard method (4-12% Bis-Tris 2D gel)
Serum dilution 1/300
Antibody detection Anti-human IgG 1:5000 HRP. ECL development 
Anti-Goat IgG 1:5000 for PYK antibody
8.9.2. Results
The patients reacted significantly more compared to the controls (Table 8.a.). One 
control bound to rabbit pyruvate kinase (DYT1 dystonia). Figure 8.9 shows the 
positive binding in patients and the positive control (commercial anti-PYK antibody).
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Table 8.a. Anti-rabbit pyruvate kinase antibodies in patients compared to controls.
Group Positive binding (%)
Patients (n=20) 13 o f 20 (65%)
Controls (n=20) 1 o f 20 (5%)
However, at least one patient w ith strong antibodies against rat PYK did not react 
with rabbit PYK, adding doubt to the usefulness o f rabbit PYK as a surrogate 
autoantigen.
8.9.3. Conclusion
Although rabbit PYK is a useful screen, the presence o f a probable false negative 
result suggests that rabbit PYK may not be a perfect surrogate autoantigen. It is likely 
that recombinant human PYK M 1 would be required for definitive assays. It was not 
possible to make recombinant human PYK M l during the time constraints o f this 
thesis.
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Chapter 9. In vitro pathogenic effects of anti-neuronal 
antibodies on neuronal function
9.1. Possible pathological function of antibodies on neuronal 
function
The glycolytic enzymes non-neuronal and neuronal enolase, aldolase C and pyruvate 
kinase M l all reside in the cytoplasm o f neurones. However, as discussed later, the 
enzymes also reside on the neuronal membrane. The enzymes are multifunctional 
proteins, and are thought to have a role on the membrane in energy metabolism, 
neuronal cell well-being and neurotransmission support (discussed in detail later).
Clearly, it is not possible to examine the potential pathogenic role o f these antibodies 
in this thesis in detail. However, I was able to examine two possible functional effects 
o f antibodies on neuronal function:
•  Effect o f anti-NNE antibodies on the function o f NNE as a plasminogen 
receptor on the neuronal membrane.
• Effect o f commercial antibodies (anti-enolase, anti-aldolase, anti-pyruvate 
kinase) on neuronal survival (measuring apoptosis). This was performed by Dr 
Jenny Pocock at the cell signalling lab, Institute o f Neurology.
9.2. Do the anti-NNE antibodies have functional effects on 
non-neuronal enolase as a plasminogen receptor?
9.2.1. Aim and background
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Non-neuronal enolase acts as a plasminogen receptor on the neuronal surface, and 
mediates interaction with dopaminergic neurones (Nakajima K et ah, 1994). The 
streptococcal enolase also acts as a plasminogen receptor, and is involved in its ability 
to invade tissue. There are previously described methods examining the interaction 
between plasminogen and enolase. I therefore followed these methods, with some 
modifications (Moscato S et al., 2000; Pancholi V  and Fischetti VA, 1998).
9.2.2. Method
In the first instance, I wanted to demonstrate that plasminogen binds to NNE. This is 
obviously essential i f  I am to assess the effects that antibodies may have on this 
interaction. I therefore purchased human plasminogen and incubated the plasminogen 
with commercial human NNE that had been electrophoresed and transferred to 
nitrocellulose. I used an anti-plasminogen antibody as my detection. To control this 
experiment, I did one blot without pre-incubation with plasminogen to see i f  there was 
plasminogen resident in the antigen preparation.
1. The protein (human NNE or rat brain fraction containing NNE) was first 
electrophoresed, transferred to nitrocellulose and blocked.
2. Once blocked, the blots were incubated overnight with 20 jig human 
plasminogen in 20 ml normal saline. In accordance with the method published 
by Pancholi, 2mmol o f PMSF (Phenylmethylsulfanylfluoride) was also added 
to the incubation solution (Pancholi V  and Fischetti VA, 1998).
3. After incubation, the blots were washed for 1.5 hours with 0.025%Tween 
with changes o f wash solution every 10 minutes.
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4. After washing, the blots were incubated with anti-plasminogen antibody 
(HRP conjugated) 1:10,000 dilution for 2 hours.
5. The blots were washed as before for 2 hours.
6. The blots were then developed using ECL.
Lane 1 2 3
Antigen Rat brain fraction 
(45-65%) 30jal
Human NNE 3pg Rat brain fraction 
(45-65%) 30 Lil
Plasminogen
incubation
20 ^ig 20 (ig None
Anti-plasminogen
Ab
+ + +
Figure 9.1. Schematic representation o f  plasminogen-enolase experiment.
enolase plasminogen
/ /
Anti-plasminogen Ab
9.2.3. Results
Using this method, plasminogen binds to human NNE (Figure 9.2). Plasminogen also 
binds to a 45 kDa protein in the rat brain antigen (presumably rat NNE). In addition, 
there is strong binding to a protein in the rat brain tissue at 38 kDa. It is possible that 
this represents glutaraldehyde 3-phosphate dehydrogenase, the other recognised 
plasminogen receptor. In the blot that was not pre-incubated with plasminogen, there 
was no antibody reactivity in the rat tissue. This demonstrates that the reactivity in the
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Figure 9.2. Plasminogen binding to human NNE (lane 2, arrowed), and to a 
similar 45 kDa protein (presumed rat NNE) and 38 kDa protein (possible GDH) 
in rat brain (lane 1). There was no anti-plasminogen antibody binding to the rat 
brain tissue that had not been pre-incubated with plasminogen (lane 3).
1 2 3 4 5 6 7
Figure 9.3. Inhibition of plasminogen binding to enolase by patient serum. 
Patient serum inhibits plasminogen binding to enolase (lanes 4 and 6), but the 
control serum (lane 7) also inhibits plasminogen binding.
1 2  3 4
Figure 9.4. Patient EW IgG pre-incubation with human NNE (lanes 5-8) has 
no effect on plasminogen-enolase binding (control in lane 4).
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rat tissue is due to plasminogen-receptor binding, not due to plasminogen resident in 
the rat tissue homogenate (Figure 9.2).
9.2.4. Conclusion
Using Western blotting, it is possible to bind plasminogen to enolase, and demonstrate 
this reaction using anti-plasminogen antibody.
9.3. Human and commercial antibody effect on plasminogen 
binding to non-neuronal enolase
9.3.1. Aim
Having established a Western blotting assay to assess plasminogen binding, I next 
aimed to examine whether antibodies binding to enolase could interrupt plasminogen 
binding. Clearly, using Western blotting, the results should be interpreted as 
provisional, as the SDS preparation alters proteins. Western blotting is not a 
physiological system. It would be preferable to use proteins in their physiological 
state.
9.3.2. Method
1. Commercial human NNE was used as the antigen substrate. 5 pg was diluted 
in SDS, DDT and double distilled water and loaded onto 2D 4-12% Bis-Tris 
gel. The gel was electrophoresed using the standard method, transferred to 
nitrocellulose and blocked as per standard Western blotting protocol.
2. The primary antibody (patient serum or control polyclonal anti-enolase 
antibody) was diluted as stated below and incubated overnight.
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3. The blot was washed in 0.05% Tween normal saline solution for 1.5 hours 
with changes o f wash solution every 10 minutes.
4. 20 |ig plasminogen was diluted in 20ml normal saline plus 2mmol PMSF, and 
incubated for 2 hours.
5. The blot (in manifold) was washed as above.
6. The secondary antibody (anti-plasminogen) was loaded 1:5000 as stated in the 
table for 2 hours.
7. The blot was washed as stated above and developed using ECL.
Lane Primary antibody Plasminogen
incubation
Secondary antibody
1 - - Anti-plasminogen HRP 
1:5000
2 Anti-enolase (C-19) 
1:1000
- Anti-goat HRP 1:5000
3 - + Anti-plasminogen HRP 
1:5000
4 GdS serum 1:150 + Anti-plasminogen HRP 
1:5000
5 GdS serum 1:500 + Anti-plasminogen HRP 
1:5000
6 EW serum 1:150 + Anti-plasminogen HRP 
1:5000
7 AC 49 serum 1:150 + Anti-plasminogen HRP 
1:5000
8 - + Anti-plasminogen HRP 
1:5000
9.3.3. Results
The anti-enolase antibody (lane 2) and plasminogen incubation (lane 3) confirmed 
that human NNE binds plasminogen (Figure 9.3). The patient serum inhibited 
plasminogen binding in patients (lanes 4 and 6), but also in the healthy control (lane 
7). This healthy control does not have anti-NNE antibodies on previous evaluation.
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9.3.4. Conclusion
Although the patient serum appeared to interfere with plasminogen binding, the 
control produced the same interference. I therefore wanted to check whether it was 
IgG that was interfering with enolase-plasminogen binding. It is possible that other 
components in the serum (complement or drugs, etc.) are interfering with the enolase- 
plasminogen interaction, specifically or otherwise. I therefore needed to purify IgG 
and de-complement the serum, and re-test this experiment.
9.4. Plasminogen binding to enoiase: interruption by patient 
IgG?
9.4.1. Aim
I therefore aimed to re-test this experiment, this time with patient IgG purified from a 
patient with previously demonstrated anti-human NNE antibodies.
9.4.2. Method
The patient IgG was purified using the method described in Protein A  IgG purification 
(chapter 5). The IgG concentration was measured using the Biuret method. The IgG 
fraction contained 1.4 !ig /p l The antigen (NNE loaded onto nitrocellulose) and 
method was the same as previously described in section 9.3. The manifold was loaded 
as stated below:
267
268
Lane Primary antibody Plasminogen
incubation
Secondary antibody
1 - - -
2 Anti-enolase (C-19) 
1:1000
- Anti-goat HRP 1:5000
3 EW lOOpl IgG - Anti-human HRP 
1:5000
4 - + Anti-plasminogen HRP 
1:5000
5 EW 250pl IgG + Anti-plasminogen HRP 
1:5000
6 EW 25pl IgG + Anti-plasminogen HRP 
1:5000
7 EW 2.5pl IgG + Anti-plasminogen HRP 
1:5000
8 EW 0.25pl IgG + Anti-plasminogen HRP 
1:5000
As can be seen, this experiment aimed to compare the plasminogen binding to human 
NNE with varying amounts o f patient IgG pre-incubated with the human NNE. Lane 
5 contained a large amount o f IgG (350 jig), almost certainly in excess o f the 
available human NNE on the blot (5pg on the whole 2D gel).
9.4.3. Results
As can be seen (Figure 9.4), the patient IgG reacts with human NNE (lane 3), 
although the background is very high, probably due to overloading the well with IgG. 
Lane 4 is the control, which had no pre-incubation o f IgG before incubation with 
plasminogen. As can be seen, lanes 5-8 had decreasing concentrations o f patient IgG 
pre-incubated with human NNE, before plasminogen incubation. There is no 
determinable alteration o f plasminogen binding with NNE secondary to IgG 
preincubation. This experiment, suggests that patient anti-NNE antibodies do not 
affect enolase-plasminogen binding under these experimental conditions (discussed 
later).
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9.4.4. Conclusion
The patient IgG chosen (EW) with anti-human NNE antibodies had no effect on 
plasminogen-enolase binding. The serum did interfere with this binding, suggesting 
that other serum constitutents, such as complement or drugs, may interfere w ith this 
interaction. However, under these experimental conditions, patient IgG alone did not 
have any effect. The conclusions are therefore:
1. Anti-human NNE IgG 1, 2 or 4 antibodies do not effect enolase-plasminogen 
binding.
2. In some patients and controls, a serum constituent other than IgG 1, 2 or 4 
inhibits enolase-plasminogen binding.
9.5. Anti-neuronal glycolytic enzyme antibody effects on 
neuronal apoptosis
9.5.1. Introduction
I next aimed to determine whether the antibodies had effects on neuronal function. 
Although non-specific, I used apoptosis as a measure o f the effects o f antibodies on 
neuronal function. These experiments were performed by Dr Jenny Pocock, Institute 
o f Neurology. In these provisional experiments, rather than using patient purified 
polyclonal IgG, I used commercial antibodies against enolase, aldolase and pyruvate 
kinase.
9.5.2. Cerebellar granule cell cultures
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Rat cerebellar neurones were cultured and used as the neuronal cell line. Primary 
cultures o f cerebellar granule cells (CGCs) were isolated from 3-4 day old Wistar rat 
pups and prepared as previously described (Evans JO and Pocock JM, 1999). Briefly, 
the rat pups were killed by cervical dislocation followed by decapitation in 
accordance with the Scientific Procedures Act, UK, 1986. Following mechanical and 
enzymatic isolation, the neurones were plated on 13 mm poly-D-lysine coated 
coverslips at a density o f 0.7 x 106 cells per coverslip and maintained in minimum 
essential medium with Earle’s salts supplemented with 25 mM KC1, 30 mM glucose, 
25 mM NaHC03 , 1 mM glutamine, 10 % foetal ca lf serum, and 50 U/ml penicillin, 50 
(Ig/ml streptomycin and 6 jig/m l ampicillin. After 24 h in vitro, 20 jiM  cytosine 
arabinoside (1 -p-D-arabinofuranosylcytosine, AraC) was added to prevent the 
proliferation o f non-neuronal cells. The cultures were maintained at 37 °C in 5 % 
CO2. Cells were used after 7 days in vitro (DIV).
9.5.3. Treatment of cells with commercial antibodies.
10|ig/ml o f commercial antibody was incubated for 24 hours. Control cells had the 
same volume o f distilled water added alone. A  control antibody (anti-Hu) was used in 
the same concentration.
9.5.4. Assessment of cellular apoptosis
The number o f apoptotic cells was assessed by Hoechst 33342 (bisbenzimide 
trihydrochloride) staining (Kingham PJ et al., 1999). Cells were fixed in phosphate 
buffered saline (PBS; 137 mM NaCl, 5.4 mM KC1, 2.9 mM NaH2P04 .2H20 , 25.8
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mM Na2HP04) with 8 % formaldehyde for 15 min at 4 °C, and then stained with 5 
mg/ml Hoechst 33342 for 15 min. The morphology o f the nucleus was viewed using 
a fluorescence microscope with excitation at 365 nm and emission at > 490nm. The 
number o f cells with pyknotic, brightly stained nuclei and those with normal, dull- 
staining nuclei were scored in 10 fields o f view per coverslip, and recorded as a 
percentage o f the total cells. Each commercial IgG sample was tested on at least 2-3 
coverslips.
9.5.5. Results of antibody effects on apoptosis
The extent o f neuronal apoptosis induced by the commercial antibodies (enolase, 
pyruvate kinase, aldolase) was compared with the control commercial antibody (HuD) 
and the control blank (Table 9.a also represented in Figure 9.5). Anti-enolase, anti­
pyruvate kinase and anti-aldolase antibodies all induced a significantly higher rate o f 
apoptosis in the cultured neurones compared to the blank control (all p<0.0005) and 
the anti-HuD (p<0.01).
Table 9.a. Percentage o f apoptotic cells after incubation with commercial antibodies.
Antibody Apoptosis % cells (+/- SEM)
Blank 10.6+/- 0.94
HuD 15.6 +/- 0.83
Enolase 32.6 +/- 1.65
Pyruvate kinase 27.2 +/- 2.2
Aldolase 27.3 +/- 1.6
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Figure 9.5. Percentage o f apoptotic cells after incubation with commercial antibodies 
(and SEM). 1: Blank. 2: Anti-HuD antibodies. 3: Anti-Enolase antibodies. 4: Anti- 
Pyruvate kinase antibodies. 5: Anti-Aldolase antibodies.
Antibody
Fig: In vitro induction o f apoptosis o f cerebellar granule cells. Anti-aldolase, pyruvate kinase and enolase antibodies all 
resulted in a significant increase in the number o f apoptoctic cells compared to no IgG. * p <  0.0001, ** p =0.0003. There 
was no significant increase in apoptosis with anti-HuD antibodies.
9.6. Conclusions o f antibody effects on neuronal function.
In conclusion, patient human anti-enolase antibodies do not appear to alter enolase 
activity as a plasminogen receptor. In contrast, the commercial antibodies against 
neuronal glycolytic enzymes induce apoptosis compared to controls, suggesting that 
antibodies against these autoantigens potentially have pathogenic function. These 
experiments w ill need to be repeated using purified human IgG specific to the
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autoantigens. In addition, more detailed pathogenic effects on neuronal function w ill 
be required, beyond the less specific markers we have measured so far (apoptosis).
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Chapter 10. Discussion of clinical and immunological 
thesis findings
10.1. Spectrum of post-streptococcal neuropsychiatric 
phenotypes
10.1.1. Post-streptococcal dyskinesias
I presented the experience o f paediatric post-streptococcal dyskinetic movement 
disorders in a tertiary care setting. As this cohort was derived from a referred sample 
and not epidemiological in design, the findings cannot truly represent a community 
sample. It is possible that the tic phenotype (PANDAS) is under-represented, as many 
o f these patients w ill be treated in the community and not referred to a hospital. In 
contrast, patients with chorea, dystonia and Parkinsonism are very likely to be 
referred for secondary and tertiary paediatric care. Also there may be referral bias 
within the tic cohort, as patients w ith impairing tics are more likely to be referred for 
opinion. Likewise, patients with associated psychiatric comorbidity are also more 
likely to be referred to tertiary care.
However, despite these limitations, this cohort highlights important findings. 
Specifically, the spectrum o f post-streptococcal dyskinesias is not restricted to chorea, 
but includes motor tics and dystonia. This cohort, now published (Dale RC et al., 
2004), provides further support for the existence o f the PANDAS phenotype, although 
PANDAS w ill remain a controversial diagnosis until more robust diagnostic assays 
become available (Kurlan R, 2004). It is perhaps not surprising that a variety o f 
movement disorders may occur in the context o f post-streptococcal neurological 
disease. Rarely do basal ganglia syndromes result in only one extrapyramidal 
phenotype; indeed a variety o f extrapyramidal movement disorders are reported in 
‘basal ganglia disorders’ such as Huntington’s disease and Wilson’s disease.
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By analysing differences between the chorea and tic subgroup, I attempted to 
determine what variables might dictate phenotypic expression. Although the patient 
age did not clearly influence the dyskinesia phenotype, the sex distribution 
demonstrated male predominance in the tic cohort and female predominance in the 
chorea subgroup. As discussed in the introduction, this sex distribution has been 
previously reported in Sydenham’s chorea after puberty (Nausieda PA et al., 1980) 
and tic disorders (Singer HS and Walkup JT, 1991), and may suggest an influence o f 
sex hormones on phenotypic expression. The fact that oestrogen can precipitate 
chorea (chorea gravidarum and oral contraceptive p ill) supports the possible role o f 
oestrogen in the chorea phenotype (Nausieda PA et al., 1979). In this cohort, it was 
notable that there was a modestly elevated prevalence o f neuropsychiatric disorders 
(particularly ADHD) preceding movement disorder onset, a finding previously 
reported by Mercadante (Mercadante M T et al., 2000). It is possible that ADHD could 
represent a specific neurodevelopmental risk factor for the later development o f post­
streptococcal movement disorders. Alternatively, the preceding psychiatric symptoms 
may be a consequence o f previously unrecognised episodes o f post-streptococcal 
autoimmunity. Only longitudinal and epidemiological studies would address these 
alternate hypotheses. It is also possible that the movement disorder phenotype is 
partly related to the particular cortico-striatal tracts involved in disease pathogenesis 
(Albin RL et al., 1989).
Vocal tics were common in the motor tic subgroup, however they were not exclusive 
to this group. Indeed, vocal tics are an unusual but previously recognised feature o f 
Sydenham’s chorea (Mercadante M T et al., 1997). Other than extrapyramidal 
movements, additional neurological features were uncommon although sleep 
disturbance (particularly insomnia) occurred in a significant proportion. It could be 
argued that the sleep disturbance is due to the disruption o f normal sleep patterns by
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extra movements. Alternatively, the aberrant neurochemistry producing the movement 
disorder could also affect sleep pathways. Recent reports o f sleep disturbance in 
Parkinson’s disease and Huntington’s disease support this putative hypothesis 
(Silvestri R et al., 1995; Rye DB and Jankovic J, 2002). The association o f post- 
infectious movement disorders with sleep disorders w ill also be discussed in the 
Parkinsonism/ encephalitis lethargica section.
Emotional and behavioural alteration was a common accompanying feature o f the 
acute disease, regardless o f the movement phenotype. The acute behavioural changes 
were often dramatic and rapid. Indeed, Swedo felt that the ‘over-night’ change in 
behaviour was characteristic o f PANDAS, and often occurs before the chorea in SC 
(Swedo SE et al., 1993; Swedo SE et al., 1998). Indeed a number o f the patients were 
admitted to hospital, such was the dramatic and surprising alteration in the child ’s 
behaviour. Frequently, the children suffered a ‘change in personality’ , and became 
emotionally labile or aggressive. After the acute phase, formal interview demonstrated 
a high prevalence o f ICD-10 psychiatric diagnoses. As demonstrated in previous 
cohorts o f SC and PANDAS (Swedo SE et al., 1998; Mercadante MT et al., 2000), 
emotional disorders (particularly obsessive-compulsive disorder and anxiety 
disorders) were the most common, and the incidence o f obsessive-compulsive 
disorder (OCD) was more common in chronic or relapsing SC (Asbahr FR et al.,
1999). Indeed, OCD in this cohort was limited to the patients whose movement 
disorder had been present for more than 1 year. The shorter mean duration o f illness 
in the SC cohort may be responsible for the reduced incidence o f OCD in this 
subgroup. Otherwise, there were no clear differences in the psychiatric morbidity 
between the chorea and tic subgroups in this study. In addition to emotional disorders, 
conduct disorders and hyperkinetic disorders (such as ADHD) were also common. By 
contrast, psychotic symptoms were not seen in this cohort, in keeping with previous
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reports (Swedo SE et al., 1993; Swedo SE et al., 1998). It would be o f interest to 
perform follow-up assessments on this cohort to see i f  the psychiatric features resolve 
or remain (as found by Freeman in SC, Freeman JM et al., 1965).
The methodology used to determine psychiatric morbidity in this thesis is criticisable 
for a number o f reasons. Firstly, the D AW BA was developed primarily for 
epidemiological studies rather than cohort studies. Although the DAW BA was 
validated by Robert Goodman during development and showed good correlation with 
conventional psychiatric methods, it would have been valuable to perform similar 
reliability checks during the psychiatric assessments included in this thesis. In 
addition, although psychiatric diagnoses are made by the DAW BA, there is little 
information regarding symptom profiles. Other interviews (such as CY-BOCS for 
OCD) would be required for more in-depth profiling.
The main difference between the chorea and tic subgroups was the presence o f 
systemic features (carditis and arthritis) that were exclusive to the chorea subgroup.
The cause o f this important difference is unknown although it must be acknowledged 
that systematic cardiac examination in PANDAS patients was not performed in this 
case series. The recent report o f echocardiographic abnormalities in PANDAS 
patients demonstrating mitral valve changes emphasises the need for careful 
investigation for asymptomatic cardiac disease in all post-streptococcal 
neuropsychiatric patients in the future (Cardona F et al., 2003).
Although some patients within this cohort have had transient disease or resolution o f 
the movement disorder within a year, a large proportion o f patients have had 
persistent or relapsing disease. The high proportion o f patients with protracted disease 
may be due to selection bias, as patients with milder transient disease are unlikely to 
be referred to a tertiary referral centre. Only epidemiological studies could 
characterise the true incidence o f chronic and persistent disease. As discussed in the
277
278
introduction, previous studies suggest that Sydenham’s chorea becomes persistent in 
20-50% o f patients (Nausieda PA et al., 1980; Cardoso F et al., 1999). Swedo’s 
proposed diagnostic criteria for PANDAS require two or more exacerbations o f motor 
tics or OCD with streptococcal infections (Swedo SE et al., 1998). I f  we believe that 
Sydenham’s chorea and PANDAS are biologically similar disorders, Swedo’s clinical 
criteria o f PANDAS would exclude a significant proportion o f PANDAS patients with 
monophasic disorders. Laboratory confirmation o f recent GAS infection is necessary 
for a diagnosis o f post-streptococcal dyskinesia, however positive GAS serology is 
common in paediatric populations and is unlikely to be a specific diagnostic tool used 
in isolation. Indeed, 18% o f the neurological controls in this thesis cohort had elevated 
streptococcal serology. Previous childhood control groups in the US have even higher 
rates o f positive streptococcal serology (Singer HS et al., 1998). This has 
consequently led to diagnostic difficulty, and even questioned whether the ‘PANDAS’ 
phenotype exists (critically reviewed in Singer HS and Loiselle C, 2003). This 
emphasises the need for improved clinical and laboratory criteria for the diagnosis o f 
PANDAS. Other investigation was usually normal, and MR imaging revealed no 
abnormalities in the majority.
The prevalence o f movement and emotional disorders in first-degree family relatives 
suggests that a genetic predisposition is important in disease development, in addition 
to the environmental trigger (Lougee L et al., 2000). It could be argued that the high 
incidence o f neuropsychiatric disease in 1st degree family members is due to a 
genetically determined neurodevelopmental vulnerability. Alternatively, the 
psychiatric disease in parents and siblings could have had a psychological impact on 
the patients. My more favoured hypothesis is that disease is related to a genetically 
determined autoimmune predisposition. The positive family history o f post­
streptococcal autoimmune syndromes (Sydenham’s chorea, PANDAS and rheumatic
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fever) in this study and previous cohorts o f SC supports this genetic immune 
hypothesis (Nausieda PA et al., 1980). Whether the genetic immune vulnerability is 
related to the B-lymphocyte marker D8/17 (as discussed in the introduction), or a 
hitherto unrecognised genetic vulnerability remains unknown. Finally, it is also 
possible that genetic vulnerability is mediated via a combination o f these mechanisms 
(neurochemical, immunological and psychological).
In conclusion, a broad spectrum o f dyskinetic extrapyramidal movements and 
neuropsychiatric disorders may occur after GAS infection. Although the clinical 
similarities between the chorea and tic subgroups suggest that SC and PANDAS may 
be two phenotypes o f the same immune mediated basal ganglia disorder, other authors 
have highlighted the differences (Murphy TK  et al., 2000). Phenotypic expression 
may depend on other variables including the specific cortico-striatal circuits involved, 
developmental status, genetic predisposition and patient’s sex. Many o f the PANDAS 
patients fulfilled diagnostic criteria for Tourette’s syndrome. Improved understanding 
o f the disease mechanism in post-streptococcal neuropsychiatric disease could 
significantly improve our knowledge o f the neurochemistry and neuroanatomy o f 
common childhood diseases.
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10.1.2. Post-streptococcal acute disseminated encephalomyelitis
The clinical features in the 10 patients w ith post-streptococcal acute disseminated 
encephalomyelitis (PSADEM) were remarkable due to the high incidence o f dystonia 
and rigidity. In contrast, extrapyramidal movement disorders are rarely reported in 
previously described ADEM  cohorts (Dale RC et al., 2000; Tenembaum S et al.,
2002). No patient had chorea or tics, clinically differentiating the PSADEM patients 
from SC or PANDAS. Seventy percent o f the patients had a behavioural alteration 
characterised by emotional lability, inappropriate laughter, separation anxiety and 
confusion. The behavioural alteration was similar to that seen in the acute stages o f 
SC and PANDAS. In addition to the movement disorder and behavioural change, 
most patients also presented w ith encephalopathy requiring rapid assessment and 
management. Despite the dramatic presentation, the majority o f the patients made a 
good recovery, although one patient has obsessive-compulsive disorder, and another 
has persistent hemidystonia. The good outcome may be related to the natural course 
o f the disease, or could be due to the prompt use o f immunosuppressive treatments in 
these cases (intravenous methylprednisolone). These children were given 
immunosuppressive treatments in the acute or hyperacute stages o f disease, because 
o f the encephalopathic presentation requiring prompt assessment, diagnosis and 
treatment. In contrast, patients w ith SC and PANDAS rarely achieve such prompt 
management. I f  prompter diagnoses and treatment could occur in SC and PANDAS 
patients, it is tempting to speculate that these children could have better outcomes. 
Interestingly as seen in SC and PANDAS, relapses may occur. In the two PSADEM 
cases that relapsed, the relapses were related to further streptococcal infections.
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The most important differentiating feature o f PSADEM from SC and PANDAS (other 
than the encephalopathic clinical features) is the presence o f an inflammatory CSF 
and the presence o f inflammatory lesions on T2-weighted MR imaging. The 
inflammatory lesions on MR imaging were most prevalent in the basal ganglia 
regions, although there were frequently disseminated lesions throughout the CNS. 
These MR imaging findings provide important information into the pathogenesis o f 
post-streptococcal neuropsychiatric disease. Although the basal ganglia appear to be 
particularly vulnerable to post-streptococcal immune mediated attack, disease also 
occurs (at a lower level) in other parts o f the CNS. This imaging finding in PSADEM 
is supported by the pathological reports o f SC (described in the introduction):
Although the basal ganglia is often the most florid ly involved brain region, other parts 
o f the CNS (particularly the cortex) are pathologically involved. The presence o f CSF 
abnormalities in some patients with PSADEM (in contrast to SC and PANDAS), also 
suggests that the inflammatory reaction is more developed in PSADEM than in SC or 
PANDAS.
In conclusion, PSADEM has a number o f similarities with SC and PANDAS (the 
presence o f an extrapyramidal movement disorder, behavioural alteration and 
relapsing remitting nature). However, PSADEM cases frequently have more 
disseminated CNS involvement (clinically and radiologically) suggesting that, 
although the basal ganglia is the most vulnerable region, the immune attack can 
generalise to the rest o f the CNS.
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10.1.3. Post-streptococcal Parkinsonism and encephalitis 
lethargica
The index cases reported in this thesis had remarkable similarity to the historical 
reports o f encephalitis lethargica (EL). This mysterious disease was last seen in 
epidemic forms in the 1920’s, and was described in detail by von Economo (von 
Economo, 1931). The central features o f the disease were sleep disorder, lethargy, 
extrapyramidal movements (Parkinsonism and dyskinesias) and neuropsychiatric 
disturbance (obsessive-compulsive disorder, catatonia, mutism, apathy and conduct 
disorders). The neuropsychiatric phenomenology o f EL led to notions that the deep 
grey matter (particularly basal ganglia) may be involved in the control o f mood, 
emotion, behaviour and volition (Cheyette SR and Cummings JL, 1995; Ward CD,
2003). Furthermore, von Economo used EL as a model o f sleep disturbance, and his 
anatomical localisation o f sleep control to the midbrain and deep grey matter has been 
confirmed by contemporary studies (Saper CB et al., 2001). The mortality o f 
epidemic EL was between 20-40%. O f the survivors, many were left with 
Parkinsonism, dyskinesias or psychiatric disease. The cases described in this series 
had similar characteristics to those described by von Economo. In this series, one o f 
the patients died, and five had reduced conscious level and required ventilation. It is 
probable that these ventilated patients would have died were it not for contemporary 
intensive care. A complete recovery occurred in a minority o f patients in this series, 
the majority are still suffering continued psychiatric and movement disorders. The 
course o f disease was monophasic or fluctuating, unlike the progressive course 
characteristic o f the metabolic, biochemical or inherited causes o f Parkinsonism.
The cerebrospinal fluid was abnormal in about 50% o f epidemic EL cases, mild 
elevation o f protein and mild lymphocytosis being characteristic (von Economo,
1931; McCall S et al., 2001). The cerebrospinal fluid abnormalities found in the
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patients in this report are similar to recent cases o f sporadic EL (Howard RS and Lees 
AJ, 1987; Blunt ST et al., 1997; K iley M  and Esiri MM, 2001), and the presence o f 
intrathecal synthesis o f oligoclonal bands have been proposed to be a useful marker o f 
disease (Williams A et al., 1979; Howard RS and Lees AJ, 1987). Either intrathecal or 
mirrored pattern o f OCB was seen in 69% o f the patients described in this report. By 
contrast, all CSF PCR studies were negative, making neurotropic viral encephalitis 
unlikely. When considered together, oligoclonal bands, CSF pleocytosis and elevated 
CSF protein were abnormal in 81% o f patients, and although in keeping with an 
immune mediated pathogenesis, are not specific to this phenotype. The MR 
neuroimaging in this cohort was abnormal in 40%; characteristic features were 
increased signal in the basal ganglia, substantia nigra and tegmentum, features 
recently proposed to be suggestive o f EL (Verscheren H and Crols R, 2001). There 
were some similarities with the EL imaging abnormalities to those seen in PSADEM, 
which further suggests that PSADEM and EL may lie on the same disease spectrum. 
The enhancement resolved after the acute stage in the few patients who had 
convalescent imaging.
The pathological features o f both epidemic EL and contemporary EL have shown 
perivascular lymphocytic (plasma cell) cuffing, which predominantly involved the 
midbrain and basal ganglia (von Economo, 1931; Rail D et al., 1981; Kiley M and 
Esiri MM, 2001). A recent post-mortem case o f a patient with the EL phenotype 
demonstrated an unexpected excess o f perivascular plasma cells, which were 
distended by IgG. The authors concluded that a brisk humoral response was occurring 
(Kiley M and Esiri MM, 2001). In the one post-mortem case, we found similar 
histopathological findings with perivenous lymphocytic cuffing predominantly o f the 
basal ganglia, although there was lymphocytic infiltration seen elsewhere in the brain 
at a lower level. The lymphocytes were both T and mature B lymphocytes. Other than
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secondary reactive astrocytes and macrophage activation, there were no other striking 
pathological features. O f note, there were no viral inclusions. Interestingly, reports 
during the 1920’s described remarkable pathological similarity between encephalitis 
lethargica and Sydenham’s chorea (Greenfield JG and Wolfsohn JM, 1922). Chronic 
changes included neuronal loss and neurofibrillary degeneration in the midbrain and 
basal ganglia. These pathological findings again suggest that, although the basal 
ganglia appears to be particularly vulnerable to this encephalitic process, the disease is 
not confined to the basal ganglia only, and occurs at a lower level elsewhere in the 
CNS.
The precipitating micro-organism o f epidemic EL remains unknown. Although EL 
has been associated with influenza (Ravenholt RT and Foege WH, 1982), von 
Economo suspected that an as yet unidentified virus or alternative process was 
responsible. Studies during the 1920’s showed no clusters o f disease suggesting an 
endemic presence as opposed to an imported epidemic (James SP, 1918). Unlike 
influenza, EL was not very contagious and even intra-familial spread was unusual 
(von Economo, 1931). Further evidence against influenza being the cause o f EL was 
that von Economo had observed EL for 3 years before the onset o f the great influenza 
pandemic. In addition, patients with EL rarely had influenza before neurological 
onset; in one early report o f 76 EL cases, only 4 had influenza in the preceding 6 
months (Stallybrass CO, 1923).
Recent PCR examination o f five acute EL brains from the 1920’s epidemic revealed 
no influenza RNA. Unlike respiratory tissue from patients who died o f the 1918 
influenza viral pneumonia, brain tissue from EL patients had no influenza RNA. The 
authors concluded that the 1918 influenza virus was unlikely to be directly 
responsible for the outbreak o f EL (McCall S et al., 2001). A separate recent study 
also demonstrated the lack o f influenza genes in archived formalin-fixed brain
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samples o f EL patients from 1916 to 1920 (Lo KC et al., 2003). Likewise 
contemporary EL cases have failed to demonstrate evidence o f invasive encephalitis 
secondary to neurotropic viruses (Duvoisin RC and Yahr MD, 1965; Williams A  et 
al., 1979; Rail D et al., 1981; Howard RS and Lees AJ, 1987; Elizan TS and Casals J, 
1989; Blunt ST et al., 1997; Kiley M and Esiri MM, 2001), although one case 
occurred as a post-infectious complication o f mycoplasma infection (Al-Mateen M et 
al., 1988). A recent review concluded that clinically, epidemiologically and 
morphologically, EL and the 1918 influenza virus represent distinct entities (Reid AH 
et al., 2001).
Interestingly, during the epidemic attention had focused on a streptococcus as a 
possible etiological agent. A  number o f investigators had detected streptococci in the 
throats o f patients suffering from EL (Wilson SAK, 1918; Harris W, 1918; von 
Economo, 1931). In addition, they were able to induce an encephalitis lethargica-like 
illness in dogs after vaccination with streptococcal organisms (von Economo, 1931). 
However, as gram positive organisms were never isolated from the brain, the authors 
concluded that it was unlikely to have been the primary etiological agent.
The hypothesis that the EL phenotype could be aetiologically similar to Sydenham’s 
chorea is potentially appealing. Any hypothesis must be able to explain why the 
clinical, neuroimaging and pathological characteristics are relatively restricted to the 
deep grey matter. Invasive viral encephalitis rarely localizes so specifically, although 
Japanese B encephalitis is one notable exception. As pharyngitis was a common 
precedent o f epidemic and contemporary EL, I examined the hypothesis that the EL 
patients described in this cohort were secondary to post-infectious autoimmunity 
directed against the deep grey matter. In this series, we were able to demonstrate 
recent streptococcal infection in significantly more EL patients compared to 
neurological and healthy control groups. It is therefore possible that streptococcus
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may play an aetiological role in this EL phenotype, as it does in SC. However a 
proportion o f the EL patients in this cohort had no evidence o f preceding 
streptococcal infection. However, autoimmune complications commonly occur many 
weeks or months after the precipitating organism, and growth o f the organism is 
rarely possible. For example, in Sydenham’s chorea the ASOT is elevated in only 
73% o f patients due to the latent onset o f neurological disease after streptococcal 
infection (Taranta A and Stollerman GH, 1956). I therefore propose that although the 
association with streptococcus is a useful line o f further investigation, alternative 
environmental triggers (such as phylogenetically related micro-organisms) may be 
important in disease evolution o f this EL phenotype.
10.1.4. Overview of the clinical spectrum of post-streptococcal 
neuropsychiatric syndromes
The clinical findings o f this thesis are now presented in schematic form (Figure 10.1).
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Figure 10.1. Schematic summary o f  the clinical spectrum ofpost-streptococcal 
neuropsychiatric disease.
Movement Psychiatry Sleep
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Agitated, anxiety
V
Hypokinetic
A
V
Depression, apathy
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A
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Hypersomnolence
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10.2. Identification of autoantigens in post-streptococcal 
neuropsychiatric disease
10.2.1. Overview of candidate autoantigens
A summary o f the autoantigens defined in this thesis are given in table 10.a. 
Table 10. a. Summary o f  autoantigens defined in this thesis
Western blotting Defined human autoantigen
40 kDa Aldolase C
45 kDa lower band Neuron-specific enolase
45 kDa upper band Non-neuronal enolase
60 kDa Pyruvate kinase M 1
98 kDa Neuron-specific enolase (dimer)
In summary, the autoantigens are all glycolytic enzymes. I w ill now discuss the 
characteristics o f the autoantigens with relevance to their existence as potential 
autoantigens for autoantibody mediated attack.
10.2.2. Localisation of candidate auto-antigens
10.2.2.1 Isoforms (isoenzymes) of candidate autoantigens
10.2.2.1.1. Enolase
Enolase exists as two isoforms: the more acidic neuron-specific enolase (NSE) pi 4.7 
and molecular weight 39.000 Daltons, and the more basic non-neuronal enolase 
(NNE) pi 5.9 and molecular weight 43,000 Daltons (Marangos PJ et al., 1978). NSE, 
also known as gamma enolase, exists primarily in neurons, wheras NNE, also known 
as alpha enolase, is ubiquitous in cells and exists primarily in glial cells in the brain
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(although also exists on neuronal membrane, discussed later) (Marangos PJ et al., 
1978).
The enzymes mainly exist as dimers with gamma gamma, alpha alpha, and alpha 
gamma forms (Marangos PJ et al., 1978; Keller A et al., 1994; Ueta H et al., 2004) 
although may exist as monomers on the neuronal surface (discussed later) (Nakajima 
K et al., 1994). NSE and NNE have 83% complete amino acid homology.
10.2.2.1.2. Aldolase C
Aldolase is also termed fructose 1,6 bisphosphate aldolase and exists as 3 isoforms A, 
B and C. Aldolase A is ubiquitous in all mammalian tissue, Aldolase B is 
predominantly found in liver, and Aldolase C is predominantly in brain (Buono P et 
al., 2001). Aldolase C is found at low levels in other tissues (about 2% o f that in brain 
(Willson VJ and Thompson RJ, 1980). Aldolase C has a relative molecular mass o f 
39,000 Daltons and pi o f 6.8 (Kukita A  et al., 1988; Buono P et al., 2001). Aldolase A  
and C have 81% homology, wheras B and C have 70% homology (Kukita A et al., 
1988).
10.2.2.1.3. Pyruvate kinase M l
Pyruvate kinase M 1 has a molecular weight o f approximately 60,000 Daltons, and a 
pi o f 8.0. It often exists as a tetramer in the cytoplasm (Farrar G and Farrar WW,
1995). Broadly there are L and M isoforms. The M  isoforms are further divided into 
M l, M2, M3 and M4 isoforms. M2 is the predominant form in spleen, leucocytes, 
lung and other systemic tissue. M l is the predominant form in muscle (including 
heart) and brain (Marie J et al., 1976). Pyruvate kinase M l and M2 have 99% 
homology.
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10.2.2.1.4. Overview of isoforms
In summary, the candidate autoantigens are generally (with the exception o f NNE) 
neuronal isoforms o f the glycolytic enzymes enolase, aldolase and pyruvate kinase.
10.2.2.2. Localisation of candidate autoantigens
10.2.2.2.1. Overview of autoantigen localisation
Autoantibodies are considered more likely to be pathogenic i f  they bind to 
autoantigens that are present on a cell wall rather than intracellular. Although 
antibodies can gain access to a cell w ith an intact cell wall, this is generally 
considered unlikely and antibodies to intracellular and nuclear antigens are less likely 
to be pathogenic (Lang B et al., 2003).
10.2.2.2.2. Enolase
Over the last two decades, with the development o f specific technologies for purifying 
different cell components, it has become possible to define cell membrane 
characteristics, with the aid o f detergents such as Triton X-100 (to loosen the strong 
lipophilic membrane bonds (Lim L et al., 1983). It has been shown that glycolytic 
enzymes not only exist within the cell cytoplasm, but also on the cell membrane. 
Neuron-specific enolase and non-neuronal enolase exist on the plasma membrane o f 
neurons (Lim L et al., 1983, Leung TK  et al., 1987, Nakajima K et al., 1994). Enolase 
may reside as a monomer (Nakajima K  et al., 1994) and/  or as a dimer (Ueta H et al., 
2004). Indeed Ueta has demonstrated recently that the alpha gamma heterodimer 
exists in synaptic plasma membranes o f neurons, making these autoantigens 
potentially available for autoantibody attack (Ueta H et al., 2004).
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10.2.2.2.3. Aldolase C
Like NSE and NNE, Aldolase C has been shown to reside within the neuronal 
membrane and also the synaptic membrane (Builliard C et al., 1997; Bahler M  et al., 
1991). The amount o f protein appears to be highest in the recycling vesicles (Builliard 
C et al., 1997).
10.2.2.2.4. Pyruvate kinase M l
Pyruvate kinase (PK) was demonstrated to reside on the neuronal membrane at the 
same time that enolase was revealed as a resident membrane protein (Leung TK  et al., 
1987; Lim L et al., 1983). Subsequently, the enzyme was shown to be tightly 
associated with the membrane, often residing in a complex (Dubinsky WP et al.,
1998, discussed later), and may be enriched in nerve endings (Gali P et al., 1981). The 
pyruvate kinase exists at the cell surface in a membrane- anchored form (Hiebert SW 
et al., 1988). The anchor domain is a class II integral membrane protein 
(haemagglutinin/ neuraminidase) (Hiebert SW et al., 1988). Hiebert determined that 
neither the compete PK molecule nor its glycosylation was necessary for intracellular 
transport to the cell surface, nor expression at the surface (Hiebert SW et al., 1988).
10.2.2.3. Regional location of autoantigens within the brain
10.2.2.3.1. Overview
Most investigation to date has suggested that post-streptococcal autoimmune 
neuropsychiatric disease results in a CNS disorder relatively localised to the basal 
ganglia. I next wanted to investigate whether the defined autoantigens are present in 
the basal ganglia, specific to the basal ganglia or enriched in the basal ganglia.
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10.2.2.3.2. Enolase
Non-neuronal enolase is present in neurons early in gestational life, but is replaced by 
neuron-specific enolase during gestational development (Gross J et al., 1990). Levels 
o f NSE increase most rapidly in the phylogenetically old areas (midbrain, thalamus) 
compared to the new areas (cerebral cortex) (Marangos PJ et al., 1980, Gross J et al., 
1990). NSE is present in neurons throughout the CNS, but at highest levels in the 
cerebral cortex, cerebellum, midbrain and basal ganglia (Jorgensen OS and Centervall 
G, 1982). There is no significant difference in the regional distribution o f the dimeric 
alpha gamma enolase (Jorgensen OS and Centervall G, 1982). Regional comparison 
o f NSE on neuronal membranes has not been done.
Non-neuronal enolase (NNE) is found in glia, but is also found on neuronal 
membranes (Nakajima K et al., 1994). Regional distribution o f NNE on neuronal 
membranes has not been examined. In the mesostriatal system, there is a correlation 
between NSE expression (and cytochrome oxidase plus tyrosine hydroxylase) and the 
establishment o f connections in the subpopulations o f dopaminergic neurons (and 
their metabolic activity) (Silverman WF, 1992; Silverman WF, 1992).
10.2.2.3.3. Aldolase C
Aldolase C is present almost exclusively in neurons within the CNS, but also in 
neuroendocrine cells (Buono P et al., 2001, Thompson RJ et al., 1982, Inagaki H et 
al., 1988). Aldolase C mRNA is 4-fold higher in CNS neurons than astroglia 
(Popovici T et al., 1990). Aldolase C mRNA is predominantly found in the cerebellar 
neurons and to a lesser extent in medulla, striatum and occipital lobe (Buono P et al., 
2001; Popovici T et al., 1990). The regional distribution o f Aldolase C on the 
neuronal membrane has not been undertaken.
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10.2.2.3.4. Pyruvate kinase
Pyruvate kinase M 1 appears to be predominantly found in the cytoplasm o f neuronal 
cell bodies, with scanty distribution in glia (Gali P et al., 1981). There is no apparent 
difference in distribution o f pyruvate kinase in different neuronal populations o f the 
cerebellum, cortex, brainstem or basal ganglia (Valenzuela A et al., 1987). Pyruvate 
kinase exists on the neuronal membrane (Lim  L et al., 1983, Leung TK et al., 1987), 
although there has been no published study examining the regional distribution o f 
pyruvate kinase on the neuronal membrane.
10.2.2.3.5. Conclusion
Although the autoantigens (apart from NNE) are enriched in, or specific to, neurons, 
there is no evidence to support basal ganglia specificity or enrichment o f any o f the 
autoantigens. There have been no studies o f regional distribution o f these proteins on 
the neuronal membrane.
10.2.3. Potential functional role of auto-antigens
10.2.3.1. Function of autoantigens as enzymes
A ll o f the autoantigens are glycolytic enzymes and are centrally involved in energy 
metabolism in cells. The neuronal isoforms o f these glycolytic enzymes are also 
involved in energy metabolism. The respective enzymes (and their enzymatic 
reaction) are described in Figure 10.2. As can be seen, the enzymes are centrally 
involved in the metabolism o f ADP and ATP. As can be seen Aldolase is involved in 
the first stage o f glycolysis, with input o f priming ATPs. Both enolase and pyruvate 
kinase are involved in the second stage o f glycolyis, with the conservation and 
production o f energy as ATP.
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Figure 10.2. Glycolysis and enzyme involvement.
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10.2.3.2. Function of enolase on neuronal membrane.
The fact that enolase (both NNE and NSE) exist on the neuronal membrane suggest
that these enzymes have specific roles at this site. The proteins derived from both 
synaptic plasma membranes and recycling vesicles do have enzymatic activity 
(Bulliard C et al., 1997). The specific activities o f enolase (and also aldolase and 
pyruvate kinase) are elevated in the synaptosomal membranes suggesting that these 
enzymes (and other glycolytic enzymes) may provide the potential for enhanced 
glycolysis at these locations (Knull HR et al., 1985).
However, it has become clear that membrane surface expressed enolase has more 
roles other than those related to energy metabolism. Indeed enolase is now considered 
a multifunctional protein with a broader role in cell function (and therefore diseases) 
than previously considered (Pancholi V, 2001). It has been shown that NNE acts as a 
plasminogen receptor on neuronal membranes (Nakajima K  et al., 1994). In addition, 
this plasminogen-enolase binding mediates interaction between microglia and 
dopaminergic neurons (Nakajima K  et al., 1994). Interestingly, studies investigating 
plasminogen effects on mesencephalic neurons showed significant increases in 
tyrosine hydroxlase staining, but no alteration in gamma-aminobutyric acid (GABA) 
uptake or glutamic acid decarboxylase activity (Nagata K  et al., 1993). These findings 
suggest that plasminogen results in a selective enhancement o f dopaminergic activity 
in mesencephalic neurons (Nagata K et al., 1993). NSE is also known to form a tight 
complex with other glycolytic enzymes (including Aldolase C) and oxidoreductase 
complexes on neuronal membranes. The role o f these complexes may include 
membrane fusion and protection o f the neurone from oxidative stress during growth 
and development. In conclusion, enolase exists on the neurone membrane surface as a 
multifunctional protein with probable roles in energy metabolism, neurotransmission 
and cell well-being.
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10.2.3.3. Function of aldolase on neuronal membrane
There has been less investigation regarding the role o f aldolase on the neuronal
membrane. However the protein does provide local membrane energy and is 
enzymatically active (Bulliard C et al., 1997). Adolase C forms an oxidoreductase 
complex with enolase and heat shock protein 70, TOAD64 and glyceraldehyde 3- 
phosphate dehydrogenase (GAPDH) on the neuronal membrane (and synaptic 
membrane). Membrane Aldolase C in this complex is bound very tightly to GAPDH. 
This complex is thought to monitor oxidative stress at the cell surface and can induce 
the appropriate cellular response (Bulliard C et al., 1997).
In addition, experiments on other cell types have shown that aldolase binds tightly 
with ATPase protein pumps on the plasma membrane. It is thought that the aldolase- 
ATPase binding allows direct coupling o f glycolysis to the proton pump (Lu M  et al., 
2001). It could therefore be speculated that aldolase and other glycolytic enzymes are 
closely involved in the energy provision and maintenance o f ion channels on the 
neuronal membrane.
10.2.3.4. Function of pyruvate kinase on neuronal membrane
As with enolase and aldolase, pyruvate kinase is tightly bound to the neuronal
membrane. Pyruvate kinase is a critical enzyme in the metabolism o f ATP and ADP. 
Important experiments have shown that membrane glycolysis provides a preferential 
source o f ATP for membrane function in order to maintain K+ channels on myocytes 
(Weiss JN and Lamp ST, 1987), ATPase and calcium uptake on smooth muscle cells 
(Hardin CD et al., 1992) and Na+ K + pumps on intestinal cells (Dubinsky WP et al., 
1998). The maintenance o f these pumps may be directly linked to functionally 
compartmentalised ATP to ADP ratios on the cell membrane (Dubinsky WP et al.,
1998). Interestingly pyruvate kinase is also influenced by the female hormone 
oestradiol-17b. Administration o f oestradiol-17b to rat brain neurons results in an
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increase in soluble and membrane (synaptic) bound pyruvate kinase four hours after 
treatment (but not other glycolytic enzymes) (Kostanyan AA  and Nazaryan KB 1991; 
Kostanyan A  and Nazaryan K, 1992). These findings suggest that rat brain glycolysis 
regulation by oestradiol is carried out in neurons due to specific pyruvate kinase 
enzyme induction (Kostanyan A  and Nazaryan K, 1992). This finding may provide a 
possible explanation for the increased vulnerability o f females to the expression o f 
chorea (chorea gravidarum and chorea on the oral contraceptive pill).
As a further example o f the multifunctional roles o f glycolyic enzymes, it has recently 
been shown that the monomer o f pyruvate kinase acts as thyroid hormone (T3) 
binding protein. Binding o f T3 to pyruvate kinase inhibits enzymatic activity, 
suggesting that this process may be centrally involved in the control o f some cellular 
metabolic effects induced by thyroid hormones (Kato H et al., 1989). Perhaps it is 
therefore not surprising that hyperthyroidism is one o f the causes o f chorea.
10.2.4. Potential functional effects of auto-antibodies
10.2.4.1. Overview
It is theoretically possible that autoantibodies bound to membrane glycolytic enzymes 
can result in impairment o f any o f the follow ing cellular functions: Energy 
metabolism, plasminogen binding, ion channel stability, neurotransmission and 
oxidative stress monitoring. Any o f these functional effects are possible, or there may 
yet be undetermined impairments. It is possible that autoantibodies can directly and 
independently mediate functional effects, or functional effects may require secondary 
complement binding or even T-cell cytotoxicity.
10.2.4.2. Autoantibody effects on neuronal function
The experiments performed in this thesis failed to demonstrate impairments o f
plasminogen-enolase binding with commercial or human anti-enolase antibodies
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alone. It is still possible that addition o f complement may result in impairment o f 
plasminogen binding and consequent neuronal dysfunction. The in vitro neuronal cell 
culture work presented in this thesis showed that commercial anti-neuronal glycolytic 
enzyme antibodies resulted in increased apoptosis. The mechanism o f this cell death is 
unknown. Other groups have assessed the potential effects o f antibodies against 
membrane glycolytic enzymes on cell function. A  group have shown that anti- 
glycolytic enzyme antibodies are capable o f impairing plasminogen binding to alpha 
enolase on leucocytes (Lopez-Alemany R et al., 2003). A separate group showed that 
the oxidoreductase activity o f aldolase C/gamma enolase/TOAD64/ heat shock 
protein 70/ GAPDH complex on neuronal cells can be impaired by antibodies to the 
different components (Bulliard C et al., 1997). In addition, this effect was synergistic 
with sequential reductions in reductase activity w ith two or more antibodies. For 
example, anti-aldolase and anti-enolase antibodies reduced reductase activity on the 
neuronal membrane by 49% and 38% respectively, wheras using both anti-aldolase 
and anti-gamma enolase antibodies synergistically resulted in 78% reduction in 
reductase activity (Bulliard C et al., 1997).
10.2.5. Previous reports of auto-antibodies
There have been a number o f previous descriptions o f autoantibodies against enolase, 
aldolase and pyruvate kinase, particularly anti-alpha enolase antibodies (Pancholi V, 
2001). Table lO.b. reviews the previous reports o f autoantibodies against these 
glycolytic enzymes. Indeed enzymes are frequent targets o f autoantibodies including:
• Anti-DNase 1 antibodies in systemic lupus erythematosus (Puccetti A  et al., 
1995)
• Anti-topoisomerase antibodies in systemic sclerosis (Douvas AS et al., 1979)
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Anti-myeloperoxidase antibodies in ANCA-positive vasculitis (Falk RJ et al., 
1988)
Anti-glucose-6-phosphate isomerase in Rheumatoid arthritis (Matsumoto I et 
al., 1999)
As can be seen, auto-antibodies against the ubiquitous forms o f the glycoytic enzymes 
(alpha enolase specifically) have been found in other disorders although direct 
comparisons between the diseases is not possible as the methodologies differed. It is 
possible that some o f the patient groups had lower, possibly less significant levels o f 
autoantibodies. In addition, anti-aldolase A antibodies (low levels) have been found to 
be natural antibodies in healthy people (Pashov A  et al., 2002). However, the most 
relevant previous report o f anti-glycolytic enzyme antibodies is in post-streptococcal 
rheumatic fever (Fontan PA et al., 2000). This group demonstrated antibodies against 
alpha enolase in patients with rheumatic fever at significantly higher levels than 
healthy controls and controls with uncomplicated streptococcal pharyngitis. In 
addition, these antibodies showed cross-reactivity with the streptococcal surface 
enolase supporting a molecular mimicry hypothesis (discussed later, Fontan PA et al., 
2000).
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Table lO.b. Previous reports o f autoantibodies against enolase, aldolase and pyruvate
kinase
Auto-
antibodies
Disease Detail Reference
Anti-alpha Cancer associated In vitro retinal cell Adamus G et al.,
enolase retinopathy apoptosis 1998
Anti-alpha Lymphocytic hypophysitis - O’Dwyer DT et
enolase (pituitary endocrinopathy) al., 2002
Anti-alpha Schizophrenia Conformational Deckmann M  et
enolase epitope al., 2002
Anti-alpha Hashimoto’s - Ochi H et al.,
enolase encephalopathy 2002
Anti-NSE Glaucoma Low titres Maruyama I et
al., 2002
Anti-alpha Discoid lupus - Gitlits V M  et al.,
enolase erythemasosus 1997
Anti-alpha SLE, systemic sclerosis, Impaired Moscato S et al.,
enolase mixed cryoglobulinaemia plasminogen 2000
binding Pratesi F et al.,
2000
Anti-alpha Rheumatoid arthritis Only 36 o f 145 Saulot V  et al.,
enolase patients 2002
Anti-Aldolase Rheumatoid arthritis - Ukaji F et al.,
A 1999
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Anti-alpha ANCA positive vasculitis With active renal Moodie FD et
enolase (37%) SLE (10/41) disease al., 1993
Anti-alpha Autoimmune - Peterson P et al.,
enolase polyglandular syndrome 1996
Anti-alpha Behcet’s disease - Lee KH et al.,
enolase 2003
Anti-alpha Primary membranous and - Wakui H et al.
enolase lupus nephropathy 1999
Anti-alpha Primary sclerosing Low titres only Orth T et al.,
enolase cholangitis 1998
Anti-alpha Ulcerative colitis (10%) - Roozendaal C et
enolase Crohn’s disease (18%) al., 1998
Anti-alpha Endometriosis - Walter M  et al.,
enolase 1995
Anti-alpha Primary biliary cirrhosis - Akisawa N et al.,
enolase 1997
Anti-alpha Rheumatic fever - Fontan PA et al.,
enolase 2000
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10.2.6. Striatal vulnerability
I f  the hypotheis that anti-neuronal glycolytic enzyme antibodies can induce 
extrapyramidal movement disorders is correct, the hypothesis should be able to 
explain why the basal ganglia (striatum) is particularly vulnerable to these antibodies. 
As yet, there has been no investigation into the regional expression o f glycolytic 
enzymes on neuronal membranes. It is possible that some neurons express these 
glycolytic enzymes at higher levels and are therefore more vulnerable to attack. 
However, there is a large body o f investigation that has demonstrated that different 
neuronal populations have different vulnerabilities to insults. Specifically, the basal 
ganglia is particularly vulnerable to hypoxia, hypoglycaemia and ischaemia (Calabresi 
P et al., 2000). Energy failure and mitochondrial respiratory failure has been proposed 
to be the most important cause o f the selective vulnerability o f the basal ganglia 
neurons in Huntington’s disease (which presents w ith chorea) (Calabresi P et al., 
2000). Interestingly the protein responsible for Huntington’s disease (Huntingtin) has 
been shown to bind to, and possibly inhibit glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), a key glycolytic enzyme in energy metabolism (Guyot MC 
et al., 1997). Likewise, the protein atropin, responsible for dentatorubral- 
pallidoluysian atrophy (another degenerative disorder presenting with extrapyramidal 
movement disorders and predominant basal ganglia degeneration) also binds to the 
key glycoytic enzyme GAPDH (Ferrante RJ et al., 1997). It has been shown that 
certain subpopulations in the striatum are particularly vulnerable to deficits in energy 
metabolism and glutamate-mediated excitotoxicity. In particular, medium spiny 
neurons (MSN) (also known as striatal GABAergic projecting cells) are highly 
vulnerable and precociously damaged in disorders affecting energy metabolism, 
whereas striatal cholinergic intemeurons (large aspiny cells) are spared by these
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insults (Mitchell IJ et al., 1999; Calabresi P et al., 2000). This selective vulnerability 
o f striatal GABAergic neurons (MSN) may be partly related to their different 
membrane properties. Specifically MSN have a high resting membrane potential and 
are more hyperpolarized compared to aspiny neurons under resting conditions 
(Calabresi P et al., 2000). Hypoxia, hypoglycaemia and ischaemia cause membrane 
depolarisation o f striatal spiny neurons (followed by activation o f calcium channels, 
release o f neurotransmittors and potential cell death), whereas cholinergic aspiny 
neurons are hyperpolarized and protected during energy failure (Calabresi P et al., 
2000). This selective vulnerability o f striatal GABAergic spiny neurons to energy 
failure may explain why antibodies binding to membrane glycolytic enzymes can 
cause the post-streptococcal CNS phenotypes. GAB A is the primary inhibitory 
neurotransmitter in the CNS. Failure o f the inhibitory striatal neurons may result in 
striatal excitation and subsequent extrapyramidal movements and psychiatric 
disorders.
10.2.7. The molecular mimicry hypothesis
For a molecular mimicry hypothesis to stand-up to scrutiny, it is necessary for the 
precipitating micro-organism to express the mimicking protein, preferably on the cell 
surface. Streptococcal organisms express the glycolytic enzymes enolase, aldolase and 
pyruvate kinase on the cell surface (Pancholi V, Fischetti VA, 1998; Buckley ND and 
Hamilton IR, 1994; W ilkins JC et al., 2003). Most investigation has been into 
streptococcal surface enolase (SEN). SEN is similar to membrane bound human 
enolase in its role as a plasminogen receptor, intimately involved in the ability o f 
streptococci to adhere to and invade pharyngeal cells (Pancholi V et al., 2003). The 
Pancholi/Fischetti group have also shown that antibodies to streptococcal surface 
enolase also cross react with human alpha enolase, supporting a cross-reactive 
molecular mimicry hypothesis (Fontan PA et al., 2000). In support o f the role o f this
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process in post-streptococcal sequealae, patients with acute rheumatic fever have 
higher levels o f anti-SEN and anti-human alpha enolase antibodies compared to 
healthy controls and controls w ith uncomplicated Streptococcal pharyngitis (Fontan 
PA et al., 2000). The mechanism o f cross-reactivity is not yet apparent. The 
streptococcal glycolytic enzymes share a high level o f amino acid homology w ith the 
human glycolytic enzymes, however it is possible that the epitope is conformational 
rather than sequential.
10.2.8. Criticism of methodology and future directions
The methods employed in this thesis, and the results from this thesis could be 
criticised for the following reasons:
1. Rat brain was employed rather than human brain. Rat brain provided me 
with the best opportunity o f purifying the candidate autoantigen, 
predominantly due to the supply o f plentiful fresh rat brain tissue. The 
preceding experiments (comparing rat with human brain) reassured me that rat 
brain was a valid surrogate for human brain. Likewise, the use o f recombinant 
human brain proteins and purified commercial human proteins, subsequently 
reassured me that the findings were valid.
2. The human antibodies have only been shown to bind to the solubilsed 
(SDS treated) autoantigens, not the membrane autoantigens. Indeed the 
Western blotting employed here may alter, expose or remove epitopes on the 
autoantigens therefore altering the protein. The work in this thesis has not 
shown that the autoantibodies bind to the membrane forms o f these glycolytic 
enzymes. Further experiments are required using the neuronal membrane in its 
physiological state (such as immunohistochemistry using intact neurons) to
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determine whether the autoantibodies bind to the membrane forms o f these 
enzymes.
3 . The effects of autoantibodies on neuronal function have only used 
commercial polyclonal antibodies. Further experiments should purify patient 
IgG (preferably only the autoantibodies that bind to autoantigens). Purified 
human IgG should be used in the neuronal cell culture experiments measuring 
apoptosis. Further experiments could further determine potential functional 
effects o f antibodies, such as measuring effects on membrane energy 
metabolism, intracellular energy metabolism and effects on neurotransmission 
and cell signalling.
4. The sensitivity and specificity of these anti-neuronal glycolytic enzyme 
autoantibodies (anti-NGE Ab) needs to be determined in larger patient 
and control cohorts. Developing a standardised ELISA may best improve 
confidence in the sensitivity and specificity. An ELISA would also allow 
opportunity to examine the potential role o f these antibodies in 
neuropsychiatric syndromes such as Tourette syndrome and obsessive- 
compulsive disorder.
5. The molecular mimicry hypothesis has only been theoretically examined. 
To properly examine a possible cross-reactive autoantibody response between 
the streptococcal epitopes and neuronal epitopes, patient IgG against the 
neuronal autoantigens needs to be purified. This IgG could then be used 
against streptococcal epitopes to examine antibody cross-reactivity (either 
using synthesised candidate streptococcal epitopes or using random peptide 
libraries). Streptococcal organisms grown from post-streptococcal 
autoimmune neuropsychiatric patients should be used rather than random
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streptococcal organisms. Molecular mimicry at the T-cell level should also be 
undertaken.
6. Other markers of autoantibody pathogenicity have not been performed.
Purified human anti- NGE Ab needs to be used in an animal model (passive 
transfer o f antibodies) to further examine antibody pathogenicity. In addition, 
purified neuronal glycolytic enzyme antigens should be immunized into 
animal models to determine whether these antigens produce CNS disease. 
Likewise purified Streptococcal glycolytic enzymes should also be immunised 
into animal models to determine pathogenicity. Finally, in order to further 
demonstrate autoantibody pathogencitiy, patients with defined anti-NGE Ab 
should be plasmapheresed to determine whether removal o f these antibodies 
results in clinical improvements.
7. Are other autoantigens relevant in post-streptococcal autoimmune 
neuropsychiatric disorders? The crude antigen use in this thesis is likely to 
contain mainly soluble cellular extracts. Membrane constituents can 
sometimes require specific purification strategies. It is possible that 
autoantibodies against other membrane constituents (other than the neuronal 
glycolytic enzymes) are relevant in post-streptococcal neuropsychiatric 
disorders. Likewise, it is possible that other neuronal glycolytic enzymes may 
be autoantigens. For example glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) is an immunogenic cell surface streptococal protein with a neuronal 
membrane analogue. GAPDH has been shown to form complexes with 
enolase, aldolase, pyruvate kinase and NaK ATPase in neuronal membrane 
channels.
8. How can autoantibodies against ubiquitous neuronal glycolytic enzymes 
produce a relatively specific neurological syndrome? The autoantigens
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defined in this thesis are (predominantly) neuronal isoforms. However, 
previous regional examination o f these glycolytic enzymes has failed to 
demonstrate enrichment o f these proteins in the basal ganglia. Indeed, these 
enzymes are relatively equally distributed in the cortex, deep grey matter and 
cerebellum. For these autoantibodies to be pathogenic, there must be other 
explanations for these antibodies to produce a relatively specific basal ganglia 
syndrome. Possible explanations include:
• The regional distribution o f these glycolytic enzymes on the membrane has not 
been examined. Regions w ith high-energy requirements (such as the basal 
ganglia) may express more glycolytic enzymes on the neuronal membranes.
•  The basal ganglia may be more vulnerable than other brain regions to the 
metabolic insult induced by these autoantibodies.
•  As previously mentioned, pathological studies have shown that the 
inflammatory infiltrate is not purely localised to the basla ganglia, but involves 
other brain regions including the cortex.
9. Are these autoantibodies specific to post-streptococcal CNS disorders?
The previous reports o f anti-enolase antibodies in a number o f autoimmune 
and immune mediated disorders raise doubt on to the specificity o f the 
antibodies. However the majority o f the autoantibodies reported in this thesis 
are to neuronal isoforms o f glycolytic enzymes enriched in, or specific to, the 
CNS. The possibility that these antibodies are an epiphenomenona or are 
secondary to tissue damage remains possible.
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Chapter 11. Conclusions
The conclusions o f this thesis are as follows:
1. The spectrum o f post-streptococcal neuropsychiatric disorders is broader than 
previously described and includes extrapyramidal movement disorders 
(chorea, tics, dystonia and Parkinsonism). Psychiatric disorders commonly co­
exist with the movement disorders, particularly emotional disorders such as 
obsessive-compulsive disorder and anxiety.
2. There appears to be a genetic vulnerability involved in disease expression. 
Likewise, the patient sex and age influence phenotypic expression. Pre­
existing neuropsychiatric disorders such as attention deficit hyperactivity 
disorder may predispose children to the development o f movement disorders 
after post-streptococcal autoimmune induction.
3. Magnetic resonance neuroimaging is typically normal, although inflammatory 
changes with particular involvement o f the basal ganglia may occur. These 
inflammatory changes were most common in the dystonic or Parkinsonian 
patients.
4. Patients w ith post-streptococcal autoimmune neuropsychiatric disorders have 
autoantibodies against neuronal glycolytic enzymes. These neuronal 
autoantigens are expressed on the neuronal membrane and have previously 
been shown to be involved in energy metabolism, cell signalling and support 
neurotransmission. Provisional investigation suggests that autoantibodies 
against these targets can have pathogenic effects on neurons. These 
immunological conclusions are summarised in Figure 11.1.
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Figure l l . l .  Summary o f  immunological conclusions form this thesis.
EN ALD PY
Ab
? T cell help
Ab BBB
A LD PYEN
7 7 7 7 7 ^ ^ 7 7 7 7 7
? Effects
Alteration in metabolism 
Alteration in cell signalling 
Alteration in neurotransmission
Key:
EN: enolase 
ALD: Aldolase 
PY: Pyruvate kinase 
BBB: Blood brain barrier 
B: B cell 
T: T cell 
Ab: antibody
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APPENDIX 1. Clinical characteristics of post-streptococcal dyskinesias and associated psychiatric 
morbidity.
Age of 
movement
Movement disorder ICD-10 psychiatric disorders Movement disorder 
course (disease duration 
in years)disorder onset 
(years) and sex
Emotional Conduct Hyperkinetic
1.2m Dystonia, chorea - - - Relapsing remitting (1.8)
1.3 f chorea - - - Persistent (1)
1.5m chorea OCD - Hyperkinesis (oth.) Persistent (13)
2m tics OCD, social phobia, depression Conduct (other) Hyperkinesis Persistent (13)
2f Chorea, dystonia - - - Resolution (0.25)
2m Myoclonus,
dystonia
Panic attacks, gen. anxiety Conduct (other) - Relapsing remitting (5)
3m tics - - - Relapsing remitting (4)
3m tics Sep. anxiety, gen. anxiety, OCD ODD - Relapsing remitting (5)
3f Stereotypies OCD ODD - Persistent (7)
4m Dystonia - - - Resolution (0.2)
4f chorea - - - Persistent (0.5)
5m tics Sep. anxiety, gen. anxiety, OCD - Hyperkinesis Persistent (5)
5f tics Trichotillomania, depression Conduct (other) - Persistent (2)
6m tics OCD - - Persistent (1)
6m tics - - - Relapsing remitting (3)
7f tics OCD - - Persistent (8)
7m Chorea, tremor - - - Relapsing remitting (7)
7f Tics, stereotypies OCD _ - Persistent (2)
I f chorea - - - Persistent (0.5)
7m tics - - Hyperkinesis Relapsing remitting (2)
7m chorea - - - Persistent (2)
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Age and sex Movement disorder ICD-10 psychiatric disorders Movement disorder 
course (disease duration
Emotional Conduct Hyperkinetic in years)
8f chorea - ODD - Relapsing remitting (1.5)
8f chorea Gen. anxiety - Hyperkinesis Resolution (0.25)
8m tics - - - Relapsing remitting (2)
8m tics - Conduct (other) - Relapsing remitting (7)
8m tics OCD - - Persistent (4)
8f tics - - - Relapsing remitting (1)
8m Dystonia, chorea Gen. anxiety, spec, phobia, depression - - Relapsing remitting (1.5)
10m chorea Gen. anxiety ODD Hyperkinesis Persistent (0.25)
lOf chorea Sep. anxiety, gen. anxiety, OCD, social 
phobia, depression
ODD - Relapsing remitting (1.5)
lOf Chorea, tremor, 
opsoclonus
Gen. anxiety - - Resolution (0.2)
11m chorea - - - Resolution (0.8)
I l f chorea - - - Resolution (0.35)
I l f chorea Depression - - Resolution (0.8)
12f chorea - Conduct (other) - Resolution (0.25)
12f tics - - - Resolution (0.2)
13m tics Gen. anxiety, specific phobia, OCD, 
depression
- - Relapsing remitting (2.5)
13f chorea Gen. anxiety, specific phobia, 
depression
ODD - Resolution (0.8)
14m chorea - _ _ Resolution (0.25)
16f Tremor, opsoclonus - - - Persistent (0.8)
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APPENDIX 2. Clinical findings in poststreptococcal acute disseminated encephalomyelitis
Patient no. Age (yr/gender) Extrapyramidal
movement
Behavioural change Other neurology Outcome (follow-up)
1 3/M Axial and limb 
cogwheel rigidity, 
dystonic posturing, rest 
tremor
Emotional lability, 
inappropriate laughter
Confusion and lethargy, 
reduced conscious ness 
(GCS 7/15), meningism
Normal (2 yr)
2 4/M Axial and limb rigidity, 
dystonic posturing
Inappropriate laughter, 
confusion
Reduced consciousness 
(GCS 5/15), 
quadriplegia
Normal (2.5 yr)
3 4/M Axial and limb rigidity, Inappropriate Irritability and lethargy, Obsessive-compulsive
rest tremor behaviour, pallilalia and 
echolalia, attention 
deficit
reduced consciousness 
(GCS 11/15), 
quadriplegia
disorder (3 yr)
4 4/M Paroxysmal
hemidystonia
Inappropriate speech Tonic clonic convulsion 
(2), somnolence, ataxic 
gait
Normal (2 yr)
5 5/M - - Hemiplegia Normal (1 yr)
6 6/M Left hemidystonia Emotional lability, - Left hemidystonia
7
separation anxiety (6mo)
7/M - Emotional lability, Somnolence, bilateral Relapse (2mo), normal
10/M
apathy optic neuritis (2.5 yr)
8 Confusion and 
disorientation, 
inappropriate speech
Reduced consciousness 
(GCS 6/15), transverse 
myelitis, autonomic
Normal (5 yr)
13/F
dysfunction
9 - - Hemiplegia Normal (1 yr)
10 14/F - Hemiplegia, tremor Relapse (13 mo), 
normal (18 mo)
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APPENDIX 3. Patient demographics and clinical characteristics of encephalitis lethargica-like patients
Age Sleep disorder Lethargy Parkinsonism Dyskinesia Psychiatric Other features
2f hypersomnolence absent bradykinesia, rigidity, rest tremor .
4m hypersomnolence present bradykinesia, rigidity, rest tremor - emotional lability encephalopathy, meningism
5m hypersomnolence present bradykinesia, rigidity - Mutism ophthalmoplegia, ptosis, nocturnal bradycardia
7f sleep inversion present bradykinesia dystonic jaw mutism, anxiety, depression, apathy hyperventilation
8m insomnia absent bradykinesia, postural instability generalised dystonia mutism, agitation, poor social interaction encephalopathy, seizures
9f sleep inversion absent bradykinesia, rigidity oculogyric crises, hemiballismus mutism, disinhibition, compulsive touching ophthalmoplegia, hiccough
10f hypersomnolence present bradykinesia - aggression, depression, apathy -
10m hypersomnolence absent bradykinesia motor tics mutism, depression -
11f insomnia absent rest tremor facial grimacing catatonia, agitation, panic attacks seizures
13f hypersomnolence present bradykinesia, postural instability - Apathy ophthalmoplegia, meningism, optic neuritis
13m hypersomnolence absent bradykinesia generalised dystonia mutism, confusion encephalopathy, memory loss
14f hypersomnolence present akinesia Blepharospasm mutism, depression, auditory hallucinations pupillary light abnormality
15f hypersomnolence present bradykinesia, rest tremor dystonic posturing Depression memory loss
15m sleep inversion absent bradykinesia, rest tremor oculogyric crises, dystonia mutism, catatonia, compulsions -
15m hypersomnolence present bradykinesia, rigidity, rest tremor oculogyric crises anxiety, paranoia pupillary light abnormality, hiccough
16m - absent bradykinesia, rigidity, rest tremor - - hyperventilation
17m sleep inversion absent bradykinesia motor and vocal tics, stereotypies mutism, catatonia, OCD, trichillomania hyperventilation
35m hypersomnolence present bradykinesia, rigidity, rest tremor - OCD, depression ophthalmoplegia
69m sleep inversion present bradykinesia, rigidity, rest tremor Stereotypies mutism, apathy, confusion encephalopathy, pinpoint pupils
69f hypersomnolence absent rigidity, rest tremor dystonia, chorea - encephalopathy, memory loss, seizures
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APPENDIX 4. Negative or normal investigations in encephalitis lethargica patien
Investigations were tailored according to the patient age, presentation and course, (number in brackets)
Aetiology Diagnostic investigation
Infectious CSF herpes simplex virus PCR (n= 12), CSF enterovirus per (n=5), CSF 
EBV PCR (n=8), CSF measles antibody (n=4), CSF bacterial culture (n= 
Lyme serology (n=6), Whipples, varicella zoster, influenza, arbovirus, pi 
adenovirus, parvovirus, bartonella, H IV (all n=2)
Systemic autoimmune disease Anti-nuclear antibody* (n=16), complement (n=5), angiotensin convertii 
antibodies (n=3)
Metabolic CSF lactate (n=14), creatinine kinase (n=4), ammonia (n=4), plasma ami 
acids (n=8), very long chain fatty acids (n=4), white cell enzymes (n=6), 
acanthocytes (n=6)
Biochemical Copper (n=12), caeruloplasmin (n=9), thyroid function tests (n=10), porj 
metabolism (n=16), urine toxicology (n=7),
Genetic Huntington’s disease (n=3), DRPLA (n=3), SCA-3 (n=2), DYT-1 (n=4)
* Anti-nuclear antibody was <1:80 in all patients.
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APPENDIX 5. Buffers, chemicals, 
hardware
solutions, standards and
Chromatography: Buffers
Buffer Uses Constituents
Sodium phosphate 
buffer, pH 7.0
Binding buffer in 
chromatography
500ml double distilled water 
0.87g Na2 HP04 
0.47g Na H2 PO4
Citric acid buffer, 
pH 3.0
Elution or binding 
buffer in 
chromatography
500ml double distilled water 
8.6 lg  Citric acid 
2.65g Sodium citrate
Tris-HCl buffer, 
pH 8.0
Binding buffer in 
chromatography
500ml double distilled water
1.2g Tris
4ml 1 Molar HC1
Chromatography: Hardware
Hardware Uses Product number
AKTA Fluid phase Fluid phase liquid 
liquid chromatography chromatography
AKTA
Pump P-920
Monitor UPC-900
Fraction Collector Frac-900/901
Compaq deskpro computer.
A ll Amersham Pharmacia Biotech
UNICORN software 
for FPLC
Software for FPLC 
computer
Version 3.20, Amersham Pharmacia 
Biotech
HiTrap Q FF, 1ml Ion exchanger, anion Amersham Biosciences, 17-5053-01
HiTrap Q FF, 5ml Ion exchanger, anion Amersham Biosciences, 17-5156-01
HiTrap SP FF, 1ml Ion exchanger, cation Amersham Biosciences, 17-5054-01
HiTrap SP FF, 5ml Ion exchanger, cation Amersham Biosciences, 17-5157-01
HiTrap desalting, 5ml Desalting, changing Amersham Biosciences, 17-1408-01
the buffer
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HIC Selection kit, lm l Hydrophobic Amersham Biosciences, 17-1349-01
interaction selection 
k it
HiTrap rProtein A FF, IgG purification 
lm l
HiTrap Butyl FF, 5ml Hydrophobic
interaction
17-5079-02
17-5197-01
Chromatography: Chemicals
Product
Sodium phosphate, monobasic, 
anhydrous Na H2 PO4
Sodium phosphate, dibasic, anhydrous 
Na2 HPO4
Citric acid, monohydrate, C6 Hg O7. H20
Citric acid, trisodium salt dihydrate 
C6H5 O7 Na3.2H20
Tris(hydroxymethyl)aminomethane,
C4H ,,N 0 3
NaCl
Hydrochloric acid, HC1, 1 Molar
Company and log. number
Sigma S-0751
Sigma S-7907
Sigma C-1909 
Sigma C-3434
Sigma T-6791
Sigma S-9625 
BDH, 190686W
PAGE, electrophoresis and ELISA: Buffers and developing 
solutions
Buffer Uses Constituents, product number
MOPS SDS 
Running buffer 
(Invitrogen)
Running buffer in PAGE 500ml (20x)
3-(N-morpholino) propane 
sulphonic acid 104.6g (1M) 
Tris base 60.6g (1M)
SDS lO.Og (69.3mM) 
EDTA 3.0g (20.5mM) 
Ultrapure water 500ml
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MES SDS running 
buffer
(Invitrogenn)
NuPAGE LDS 
sample buffer (4x)
Colormetric
developing
solution
Enhanced
chemiluminescent
developing
solution
IEF pH 3-10 
sample buffer (2x)
IEF Anode (lower) 
buffer (50x)
IEF Cathode 
(upper) (5 Ox)
Acetate buffer
0.05Molar 
Carbonate buffer
Detector solution 
for ELISA
TCA fixation 
buffer
Running buffer in PAGE 500ml (20x)
2-(N-morpholino) ethane sulphonic 
acid 97.6g (1M)
Tris base 60.6g (1M)
SDS lO.Og (69.3mM)
EDTA 3.0g (20.5mM)
Ultrapure water 500ml
Sample solubilisation for 
PAGE
Invitrogen, NP0007
Western blotting 4-Chloro-l-Naphthol 20pg 
Hydrogen peroxide 50pl 
Methanol 20ml 
Acetate buffer 5 ml 
Distilled water 75ml
Western blotting Supersignal West Pico 
Chemiluminescent substrate, Pierce 
kit, 34080
IEF buffer before 
isoelectric focussing
IEF anode
Invitrogen, LC5311
Invitrogen, LC5300
IEF cathode Invitrogen, LC5370
For colormetric 
development solution
Binding antigen to 
ELISA plate
136g Sodium acetate trihydrate 
22.5g glacial acetic acid 
5 litres distilled water 
For working strength, dilute 1:10
0.5M: 1 litre o f distilled water with 
13.85gNa2C03 and26.1g 
NaHCOi. working strength must be 
diluted 1:10.
Detection o f antibody 
reactivity
Fixing IEF gels
1 lm l o f acetate buffer (working 
strength), 20pg OPD, 1 lp l 
Hydrogen peroxide.
In 1000ml double distilled water, 
lOOg TCA 
lOg SSA
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PAGE, electrophoresis and ELISA: Hardware
Product Product number
Pre-cast NuPAGE 4-12% Bis-Tris gels, Invitrogen, NP0326BOX
2D (10 gels)
Pre-cast NuPAGE 4-12% Bis-Tris gels, Invitrogen, NP0321BOX
10 well (10 gels)
Pre-cast NuPAGE 10% Bis-Tris gels, 9 Invitrogen, NP0307BOX
well (10 gels)
Pre-cast IEF gels, pH 3-10, 10 wells (10 Invitrogen, EC6655A
gels)
PowerEase 500 electrophoresis tank Invitrogen, El8700EU
Trans-Blot transfer medium, cut to 9cm Bio-Rad 162-0094
square (nitrocellulose)
Nunc-immuno Plate, Maxisorp surface Nunc brand products
PAGE, electrophoresis and ELISA: Chemicals and solutions
Product
Colloidal blue staining kit- Stainer A  
Colloidal blue staining kit- Stainer B 
Silver staining kit
Molecular weight marker- SeeBlue plus 2
Ethyl Alcohol, C2H5OH
Methanol, CH3OH
Acetic Acid
Coumassie R-250 0.1%
Company and log. Number
Invitrogen, product number 46-7015
Invitrogen, product number 46-7016
Amersham Biosciences, product number 
17-1150-01
Invitrogen, product number LC5925 
Hayman Ltd. UN 1170 
Hayman Ltd. UN 1230 
BDH, 27013BV
342
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Tri-Chloro-Acetic acid Sigma, T-6399
Sulfosalicylic acid (SSA)
Tween 20 (Polyoxyethylenesorbitan Sigma P-1379
monolaurate)
4-Chloro-1 -Naphthol Sigma C-8890
o-Phenylene-Diamine (OPD) Sigma P-1526
Hydrogen peroxide (H2O2) 100 volumes Fisher Chemicals H/1750/15 
Bovine specific albumin (BSA) Sigma A-7906
Proteomics and protein purification: Buffers
Product Company
Tissue Protein extraction reagent (T- Pierce, USA (no. 78510)
PER)
Protease inhibitor cocktail for Sigma (P 8340)
mammalian tissues
Proteomics and protein purification: Hardware
Product Company
Millipore microcentrifuge Microcon YM-10, 42406
Proteomics and protein purification: Chemicals
Chemical
Ammonium sulphate, (NH4) 2 SO4 
DL-Dithriothreitol (DDT)
Biuret protein measurement, Reagent A 
Biuret protein measurement, Reagent B
Company, product number
Sigma A-2939 
Sigma D-0632
Bio-Rad Dc Protein assay, 500-0113 
Bio-Rad Dc Protein assay, 500-0116
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Commercial Antibodies and antigens
Product
Human neuron-specific enolase (NSE), 
(500fig)
Human non-neuronal enolase (NNE),
(50fig)
Enolase from Baker’s yeast, yeast (9mg 
solid, ~6.5mg protein)
Enolase from rabbit muscle, (5.5mg 
protein/ml)
Plasminogen from human plasma, 
lyophilised powder, 6-9 units/mg protein
Goat anti-human plasminogen HRP 
conjugated, lOmg/ml
Goat anti-pyruvate kinase, 1 O jL ig /p ,l
Goat anti-enolase C-19, 200jiig/ml
Goat anti-aldolase, 10 mg/ml
Rabbit anti-human IgG, HRP conjugated
Rabbit anti-goat Immunoglobulins, HRP 
conjugated
Company, source
Advanced Immunochemical incorporated 
(via Insight Biotechnology limited), 
purified using chromatography,
Accurate chemical and scientific 
corporation, Westbury, New York. 
Purified using chromography from brain.
Sigma-Aldrich, purified from S. 
cerevisiae, E6126
Sigma-Aldrich, purified from rabbit 
muscle, E0379
Sigma-Aldrich, purified from human 
plasma, P5661
Abeam, ab7336-l
Abeam, ab6191
Santa Cruz Biotechnology, sc-7455 
Abeam, ab6190-100 
Dako, P0406 
Dako, P0160
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